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Prologue 
General introduction 
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After finishing my medical study in 1976 I started training in Internal 
Medicine (Juliana Ziekenhuis Apeldoorn, dr. A. van Gelder). 
Afterwards my interest was awakened by anesthesiology, which 
made me follow a training in anesthesiology as of 1978 (Academic 
Hospital Utrecht (AZU), prof. dr. B. Smalhout). During these years I 
was regularly confronted with patients with cancer and pain. 
Regardless of all our efforts to relieve this pain, it was often not 
possible to make the patient comfortable. In 1978 prof. M. Mauve 
started a pain clinic as a subdivision of the AZU department of 
Anesthesiology. Mauve was for many years a family doctor before 
becoming one of the first anesthesiologists in the Netherlands trained 
by prof. Vermeulen Cranch in Amsterdam, and he was convinced of 
the necessity of multidimensional assessment and treatment of pain. 
We, his assistants, were trained with this conviction.   
The oncologist, dr. J. Schornagel asked our help for the treatment of 
patients with pain. Therefore pain in patients with cancer withheld our 
special interest in the search for scientific information on the various 
aspects of pain. 
In 1979 in the book series: “Advances in Pain Research and 
Therapy” the proceedings of the International Symposium on Pain of 
Advanced Cancer were published.1 This symposium was held in 
Venice in 1978 and was attended by many specialists in pain 
medicine and palliative care. Keynote lecturers were world-renowned 
scientists as John J. Bonica, Vittorio Ventafridda, John D. Loeser, 
Kathleen Foley and Cicely Saunders.  
In his lecture on ”The Importance of the Problem” (of cancer pain) 
Bonica, the founder of the International Association for the Study of 
Pain (IASP)2 gave an outline of the reasons for inadequate pain relief. 
According to Bonica, the two main reasons are: first the voids in our 
knowledge of the basic mechanisms and physiopathology of cancer 
pain, and second the improper or inadequate application of 
knowledge currently available for the care of patients with cancer and 
pain.3 
Bonica gave the following recommendations for improvement: 
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Much greater research efforts which should include: a. 
comprehensive epidemiological studies on the incidence and 
magnitude of cancer pain with each type of tumor; b. study of the 
neurophysiologic and biochemical and physiopathological 
mechanisms of cancer pain; c. evaluation of the efficacy of the 
methods currently used to relieve cancer pain; and d. the 
development of new therapeutic modalities. 
Intensive educational programs for medical students and other health 
care professionals, as well as practicing physicians, including a. 
knowledge about the causes and mechanisms of pain; b. the efficacy, 
indications, limitations, and complications of current methods of pain 
relief; and c. specific guidelines about proper management of these 
patients. 
Intensive educational campaigns for the public, patients and families, 
as well as federal agencies. 
Provision of better sources of information through the oncologic 
literature, books and special articles, and brochures on cancer pain. 
Cardinal Albino Luciani, the Patriach of Venice, opened the 
symposium in Venice and stated that physicians should use all their 
knowledge, skills and energy to apply the best means at their 
disposal to relieve the pain of patients with advanced cancer. He 
outlined, that the venue of the symposium was the island of St. 
Giorgio, which name was changed by its owner, Count Cini, in “The 
Island of Hope”. The cardinal wished that the symposium would give 
hope for better treatment of pain in patients with cancer. Three 
months after this symposium cardinal Albini Luciani was elected 
Pope John Paul I. He was called “The Pastoral Pope” as he was very 
much interested in the welfare and the rights of the individual. It was 
hoped, that he could be of importance for “the cause of pain” and as 
a pope could use his influence to help implement the 
recommendations of the symposium in the world. Unfortunately Pope 
John Paul I died 33 days after his election under till now not 
elucidated circumstances. Post aut propter the assessment and 
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treatment of pain in patients with cancer is thirty-six years later still 
insufficient, so is seems that this hope was in vain. 
Being myself for more than thirty-six years involved in the treatment 
of pain in patients with cancer, the continuing inadequacy of relieving 
the pain of these patients was the motivation to do the research, that 
is the basis of this thesis. After a short outline of the epidemiology of 
cancer and the cancer related pain, the development of guidelines on 
the treatment of cancer pain is described. Afterwards the assessment 
of pain in patients with cancer and a modern way for its improvement 
is outlined. In the following chapters the pharmacological and 
interventional treatment of pain are discussed. The next chapter 
concerns the role of opioid rotation in difficult pain problems. The last 
chapter describes the evaluation of the effect of the introduction of 
the Dutch evidence based guideline on the diagnosis and treatment 
of pain in patients with cancer by the Dutch anesthesiologists/pain 
specialists by means of a case vignette study.  
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Chapter 1 
Introduction 
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The epidemiology and symptomatology of cancer. 
Cancer is the primary cause of death in the Netherlands. In 2012, 
43,471 patients died of cancer; this is an increase of 1.3% compared 
to 2011. There were 101,200 new cancer diagnoses in 2012. With 
the increased life expectancy it is projected that the incidence of new 
cancer diagnoses will increase each year with 3%. 4 
Cancer is popularly called, “the feared disease”, although the overall 
survival rate of cancer increases each year. The five-year survival 
rate of different cancer types differs largely, from 86% in breast 
cancer to 16% in lung cancer and only 6% in pancreatic cancer. It is 
realistic to fear that cancer will shorten the patient’s life.5 Besides, 
patients fear excessive suffering caused by cancer induced 
symptoms such as: fatigue, pain, lack of energy, weakness and loss 
of appetite, that are present in more than fifty percent of the patients 
in the palliative phase. The prevalence depends on the registration 
method for these symptoms that can be a questionnaire, a 
standardized interview or analysis of the medical record. Fatigue and 
pain are the most prevalent symptoms, appearing in 66 to 77 % of 
the studied patients.6, 7 Several aspects of the assessment and 
treatment of pain in patients with cancer will be described in this 
thesis. 
The problem of pain symptoms in patients with cancer. 
Pain is one of the most prevalent symptoms in patients with cancer, 
not only in the palliative phase, but also during treatment and in the 
remission phase or when the patient is cured from cancer. The 
prevalence of pain is 64% in the end stage of the disease, 33% after 
curative treatment and 59% during treatment. 8   
The frequency of pain depends of the primary tumor site. Hundred 
percent of the patients with advanced multiple myeloma and sarcoma 
experience pain. Pain prevalence is 80% in head and neck cancer, 
77% in genitourinary malignancies, 74% in cancer of the esophagus 
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and 74% in prostatic cancer. Pain in leukemia is with 5% far less 
prominent.9 
The burden of pain in patients with cancer is not just a result of tumor 
size and localization, but is also determined by the way patients and 
their caregivers experience the impact of their illness, its treatment 
and prognosis on their lives and wellbeing. This should be taken into 
consideration when assessing the pain.10 
According to the literature, adequate pain relief in patients with 
cancer could be accomplished in 71% to 86% of the patients. 11, 12 
Unfortunately nowadays still nearly 50% of the patients with pain due 
to cancer are undertreated.13  
There are several reasons, which explain this under treatment. These 
reasons are doctor related, inadequate assessment and inadequate 
knowledge of treatment possibilities of pain,14, 15 and patient related, 
fear of opioid addiction, fear of distraction of the attention from 
causative treatment and fear not to behave as a “good” patient.16, 17       
In this thesis several methods to improve the treatment of pain in 
patients with cancer will be explored. 
National/international guidelines on diagnosis and treatment of 
pain in patients with cancer. 
Clinical Practice Guidelines (CPG) aim to assist practitioners and 
patients in making appropriate choices in specific clinical 
circumstances.18   The first CPG on pain in patients with cancer was 
published by the World Health Organization (WHO) in 1986.19 This 
publication led to an enormous improvement of the treatment of pain 
in patients with cancer.20   
The WHO guideline was adapted in 1996 according to further 
experience of and insights in the treatment of cancer pain.21 A survey 
from the European Federation of IASP (International Association on 
the Study of Pain) Chapters (EFIC) showed the existence of national 
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CPG’s on cancer pain in five European countries, France, Italy, the 
Netherlands, Norway and the United Kingdom. 22  
Several oncological societies published their own CPG on cancer 
pain, for example the European Society of Medical Oncology 
(ESMO)23 and the National Comprehensive Cancer Network in the 
United States of America,24 which are more comprehensive than the 
national CPG’s. 
The development of the Dutch Clinical Practice Guideline on the 
diagnosis and treatment of pain in patients with cancer will be 
outlined in the first part of chapter 2 of this thesis. 
In the second part of this chapter the pharmacologic treatment of pain 
in patients with cancer is discussed. Evidence based 
recommendations for the prescription of non-opioids, strong opioids 
and adjuvant analgesics are given. The advice to omit step 2 of the 
WHO analgesic ladder is supported by two publications. 25, 26 
The occurrence and treatment of side effects of strong opioids  is 
described according to the recent literature. 
The assessment of pain. 
Thorough and regular assessment of the presence and level of pain 
in patients with cancer is an important prerequisite for adequate pain 
treatment.27 Pain measurement tools such as the Visual Analogue 
Scale (VAS) and the Numeric Rating Scale (NRS) are reliable and 
valid instruments for the pain registration in patients with cancer,28 the 
latter is easier to use in clinical practice. 29, 30 The pain intensity 
measured with a standard scale gives important information on the 
necessity to adapt the treatment. A pain level of 5 or higher indicates 
that the patient suffers severe pain, justifying an urgent need for 
treatment changes. 28  
Multidimensional assessment of pain can be achieved with validated 
questionnaires as the short form of the McGill Pain Questionnaire 
(SF-MPQ),31 the Brief Pain Inventory (BPI)32 and related items.33  
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Despite these easy accessible tools for pain assessment, registration 
of pain in patients with cancer is still insufficient.15, 34  
In chapter 3 of this thesis the evaluation of pain registration in 
different hospitals in the eastern part of the Netherlands is outlined. 
Innovative techniques in pain assessment. 
As stated in paragraph 1.4, physicians often assess insufficiently pain 
in patients with cancer. The physicians should be forced to ask for or 
look at the pain scores of their patients. When patients use a pain 
diary accurate information is obtained.35 Unfortunately the diary is not 
consistently filled-out by all patients.36 The pain diary and hence the 
pain scores are reviewed retrospectively, when the patient is seen by 
a nurse or physician. In this way, adaptation of treatment can be very 
tardy, and may lead to unnecessary longer suffering by the patients. 
In the twenty-first century technology is available to fasten the 
communication between patients and nursing or medical attendants. 
One such technique is the use of Short Message Service (SMS) and 
Interactive Voice Response (IVR) through a mobile phone. An 
automatically generated message is sent to the patient, who can 
answer immediately by SMS. This has been practiced for example in 
the treatment of asthma37 and the use of oral anti-coagulants.38  We 
used this technique in pain management. When the patient reports a 
pain score implying insufficient pain relief, a message is sent to the 
responsible nurse to contact the patient. Our results with this new 
technology are described in chapter 4 of this thesis.     
Interventional pain treatment in patients with cancer. 
The recommendations of the World Health Organization, published in 
1986 are followed throughout the world for the management of pain 
in patients with cancer. 19  Analgesics are prescribed in a  step wise 
order with increasing strength. The so-called analgesic ladder starts 
with paracetamol and/or Non Steroidal Anti Inflammatory Drugs 
(NSAIDs); the second step combines the first step with weak opioids; 
the third step combines the first step with strong opioids. When the 
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WHO recommendations were revised in 1996 a fourth step was 
added because there were still situations where the three-step ladder 
did not provide sufficient pain relief. The invasive pain treatment 
could provide relief for those patients still suffering and was 
designated the 4th step in the analgesic ladder. 39  
In the Dutch clinical practice guideline on the diagnosis and treatment 
of pain in patients with cancer the recommendations of the WHO 
ladder were modified according to the recent literature. 40  The 
second step was abandoned in favor of an earlier start with strong 
opioids. 25, 26 
Another modification was to consider the use of invasive pain 
treatment in patients with pain due to cancer not as a last resort, 
when other treatments failed, but earlier in the course of the illness. 
This concerns especially the use of the celiac plexus block in patients 
with pancreatic carcinoma. In these patients pain is often difficult to 
treat and the use of a celiac plexus block can be considered, when 
treatment according to the first step of the WHO ladder gives 
insufficient pain relief.41 
More recent literature about invasive pain treatment in patients with 
cancer is in accordance with the recommendations of the guideline.42-
44 
An overview of the indications for invasive pain treatment and the 
evidence is given in chapter 5 of this thesis. 
Opioid rotation in patients with inadequate response to opioids. 
Opioids are the mainstay of treatment in patients with pain due to 
cancer.45 The opioid dose titration can be achieved using the oral or 
the transdermal route. Morphine, oxycodone and hydromorphone are 
given orally, fentanyl and buprenorphine transdermally. There are no 
important differences between these drugs; therefore each of them 
can be used as first choice 46 in step III of the WHO analgesic 
ladder.39 The dosage is regularly adapted until the pain relief is 
sufficient or the side effects of the opioids prevent further dose 
Chapter 1 
   11 
increase. The most frequent side effects of opioids in patients with 
cancer are nausea, vomitus, constipation, sedation and respiratory 
depression.47    
In the case of insufficient pain relief despite optimizing the dose of the 
chosen opioid, the transition to another opioid can be considered. 
This technique is called opioid rotation or switching.48 There are 
several genetic, metabolic and pharmacologic considerations for the 
effectiveness of opioid rotation.49 In chapter 6 of this thesis an outline 
of the evidence of opioid rotation will be given. 
Evaluation of the clinical practice guideline by indicators. 
After the completion and publication of the Dutch clinical practice 
guideline on the diagnosis and treatment of pain in patients with 
cancer the National Health Care Institute (Stuurgroep Zichtbare Zorg 
Ziekenhuizen)50 composed a working party to develop indicators for 
the evaluation of the implementation of the guideline in the Dutch 
hospitals and the quality of care provided to patients with cancer and 
pain. The working party consisted predominantly of the same 
members as those who wrote the clinical practice guideline.  
An indicator in health care is meant to provide insight in the quality of 
the provided care in a specific situation. Quality indicators are 
developed according to the Appraisal of Indicators, Research and 
Evaluation (AIRE)-instrument. 51 There are three specific quality 
indicators: 
-A structure quality indicator represents the 
characteristics of settings where care is delivered, for 
example the availability of specific facilities. 
-A process quality indicator evaluates the activities and 
tasks in patients’ episodes of care, for example the 
physician’s activities in making a diagnosis or 
implementing a treatment. 
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-An outcome quality indicator evaluates the effect of the 
provided care on the individual patient or the society as a 
whole.   
Four indicators were established to evaluate how the guideline was 
implemented in the hospitals in the Netherlands and to study the 
quality of care given to patients with pain and cancer. 
Structural pain assessment with the Numeric Rating Scale (NRS), 
Visual Analogue Scale (VAS) or Verbal Rating Scale (VRS). The 
indicator demanded the use of a pain assessment instrument twice 
daily in clinical patients with cancer.52  
The percentage of patients with moderate to severe pain. All clinical 
patients with cancer and a pain score higher than 5 measured with 
the NRS or VAS, and all patients with at least the pain score 
moderate on the VRS must be registered.30 
The presence of a multidimensional pain treatment protocol for 
patients with pain and cancer. Each hospital must report the 
presence or absence of such a protocol.53 
The way education to patients with pain and cancer is organized. 
Each hospital is asked to return the questionnaire on this subject.54   
The National Health Care Institute decided to give priority to the 
implementation of other indicators in other diseases in the Dutch 
hospitals. The indicators on cancer pain treatment, that were 
developed by the working party, were unfortunately never 
implemented. 
Evaluation of the implementation of guidelines by case vignette 
studies. 
The publication of guidelines does not automatically imply their use in 
daily practice; this holds even for Clinical Practice Guidelines.55 A 
case vignette study is a validated tool to measure guideline 
adherence in health care practice.56 The case history of a fictitious 
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patient based on a realistic clinical situation, is provided together with 
questions to explore what a physician intends to do, when confronted 
with the actual patient.57 A vignette creates a normal sequence of 
events in an actual patient from taking the patient history to making a 
diagnosis and a treatment plan.58 The use of a case vignette appears 
to be comparable with using standardized patients to assess the use 
of clinical practice guidelines, but is much cheaper.59  
A disadvantage of a vignette is that the physicians know, that they 
are being evaluated, and that in real practice for example because of 
lack of time a different choice could be made. Vignettes are of little 
value to assess skills as communication and physical exam.60 
The evaluation with a case vignette study of the diagnosis and 
treatment of patients with pain and cancer by Dutch 
anesthesiologists/pain specialist after publication of the Dutch 
guideline is described in chapter 7 of this thesis. 
Aim of the thesis and research objectives. 
Pain is one of the most prevalent and feared symptoms in patients 
with cancer. Despite the efforts of researchers, physicians and 
patients during the last decades, the assessment and treatment of 
pain in these patients is still insufficient in many cases. The number 
of patients with cancer will increase in the coming years. 
In this perspective it is logical to further explore the bottlenecks in 
assessment and treatment of pain in patients with cancer. The main 
objectives of this thesis are: to analyze the possibilities to reduce the 
patients’ suffering and to ameliorate the physicians’ approach to 
these problems.  
In order to achieve this goal the following research questions were 
investigated and will be discussed: 
Is it possible to create a multidisciplinary (including patient 
participation) evidence based clinical practice guideline with 
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recommendations on the diagnosis and treatment of pain in patients 
with cancer? 
Do medical specialists document pain in patients with cancer in their 
medical records according to the recommendations of the guideline? 
Is telemedicine a practicable tool to improve patient pain monitoring 
and pain management? 
How can more sophisticated techniques as invasive pain treatment 
and opioid rotation be used to improve the treatment of pain in 
cancer? 
Do medical specialists apply the national multidisciplinary evidence 
based guideline in their daily practice: is evaluation by a vignette 
case study possible and feasible to study this?    
 Chapter 2 describes the procedure of the composition of the 
evidence based Dutch clinical practice guideline on the diagnosis and 
treatment of pain in patients with cancer. The training of the members 
of the working party, the literature search, the conclusions and the 
recommendations, which are relevant for the research questions from 
this thesis will be outlined. In the second part of this chapter the 
pharmacologic treatment of pain due to cancer is outlined, followed 
by the treatment of the most frequent side effects of strong opioids.  
Chapter 3 contains the study of the pain assessment by medical 
oncologists in different hospitals in the eastern part of the 
Netherlands.  
Chapter 4 presents the study of the use of telemedicine, Short 
Message Service (SMS) and Interactive Voice Response (IVR) in 
pain monitoring and management by patients at home.  
Chapter 5 outlines the role of interventional pain treatment in patients 
with cancer. The indications for the procedures, the evidence from 
the literature for these procedures and optimal time to perform a 
specific procedure are described. 
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Chapter 6 concerns opioid rotation in the management of situations 
in which the normal course of treatment with opioids in patients with 
pain due to cancer is not effective. This chapter describes the 
recommendations on how to perform opioid switching, the possible 
pitfalls and the established evidence. 
Chapter 7 presents a vignette-based case study evaluating how 
anesthesiologists/ pain specialists in the Netherlands follow the 
recommendations of the Dutch clinical practice guideline on the 
diagnosis and treatment of pain in patients with cancer in their daily 
practice. 
Chapter 8 contains the discussion of the research questions from the 
articles, which were presented in the previous chapters.   
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Abstract 
 
The development of new analgesic drugs and administration forms 
may offer new possibilities for the management of pain in patients 
with cancer. A multidisciplinary group of experts analyzed the 
available literature to elaborate an evidence-based answer to the 
predefined clinical questions. The participants were representatives 
of the different scientific societies involved in the management of 
patients with cancer, but also patient representatives were included in 
the development process. The use of interventional pain 
management techniques was already published. We discuss here the 
role of the different analgesics, including the adjuvant analgesics. 
Attention is also paid to the incidence of side effects of opioid 
treatment and the possible treatments. The quality of the evidence 
and the grade of the recommendation are defined according to a 
well-defined system. Were necessary comments and remarks are 
listed.  
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Introduction 
Introduction 
With increasing age, the incidence of cancer is increasing 1. Also, 
more people becoming older induces a relative and absolute rise in 
the number of people with cancer1. Pain is one of the most prevalent 
symptoms for patients with cancer 2. This pain strongly influences 
their quality of life that often turns to a burden that can be badly 
influenced.3 In patients with cancer, pain can be caused by a wide 
range of factors: directly by the tumor pressure itself, for instance as 
the tumor invades into organs or impinges upon nerves, or by 
functional disorders resulting from the tumor, such as occlusion of the 
intestines or bone fractures, or by general physical deterioration as a 
consequence of longstanding cancer, such as cachexia or pressure 
ulcers4. Cancer treatment itself can also have painful consequences, 
such as mucositis, dermatitis, direct nerve damage and 
polyneuropathy. The wide range of potential causes of pain and the 
progressive nature of cancer require a careful assessment and 
planning of the causal and pain treatment in relation to specific 
contextual and multidimensional situations. Pain is a 
multidimensional problem highly connected to complex 
pathophysiological processes resulting in somatic, psychological, 
social and existential dimensions of pain and suffering and requiring 
a mandatory stepwise involvement of a multidisciplinary assessment 
and mostly a multi- and interdisciplinary treatment advanced care 
plan.  
The publication of the World Health Organization (WHO) three-step 
ladder for pain management in patients with a terminal disease can 
be considered a historical turning point in the management of cancer 
pain. This simple guideline has the intention to stimulate physicians 
to adopt this guideline in all their patients with cancer and to improve 
the use the different analgesics in a step-wise manner avoiding 
unwanted side effects and relieving the pain experienced by their 
patients. 5 Consequently, the accurate use of strong opioids in the 
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third level of this ladder should be the key for successful treatment of 
pain in patients with cancer.  Recently, several developments in the 
knowledge of pain and its underlying mechanisms and recent 
advances in the pharmacologic opportunities, justified to revise 
structurally all literature published on pain in patients with cancer and 
to publish for the first time a multidisciplinary evidence based national 
guideline on the diagnosis and treatment of pain in patients with 
cancer in the Netherlands. This guideline was a collaborative initiative 
of the members of the Dutch scientific organizations involved in the 
treatment of patients with cancer and/or pain, the comprehensive 
Dutch Cancer Institute and the Dutch Health Care Institute.  
Methods:  
Composition of a multidisciplinary group of experts:  
From all scientific societies involved in the diagnosis and treatment of 
pain, one mandated expert who was especially interested in cancer 
pain was delegated to participate in the taskforce. A total of 25 
experts were delegated from 16 scientific societies (see addendum 1 
for the total list of workgroup members).  Special attention was given 
to the distribution of the geographical region of origin of the experts in 
order to cover the Netherlands completely.  An equal distribution 
between academic and non-academic working professionals, from 
medical and paramedical societies was observed. An additional 
criterion to be selected as an expert from a scientific society was that 
there were no relationships with the pharmaceutical or device 
companies. Additionally three external experts were selected for 
external continuous review and quality control (see addendum 1 – list 
of experts)  
This taskforce was supported by special trained methodological 
experts in evidence-based guidelines from the Dutch Health Care 
Institute and administratively supported by two scientific collaborators 
of the Dutch Comprehensive Cancer Institute. All experts had 
followed a training course on the evaluation and writing of evidence-
based guidelines.   
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For the first time in the history of the production of clinical evidence-
based guidelines an active participation and involvement of patients 
and patients’ organizations was established. These patients were 
specially trained and supported to meet their task of participating in 
all meetings and to communicate their opinion and expertise on all 
formulated recommendations expressed in this guideline. For special 
topics, focus groups were organized with additional patients’ groups 
who were selected by the National Federation of Cancer Patients. An 
expert nurse and a methodological expert guided each a focus group. 
On all occasions patients were asked to give their free opinion on the 
opportunities, possibilities and limitations of each recommendation 
and the whole taskforce and individual experts were asked to take 
these patients’ remarks into account. The chair of the taskforce paid 
during each meeting special attention to make sure that the remarks 
and advices of patients were correctly honored and resulted in 
comprehensive recommendations oriented on the daily clinical 
practice.  
Procedure:  
The guideline is a document with recommendations to support daily 
clinical practice. The guideline is the compilation of the results of 
scientific research and additional expert opinion directed towards the 
best clinical practice of that moment with available literature.  As a 
start of this guideline, a dedicated bottleneck analysis was performed 
in collaboration with the tumor working parties situated in each 
regional comprehensive cancer center throughout the Netherlands. 
On the basis of this analysis the special taskforce formulated clinical 
questions (see addendum 2- questions) describing the daily clinical 
practice around the diagnostic, therapeutic and care program for pain 
in patients with cancer. All experts were subdivided into project 
groups addressing specific questions and areas of pain diagnosis 
and treatment.  
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Literature search 
The Cochrane Library, Medline, Embase, Cinahl and Psychinfo were 
searched for relevant articles in English, German, French and Dutch. 
To define the study population the MESH (Medical Subject Heading 
“neoplasm” and the free text words “cancer”, “tumor”, “tumour”, 
“oncology”, “carcinoma”, and “malignancy” were used. The condition 
was searched with the free text word “pain” and the MESH terms 
“pain”, “pain-measurement”, “palliative-care”. This search was 
complemented with hand search of the reference lists of relevant 
articles.  
Selection criteria to withhold a publication were: high level of 
evidence e.g. meta-analyses, systematic reviews, randomized 
controlled trials (RCT’s) and controlled trials (CT’s) 
If none of this information was available for a given subject, 
comparative cohort studies, comparative patient control studies or 
non-comparative research was retrieved. In this publication only 
publications about the epidemiology and pharmacological treatment 
of pain in patients with cancer were represented. In other publications 
the interventional treatment and opioid rotation were already 
described6, 7  
The search covered the period 1989 until May 2006 and for some 
topics 1976 until March 2007. 
Evidence rating  
The recommendations received a level based on the quality of the 
available evidence. Studies were selected based on their 
methodological strength. Systematic reviews and meta-analysis are 
considered having the highest evidential strength.  Comparative 
cohort studies and comparative patients studies were considered 
level B. Additionally, study size, follow-up, adequate description of in- 
and exclusion criteria were considered and finally if the data are of 
importance for the Dutch Health Care system.   
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The experts of the taskforce evaluated the quality of all publications 
selected with the support of the evidence-based guideline 
development (EBGD) assessment forms. Consequently all studies 
that met basic quality criteria were graded to their strength of 
evidence described in table 1.  Subgroups of experts of the taskforce, 
evaluated literature, formulated recommendations in relation with the 
strength of evidence and proposed these for discussion within the 
taskforce. (Table 2)  In case of general agreement the 
recommendation was accepted for the concept report. If no 
agreement could be reached, the recommendations were further 
analyzed, explored and additional literature was searched for 
reformulation and again discussion within the complete taskforce. 
This procedure was repeated until full agreement was reached for all 
research questions and all recommendations were formulated 
together with their level of evidence. A total of 12 plenary taskforce 
meetings were held to complete the recommendations for the 21 
research questions. After the taskforce completed their 
recommendations and comments, the draft guideline was sent to all 
scientific and other relevant organizations to give their comments and 
additional external review and their final agreement to the draft 
guideline. After this process, finally, the draft guideline was presented 
during an open symposium to all professional and patient 
organizations for final open comments and remarks. Once all 
remarks were considered and dealt with, the final national evidence 
based guideline was sent to the Boards of the scientific organizations 
involved in the diagnosis and treatment of pain in the Netherlands for 
final approval. Formal approval was obtained in October 2008).     
Presentation of data in this publication: all relevant recommendations 
concerning the pharmacological treatment of pain in patients with 
cancer together with the level of evidence are summarized in the 
tables.  
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Table 1 Summary of the quality assessment  
A1 Systematic review of minimum two independently performed 
randomized controlled double blind trials 
A2 Randomized controlled double blind trial of good quality and size 
B  Comparative trial such as case-controlled trial or cohort research 
C Non-comparative trials 
D Expert opinion 
 
Table 2: Level of recommendations 
 Recommendation based on 
1 A1 level evidence or minimum 2 independently performed trials of A2 
level, with consistent outcome 
2 1 A2 level study or minimum 2 independently performed B level trials 
3 1 trial of level B or C 
4 Expert opinion 
 
Results:  
Epidemiology of pain in patients with cancer:  
Several reviews are published on this topic, however no systematic 
research was performed making a clear estimate on the exact 
prevalence of pain in patients with cancer impossible 8, 9. It was also 
impossible to give an indication on the factors influencing the 
prevalence, such as disease, tumor type, age and gender. A total of 
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160 articles were analyzed from the period 1966 until 2005. Of these 
54 were used for further analysis of which 45 articles researched 
prevalence of pain in patients with cancer as a primary target and 9 
as a secondary target. This analysis shows that the prevalence of 
pain in patients with cancer is high: 33% of the patients after their 
curative treatment, 59% of the patients during their treatment and 
64% of the patients with advanced cancer disease suffer pain. Since 
the number of patients with cancer is increasing, it is expected that, 
even with a constant incidence of pain in patients with cancer, the 
problem of pain in patients with cancer will follow the increase of the 
prevalence of cancer.10-14   
The main merit of the well-known WHO ladder for the treatment of 
pain in cancer patients is that it offers physicians support in deciding 
to use stronger agents, especially in patients with cancer. 5 
In addition to this stepwise increase in the potency of medication, the 
WHO provides some further basic principles. It recommends 
administering analgesics ‘by the clock’, i.e. at regular moments, 
based on their pharmacologic characteristics. This dosing scheme 
should result in a constant level of analgesia and prevent 
breakthrough pain. The dosage needed to achieve satisfactory pain 
relief is usually lower if the analgesic is administered by the clock 
than if it is administered based on the patient’s complaints. The 
preferred method of administration is oral or transdermal, in view of 
their flexibility and simplicity.15 
Non-opioids 
Paracetamol/acetaminophen 
WHO step 1 medication, paracetamol (acetaminophen), aspirin and 
non-steroidal anti-inflammatory drugs (NSAIDs), is recommended for 
the treatment of moderate pain. Paracetamol is preferred as it is well 
tolerated. The evidence for its effectiveness in patients with cancer is 
limited and relies on an older study comparing the effect of 
paracetamol (650 mg), butorfanol (4mg) and placebo during 6 hrs. 
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after a single administration. 16 The feedback of the patient a few 
days after the start of treatment should be used as guide for the 
efficacy.  
In patients whose pain due to cancer is stabilized with strong opioids 
(morphine or hydromorphone) addition of paracetamol showed no 
additional effect in one study.17 In another study, however, the 
patients reported better pain control and increased feeling of well-
being.18 Table 3 summarizes the conclusions, level of evidence and 
recommendations for the use of paracetamol for pain in patients with 
cancer 
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Table 3: Conclusions, levels of evidence and recommendations for 
the use of paracetamol for pain in patients with cancer 
Conclusion LoE LoR Refs Recommen-
dations 
Remarks 
The workgroup 
believes that 
paracetamol can 
be effective as a 
first step in the 
management of 
moderate pain in 
patients with pain 
due to cancer. 
 
 
 
D 
 
 
 
4 
 
 
 
17 
 18 
Paracetamol as 
monotherapy can be 
the first step in the 
treatment of 
moderate pain in 
patients with cancer.  
If this provides 
insufficient pain 
relief opioid 
treatment can be 
initiated. 
In consensus with 
the patient the 
combination opioid 
and paracetamol 
may be continued. 
The benefit of pain 
relief by 
paracetamol should 
be weighted against 
the burden of the 
extra medication 
intake. 
Combining opioids 
with paracetamol 
has the objective 
to improve pain 
control and induce 
an opioid sparing 
effect.  
It is impossible to 
conclude 
regarding the 
continuation or 
addition of 
paracetamol to the 
treatment of pain 
in patients with 
cancer who are 
under a stable 
dose of opioids. 
     
LoE= Level of Evidence; LoR = Level of Recommendation, Refs= references 
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Non-steroidal anti-inflammatory drugs (NSAIDs) 
Paracetamol may be combined with NSAIDs if the optimum dosage 
of the former fails to sufficiently control the pain. In view of the 
mechanism of action of NSAIDs, these are primarily indicated for the 
treatment of pain associated with inflammation. There is no research 
comparing the combination paracetamol and NSAID with 
paracetamol alone.  
The available studies limit the research to the effect of non-selective 
NSAIDs and a large part of the studies have investigated only the 
effect of a single dose. The comparisons between NSAIDs show a 
difference in efficacy and in incidence of side effects.19 Treatment 
with NSAIDs should be limited in time, because of their potential 
adverse effects (e.g. gastro intestinal problems). 
Although COX2-selective NSAIDs are recommended because of the 
improved gastro-intestinal tolerance, there is no clear evidence that 
patients with cancer also tolerate these agents better. 19 Table 4 
summarizes the conclusions, levels of evidence and 
recommendations for the use of non-steroidal anti-inflammatory 
drugs for pain in patients with cancer.  
Strong opioids   
If the WHO step 1 analgesics, whether or not combined with adjuvant 
analgesics, do not provide sufficient pain relief, the usual 
recommendation is to progress to step 2, the group including the so-
called weak opioids, such as codeine and tramadol. Research among 
patients with cancer has shown, however, that switching over 
immediately to strong opioids (WHO step 3 agents), the most familiar 
of which is morphine, leads to faster pain relief and fewer dosage 
adjustments.61, 62 It would therefore appear logical to switch these 
patients straight to step 3 and use strong opioids if treatment with 
WHO step 1 agents proves inadequate. One should remember, 
however, that this option should be thoroughly discussed with the 
patients, since laws in some countries ban users of strong opioids 
from driving a car.  
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Table 4: Conclusions, Levels of evidence and recommendations for 
the use of non-steroidal anti-inflammatory drugs for pain in patients 
with cancer 
Conclusion LoE LoR Refs Recommen-
dations 
Remarks 
It is considered that 
one single 
administration of a 
non-selective NSAID 
is more effective 
than one single 
administration of 
placebo for the 
treatment of pain in 
patients with cancer 
 
 
B 
 
 
2 
 
 
20-33 
The use of non-
selective 
NSAID’s alone 
or in 
combination with 
paracetamol 
and/or opioids, 
must be 
considered for 
the treatment of 
moderate to 
severe pain in 
patients with 
cancer when 
optimal doses of 
paracetamol and 
opioids do not 
provide 
satisfactory pain 
relief. The risks 
(gastrointestinal 
damage) should 
be balanced with 
the potential 
benefits for each 
individual 
patient. 
Although the study 
methodology is not 
ideal, based on the 
clinical experience the 
workgroup considers 
that there is a place 
for NSAIDs’ in the 
treatment of pain in 
patients with cancer. 
The assumption that 
NSAIDs are effective 
in the management of 
inflammatory pain and 
bone pain could not be 
supported by the 
literature. 
Because there is no 
proof of efficacy of the 
selective COX-2 
inhibitors in the 
management of pain 
in patients with cancer 
and the more frequent 
occurrence of 
cardiovascular 
complications with 
these products, their 
use cannot be 
supported in this 
population.  
There are no 
indications of efficacy 
and side effects to 
express a preference 
for specific non-
selective NSAIDs 
 
It is considered that 
there are no 
consistent 
differences in 
efficacy and side 
effects between the 
non-selective 
NSAID’s in the 
treatment of pain in 
patients with cancer  
 
 
 
B 
 
 
 
2 
 
 
 
32 
34-50 
It is impossible to 
make a statement 
about the 
differences in 
efficacy and side 
effects of NSAID’s in 
comparison with 
opioids in the 
treatment of pain in 
patients with cancer 
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Table 4: cont.       
It is considered that a 
combination of a non-
selective NSAID with 
an opioid for a short 
period (<10 days) 
results in a better pain 
control, lower doses of 
opioids and/or less 
side effects than a 
treatment with an 
NSAID or an opioid 
alone for the treatment 
of pain in patients with 
cancer 
 
 
 
 
 
 
 
B 
 
 
 
 
 
 
 
2 
 
 
 
 
 
 
 
26, 
50-
60 
 
The risks 
(gastrointestinal 
damage, renal failure 
and prolonged bleeding 
time) should be 
assessed for the 
individual patient. When 
the use of NSAIDs is 
considered in patients 
with risk factors 
gastrointestinal 
protective measures 
should be taken. 
 
 
In addition to morphine, the group of strong opioids includes 
hydromorphone, oxycodone, buprenorphine, fentanyl and 
methadone. All of these are agonists of opioid receptors, especially 
the µ-opioid receptor, and as such have a strong analgesic effect and 
have similar side effects. Nevertheless, there are certain differences 
in the potency and specificity of their agonistic effects, which means 
that each has its own place in cancer pain relief. In addition, 
individual patients may differ greatly in their sensitivity to the various 
opioids, in terms of both pain relief and the risk of adverse effects, 
possibly due to differences in genetically determined receptor affinity. 
Optimum treatment with strong opioids is based on the administration 
at regular moments of slow-release agents (which have a longer 
lasting effect, usually 12 hours) and an immediate-release agent, the 
latter intended primarily to treat breakthrough pain.  
Treatment with strong opioids should start with the lowest possible 
dosage, especially for opioid-naive patients. Table 5 summarizes the 
pharmacokinetic characteristics of the main strong opioids  
Treatment may start with immediate release opioids, and switch to 
slow-release preparations, based on the conversion table, after 
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reasonable pain relief has been achieved. Another option is to start 
immediately with a low dose of slow-release opioids, combined with 
immediate-release opioids. While pain relief is achieved just as soon 
in both titration schemes, research has found that significantly less 
fatigue was reported when slow-release morphine was started 
immediately. 65 
Table 5: Pharmacokinetic characteristics of the main strong opioids  
Duration of action of various preparations 
Preparation Effect after         Max Effect Duration of action 
Morphine IR 
Hydromorphone IR 
Morphine unit dose vial/syrup 
30’                      40-60’ 
41’                      60-90’ 
10-15’                 45 
4 h 
4 h 
4 h  
Morphine SR 
Hydromorphone SR 
Oxycodone 
45-60’                 3.5 u 
45-60’                 1.5u 
45-60’ 
 8-12 h  
 8-12 h 
 8-12 h 
Morphine IM 5-10’                  25-40’  1-2 h 
Morphine IV 2-5’                      20’ 1 h 
Buprenorphine transdermal 12-14 h  48-72 h 
Fentanyl transdermal 12 h 48-72 h 
Based on information from the Dutch Farmaceutisch Kompas and Compendium. IR= immediate 
release, SR = slow release.62, 63 
The effects of opioid treatment can be assessed after the maximum 
serum concentration has been reached. The time between the first 
drug administration and the achievement of the maximum 
concentration depends on: the route of administration (very fast after 
intravenous administration, reasonably fast after transmucosal, 
subcutaneous or intramuscular administration and slowest after oral 
or transcutaneous administration), the formulation (immediate or slow 
release) and the specific pharmacologic characteristics of the agent. 
If the medication is being used in chronic pain management with a 
dosing interval of less than 3-4 times the half-life, its effect can be 
assessed when the stable situation has been reached, which is after 
4-5 times the half-life of the opioid and its active metabolite(s). Serum 
concentrations of slow-release agents and transcutaneously 
administered agents are determined by the formulation rather than by 
the specific characteristics of the agent. If the effect is insufficient, 
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increasing the opioid dosage is preferred over reducing the 
administration interval. The dosage should be increased by 25-50% 
in case of moderate pain, and by 50-100% in case of severe pain.  
The rate of dosage increase is partly determined by the need for 
breakthrough medication. This always involves an agent with a short 
half-life and an immediate-release formulation, in order to facilitate 
titration. In most cases of breakthrough pain, it is sufficient to 
administer 1/6 of the prescribed daily dose at 3-hour intervals.   
The conclusions, levels of evidence and recommendations 
concerning opioid rotation or opioid switch were published in 2010. 66 
Table 6 summarizes the evidence and recommendations for strong 
opiods. 
Methadone  
Methadone is a special opioid as it is an agonist of both the µ and δ 
opioid receptors. At the same time, it is also an NMDA (N-methyl-D-
aspartate) antagonist and a strong serotonin and norepinephrine re-
uptake inhibitor. On the other hand, the product has a non-linear 
pharmacokinetic profile, with large inter-individual differences.  
A comparative study of methadone and morphine, lasting 28 days, 
found no difference in pain reduction or side effects between the 
two.67  
Since methadone is rather difficult to use, because of its difficult 
pharmacokinetic profile, this product should be considered for use in 
opioid rotation schemes and not as a first choice opioid. Due to its 
specific effect on NMDA receptors, methadone is also used to treat 
uncontrolled neuropathic pain. Methadone does, however, have a 
biphasic effect as a result of redistribution, making the product more 
difficult to handle during the start-up phase. In addition, it has a very 
long half-life, which may cause intoxication in case of chronic 
administration. In very specific circumstances, methadone can 
represent a valuable addition to pain relief treatment for patients with 
cancer, provided the patient can be closely supervised by an 
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experienced physician of the pain treatment team or palliative 
consultation team.  
Table 6: Conclusions, levels of evidence and recommendations 
regarding the use of opioids in the management of pain in patients 
with cancer 
Conclusion LoE LoR Refs Recommendations Remarks 
There are indications 
that strong opioids 
reduce pain in patients 
with cancer 
 
 
C 
 
 
3 
 
 
68-
73 
The strong opioids 
(morphine, fentanyl, 
oxycodone or 
hydromorphone) are 
the preferred 
analgesics for the 
management of 
moderate to severe 
pain in patients with 
cancer.  
 
Even in absence of 
placebo-controlled trials, 
the clinical experience 
clearly shows the efficacy 
of opioids in the 
management of pain in 
patients with cancer.   
There is no indication to 
express a preference for a 
given opioid. 
It is demonstrated that 
oral administration of 
morphine, oxycodone 
and hydromorphone 
slow release 
preparations and 
immediate release 
preparations have a 
comparable effect on 
the pain of patients 
with cancer 
 
 
A 
 
 
1 
 
 
71, 
73-
76 
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Table 6: cont.      
It is demonstrated that 
administration form, 
dosing units and 
dosing interval of slow 
release morphine have 
no influence on the 
efficacy of pain relief in 
patients with cancer 
 
A 
 
1 
 
73, 
77-
79 
Methadone should 
only be prescribed by 
physicians who have 
experience with this 
drug. 
 
The 1-2 daily 
administration of 
morphine, oxycodone or 
hydromorphone in slow 
release preparation have 
considerable practical 
advantages for the patient 
compared with the 
immediate release 
preparations that require 
4-6x daily administration 
It is demonstrated that 
transdermal fentanyl is 
equally effective as 
slow release morphine 
in the management of 
pain in patients with 
cancer.  
 
 
A 
 
 
1 
 
 
68, 
80, 
81 
The combination of 
these drugs as 
maintenance therapy 
is not recommended.  
 
Arguments in favor of 
morphine are the long 
standing experience and 
the favorable price. The 
transdermal administration 
and the reduced risk of 
constipation and 
drowsiness are arguments 
in favor of fentanyl. 
It is demonstrated that 
the side effects: 
constipation and 
drowsiness occur less 
often with fentanyl 
compared to 
morphine. 
 
A 
 
1 
 
68, 
81 
If oral opioids are 
chosen for the 
treatment of 
background pain in 
patients with cancer, 
slow release opioids 
should be prescribed 
(morphine, oxycodone 
of hydromorphone  
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Table 6: cont.      
It is demonstrated that 
oxycodone slow release 
is equally effective as 
morphine in the pain 
treatment in patient with 
cancer 
 
 
A 
 
 
1 
 
 
72 
  
It is considered that 
oxycodone is equally 
effective as 
hydromorphone in the 
pain treatment of 
patients with cancer 
 
 
A2 
 
 
2 
 
 
78 
It is demonstrated that 
hydromorphone is 
equally effective as 
morphine in the pain 
treatment of patients 
with cancer 
 
 
A 
 
 
1 
 
 
71 
It is demonstrated that 
methadone is equally 
effective as morphine for 
the pain treatment of 
patients with cancer 
 
 
A 
 
 
1 
 
 
67, 
70 
 
 
It is considered that 
transdermal 
buprenorphine is 
effective in pain 
treatment of patients 
with cancer 
 
 
B 
C 
 
 
2 
 
 
82- 
85 
It is the experts’ opinion 
that for the 
pharmacological 
treatment of pain in 
patients with cancer the 
oral and transdermal 
administration routes 
have benefits over other 
administration routes 
 
 
D 
 
 
4 
 
 
86-
89 
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Table 6: cont.      
It is considered that 
rectal morphine slow 
release administration is 
equally effective as oral 
administration for the 
pain treatment of 
patients with cancer 
 
B 
 
2 
 
90, 
91 
 
 
There are indications 
that optimal dose 
titration of the opioids 
improves pain in 
patients with cancer 
usually within 24 hours 
 
C 
 
3 
 
92 
 
 
It is considered that 
parenteral opioid 
administration provides 
more rapid pain control 
than oral administration 
 
A2 
 
2 
 
93 
 
It is considered that 
dose titration with 
immediate release 
morphine not leads to 
faster pain control in 
patients with cancer 
than dose titration with 
slow release morphine 
 
A 
 
2 
 
75 
 
It is the experts’ opinion 
that fast and optimal 
dose titration is 
dependent on the effect 
of opioids, the 
occurrence of side 
effects and the need for 
breakthrough medication 
 
D 
 
4 
 
86- 
89 
 
There are indications 
that the use of opioids in 
patients with cancer and 
pain does not induce 
addiction 
 
C 
 
3 
 
94- 
96 
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Breakthrough medication  
Three forms of breakthrough pain are distinguished: 
• Incident pain, occurring as a consequence of a specific event, 
such as a movement or nursing activity. 
• Non-incident or spontaneous pain, not related to any specific 
activities. 
• End-of-dose pain due to inadequate dosage of analgesics or 
a dosing interval that is too long.  
Although most guidelines do not distinguish between the types of 
breakthrough pain and their treatment, clear information about the 
type of breakthrough pain can help determine the required 
therapeutic intervention.  
Incident pain is treated with an immediate-release opioid. The 
recommended dosage for the breakthrough medication is 1/6 of the 
daily dose for the maintenance therapy. This medication should be 
administered as soon as possible after the incident pain occurs. If the 
occurrence of incident pain is predictable (for instance with nursing 
interventions), the breakthrough medication should be given 
prophylactically.  
In case of spontaneous pain, it is recommended to detect the 
underlying cause and if possible initiate specific treatment for this 
cause (possibly by means of adjuvant analgesics). 
End-of-dose pain should be addressed by reviewing the dosage 
scheme of the maintenance therapy. Table 7 summarizes the 
conclusions, levels of evidence and recommendations for the use of 
rapid onset opioids in breakthrough pain in patients with cancer. 
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Table 7: Conclusions, levels of evidence and recommendations for 
the use of rapid onset opioids in breakthrough pain in patients with 
cancer  
Conclusion LoE LoR Refs Recommen-
dations 
Remarks 
It is considered that 
oromucosal fentanyl 
citrate is more 
effective than 
placebo for the 
treatment of 
breakthrough pain in 
patients with cancer 
 
 
A2 
 
 
2 
 
 
97 
Oromucosal 
fentanyl (OTFC) 
may be used for 
the treatment of 
breakthrough 
pain in patients 
with cancer, 
regardless of the 
type of opioid 
that is used for 
the maintenance 
treatment. 
The starting 
dose of OTFC 
as rescue 
medication is 
400 µg (200 µg 
when the daily 
morphine dose 
is < 40 mg). 
The dose of the 
other short 
acting opioids 
(morphine, 
oxycodone or 
hydromorphone) 
is 1/6 of the daily 
dose; this dose 
can be adapted 
based on the 
pain reducing 
effect and the 
side effects.pain. 
OTFC may be used 
for the treatment of 
breakthrough pain in 
combination with all 
the opioids used for 
the maintenance 
treatment. There are 
advantages in using 
the same opioid for 
the maintenance 
and breakthrough 
therapy  
The choice of a 
product for the 
management of 
breakthrough pain 
can be based on the 
speed and duration 
of action. OTFC is 
preferred if rapid 
action is required, 
when a longer 
lasting effect is 
necessary another 
short acting opioid 
may be used.In 
practice the 
breakthrough 
medication may be 
used on fixed times, 
without the 
necessity to prevent 
predictable 
breakthrough pain. 
This is a 
maintenance 
treatment. 
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Table 7: cont      
It is considered that 
oromucosal fentanyl 
citrate is more 
effective than short 
acting morphine for 
the treatment of 
breakthrough pain in 
patients with cancer 
 
 
 
A 
B 
 
 
 
2 
 
 
 
98, 
99 
  
There are 
indications that there 
is no quantitative 
relation between the 
dose oromucosal 
fentanyl citrate 
required for the 
treatment of 
breakthrough pain in 
patients with cancer 
and the daily dose of 
opioid required for 
the maintenance 
treatment 
 
 
 
 
C 
 
 
 
 
3 
 
 
 
 
100, 
101 
The medication 
for breakthrough 
pain may only 
be used in case 
of breakthrough 
pain or in order 
to prevent 
predictable 
breakthrough 
pain 
 
There are 
indications that there 
is no quantitative 
relation between the 
dose of a short 
acting opioid needed 
for the treatment of 
breakthrough pain in 
patients with cancer 
and the daily dose of 
an opioid needed for 
the maintenance 
treatment 
 
 
 
 
 
 
C 
 
 
 
 
 
 
3 
 
 
 
 
 
 
98 
 
Analgesic medication dosage for patients with renal 
failure  
In theory, not only kidney disorders but also liver disorders affect the 
clearance rate of pain relief medication. In practice, however, liver 
function disorders are difficult to assess. In addition, the liver 
possesses a large functional reserve, which means that the risk of 
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overdose of the pain relief medication metabolized by the liver only 
arises in case of very severe liver disorders. 
Renal function disorders are common among patients with cancer, 
and often result from cancer treatment. They can be caused by 
discharge problems or be related to comorbidity. Cancer treatment 
may aggravate existing renal function problems, temporarily or 
permanently, either through tumor lysis or as a result of 
nephrotoxicity of the chemotherapy or other medication. In the 
terminal stages, renal function disorder may also result from 
dehydration. 
A recent critical review study evaluated common medications from 
the WHO analgesic ladder in terms of pharmacokinetics, data on the 
effects of kidney disorders and potential nephrotoxicity. 14  
Patients with renal function disorder who are being treated with step 
1 medication should use specially adjusted dosages of 
paracetamol.19 The use of NSAIDs for patients with renal function 
disorders can cause their kidney function to deteriorate. Of the step 2 
agents, the preferred option is tramadol in specially adjusted dosage.  
The active metabolites of morphine may accumulate in patients with 
a creatinine clearance < 50 ml/min. If a patient needs medication of 
step 3, fentanyl and methadone can be used in normal dosages. The 
dosage of hydromorphone only needs to be adjusted for patients with 
severe kidney function disorders.  
Side effects and their treatment 
Since the most common side effect of treatment with opioids is 
constipation, a laxative should always be prescribed when a patient 
starts opioid treatment. The preferred option is an osmotic laxative 
(such as macrogol/electrolytes, magnesium (hydr)oxide or lactulose). 
Patients with existing constipation may combine these agents with a 
contact laxative. Recently developed treatment options target the 
inhibitory action of opiates as they bind to morphine receptors in the 
intestinal wall. Morphine antagonists like naloxone can be 
administered orally, because they are active in the intestine but are 
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removed by the first-pass effect in the liver to such an extent that no 
systemic withdrawal of morphine occurs. Methylnaltrexone does not 
cross the blood-brain barrier and can be used parenterally to directly 
counteract the paralyzing effect of morphine on the intestine.102, 103  
 The conclusions, levels of evidence and recommendation for the 
treatment of opioid induced constipation during the treatment of pain 
in patients with cancer are summarized in table 8. 
Nausea and vomiting due to opioid therapy are preferably treated 
with metoclopramide (central and peripheral effects), haloperidol 
(central effect) or domperidone (central and peripheral effects). 
Metoclopramide and domperidone are prokinetic agents and 
dopamine antagonists, which means that they influence not only the 
emetic effect of opioids by inhibiting stomach voiding, but also the 
stimulation of the chemoreceptor trigger zone. Haloperidol (which is 
only a dopamine antagonist) is an alternative option, while combining 
it with metoclopramide is not a rational choice, as they both have the 
same mechanism of action. Ondansetron may be an alternative 
option, but because of the frequently occurrence of constipation it 
must not be used continuously.107 If a patient has previously 
experienced severe nausea due to opioids, anti-emetics should be 
started prophylactically, and the opioid dosage should be gradually 
increased.105 Opioids are likely to produce anticipatory nausea and 
may lead to vomiting due to a subconscious “Pavlov” reflex. Since 
such nausea is very hard to alleviate, it is very important to take 
opioid-induced nausea seriously and treat it effectively. 
Table 9 summarizes the conclusions, levels of evidence and 
recommendations for the use of drugs in the treatment of opioid 
induced nausea and vomiting in patients with cancer 
. 
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Table 8: Conclusions, levels of evidence and recommendation for the 
treatment of opioid induced constipation during the treatment of pain 
in patients with cancer 
Conclusion LoE LoR Refs Recommen-
dations 
Remarks 
There are indications 
that 
macrogol/electrolytes, 
lactulose, senna and 
naloxone are 
effective for the 
treatment of 
constipation as a 
consequence of 
opioid use 
 
C 
 
3 
 
104-
106 
An opioid 
treatment for pain 
in patients with 
cancer should 
always be 
accompanied by 
the prescription of 
laxatives. 
An osmotic 
laxative 
(macrogol/electrol
ytes, magnesium 
(hydr)oxide or 
lactulose) is 
preferred for the 
treatment of opioid 
induced 
constipation. This 
can be combined 
with contact 
laxatives (senna or 
bisacodyl) if 
necessary.  
 
There is only 
limited literature 
concerning opioid 
induced 
constipation. 
Several laxatives 
have been tested 
and are generally 
active. The 
working 
mechanism of 
opioid antagonists 
makes these 
products a 
suitable choice 
although there is 
up till now little 
documentation. 
It is demonstrated 
that transdermal 
fentanyl causes less 
constipation than 
morphine 
 
A1 
 
1 
 
68 
For patients with 
chronic morphine 
induced 
constipation opioid 
rotation for 
transdermal 
fentanyl is 
recommended.  
The laxative 
treatment should 
be continued. 
 
Chapter 2 
 47 
Table 9: Conclusions, levels of evidence and recommendations for 
the use of drugs in the treatment of opioid induced nausea and 
vomiting in patients with cancer 
Conclusion LoE LoR Refs Recommen-
dations 
Remarks 
There are indications 
that cyclizine, 
scopolamine, 
ondansetron, 
prochlorperazine and 
droperidol are 
effective for the 
management of 
nausea and vomiting 
induced by opioids 
 
C 
 
3 
 
105 
Metoclopramide or 
domperidone are, 
based on the 
mode of action the 
first choice 
treatment for 
opioid induced 
nausea and 
vomiting 
Alternatively 
haloperidol and 
ondansetron can 
be considered.  
There is no proof in 
the literature to 
support 
recommendations 
on the best anti-
emetic for patients 
treated with opioids. 
Opioid induced 
nausea is caused by 
an inhibition of 
stomach emptying 
and/or stimulation of 
the chemo trigger 
zone, therefore 
metoclopramide and 
domperidone, that 
are both prokinetics 
and dopamine 
antagonists, are the 
first choice. 
Haloperidol (a 
dopamine-
antagonist)  may be 
an alternative. A 
combination with 
metoclopramide 
increases the risk of 
extrapyramidal side 
effects, because of 
the similar mode of 
action. Ondansetron 
(a serotonin-
antagonist) is 
another alternative, 
but the constipation 
that occurs 
frequently is an 
obstacle. 
There are indications 
that opioid rotation 
reduces nausea and 
vomiting 
 
C 
 
3 
 
104, 
108 
There are indications 
that the subcutaneous 
morphine 
administration reduces 
nausea and vomiting 
 
C 
 
3 
 
109, 
110 
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Central nervous system side effects like sedation and hallucinations 
can be reduced by opioid rotation. A study of transdermal fentanyl 
has shown that this induced satisfactory pain relief with fewer side 
effects than oral opioids. 109 Opioids can cause delirium in older 
and/or terminal patients. A common error is to interpret the resulting 
agitation as pain and increase the opioid dosage. The primary 
treatment option should be non-medicinal management, focusing on 
communicative and nursing aspects. Patients should receive enough 
fluids and suitable nutrition, and their safety should be ensured.111 
The drug of first choice for pharmacologic treatment is haloperidol, 
while opioid rotation may also be considered.  
Not spontaneous disappearing sedation can be treated by 
methylphenidate or modafinil.104,112-114 The conclusions, levels of 
evidence and recommendations on opioid induced sedation in 
patients with cancer are summarized in table 10. 
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Table 10: Conclusions, levels of evidence and recommendations on 
opioid induced sedation in patients with cancer  
Conclusion LoE LoR Refs Recommen-
dations 
Remarks 
There are indications that 
opioid induced sedation 
can be reduced by 
methylphenidate 
 
C 
 
3 
 
104, 
112, 
115 
Drowsiness in 
patients with 
cancer treated 
with opioids 
usually 
disappears 
spontaneously 
within a few 
days. In patients 
with persistent 
drowsiness 
opioid rotation to 
fentanyl is 
recommended.  
In patients with 
persistent 
sedation due to 
opioids, 
methylphenidate 
or modafinil can 
be prescribed 
 
There are indications that 
opioid induced sedation 
can be reduced by 
modafinil 
 
 
C 
 
 
3 
 
 
113, 
114 
It is demonstrated that 
transdermal fentanyl 
causes less drowsiness/ 
sedation than oral 
morphine 
 
 
A 
 
 
1 
 
 
68 
There are indications that 
opioid rotation from 
morphine to methadone 
causes less drowsiness/ 
sedation 
 
 
C 
 
 
3 
 
 
104 
There are indications that 
changing from oral to 
subcutaneous morphine 
causes less drowsiness/ 
sedation 
 
 
C 
 
 
3 
 
 
109 
It is the experts’ opinion 
that non-pharmacological 
treatment is effective for 
the treatment of opioid 
induced delirium 
 
 
D 
 
 
4 
 
It is the experts’ opinion 
that haloperidol is effective 
for the treatment of opioid 
induced delirium 
 
 
D 
 
 
4 
 
There are indications that 
the symptoms of delirium 
are reduced by opioid 
rotation 
 
 
C 
 
 
3 
 
104, 
116, 
117 
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Myoclonias are sudden involuntary muscle contractions associated 
with high doses of opioids. Persistent myoclonias after reduction of 
the opioid dosage can be treated by the use of clonazepam, 
diazepam, midazolam, dantrolene, baclofen or valproic acid . There is 
some evidence that opioid rotation may be effective in treating opioid-
induced myoclonus. 21  
Pruritus is a problem in about 13 to 15% of patients being treated 
with opioids, especially with spinal administration. The only available 
research findings relate to pruritus resulting from perioperative 
spinally administered opioids, for which ondansetron, naloxone and 
methylnaltrexon proved effective. Table 11 summarizes the 
conclusions, levels of evidence and recommendation for the 
treatment of opioid induced myoclonias in patients with cancer.  
Respiratory depression is a well-known effect of high doses of 
opioids, especially among elderly patients in the acute postoperative 
stage. Although chronic opioid use usually results in patients 
becoming tolerant of this effect, the respiratory rate of such patients 
should be checked. Respiratory function should be observed. In case 
of severe respiratory depression, the use of naloxone may be 
considered.  
Hyperalgesia due to opioid use 
Some animal experiments have clearly shown that higher dosages of 
opioids cause hyperalgesia, a phenomenon, which can be reduced 
by reducing the dosage or terminating opioid administration. There 
are also literature reports on hyperalgesia as a result of morphine use 
in humans. 127 
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Table 11: Conclusions, levels of evidence and recommendation for 
the treatment of opioid induced myoclonias in patients with cancer   
Conclusion LoE LoR Refs Recommen-
dations 
Remarks 
It is the experts’ 
opinion that 
clonazepam, 
diazepam, 
midazolam, 
dantrolene, baclofen 
and valproic acid 
may have an effect 
in the treatment of 
opioid induced 
myoclonias in 
patients with cancer 
 
D 
 
4 
 
104, 
105 
Myoclonia due 
to high doses 
opioid is 
preferentially 
treated by 
reducing the 
dose or opioid 
rotation. 
Symptomatic 
treatment can 
be done with 
clonazepam , 
a muscle 
relaxant 
 
There are 
indications that 
opioid rotation is 
effective for the 
management of 
myoclonias in 
patients with cancer 
 
C 
 
3 
 
104, 
118, 
119 
 
It is demonstrated 
that ondansetron 
reduces the pruritus 
induced by spinal 
administration of 
opioids in post 
operative patients 
 
A 
 
1 
 
120-
124 
For the 
treatment of 
pruritus 
induced by 
opioids 
ondansetron is 
the first choice 
treatment  
The effect of ondansetron 
is predominantly 
demonstrated for the 
treatment of pruritus 
caused by postoperative 
spinal morphine 
administration. It can be 
assumed that it can also 
be used in other 
conditions of pruritus 
caused by spinal morphine 
administration, or by the 
oral administration of 
morphine or other opioids. 
The use of naloxone is not 
recommended because of 
its central activity and the 
risk of antagonizing the 
analgesic effect and 
inducing severance of 
symptoms. 
It is demonstrated 
that naloxone 
reduces pruritus in 
postoperative 
patients with opioid 
induced pruritus 
 
A 
 
1 
 
125, 
126 
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The role of adjuvant analgesics  
Adjuvant analgesics, also known as co-analgesics, have been 
described as the agents of first choice for the treatment of 
neuropathic pain. These agents mainly include the tricyclic 
antidepressants (TCAs) like amitriptyline, and anti-epileptics 
like gabapentin and pregabalin. A recently published 
comprehensive literature review discusses in depth the 
potential causes of neuropathic pain in patients with cancer and 
the treatment selection.128 We summarize here the most 
important issues. In view of their side-effects, the TCAs are 
often less suitable for patients with cancer, especially if a 
patient has a cardiac problem, a tendency toward urine 
retention, closed angle glaucoma, or cognitive disorders. 
Although there has been little research into the effectiveness of 
TCAs in treating neuropathic pain due to cancer, extrapolation 
of available data on the treatment of neuropathic pain suggests 
that these agents may be effective.129  
The effectiveness of gabapentin in the treatment of neuropathic 
pain in cancer patients has been assessed in a number of 
studies.130-133 This agent is to be preferred as it is better 
tolerated than TCA’s. Pregabalin has not yet been evaluated for 
the treatment of pain due to cancer, but as the mechanism of 
action of this product is similar to that of gabapentin, and in 
view of its proven effectiveness in treating neuropathic pain in 
non-cancer patients, it is reasonable to assume that it will also 
be effective in the treatment of cancer patients. 129  
The role of treatment with local anesthetics and capsaicin 
appears to be limited to the local treatment of predominantly 
post surgical pain  
The effectiveness of the NMDA (N-methyl-D-aspartate) 
receptor antagonist ketamine has been shown in uncontrolled 
studies among cancer patients suffering from neuropathic pain, 
although comparative research has failed to confirm these 
findings. 134  
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S-ketamine is the active stereoisomer of ketamine. S-ketamine 
is a powerful NMDA receptor antagonist, which can also 
enhance opioid-induced analgesia.135-137 Side effects, which 
occur especially with higher dosages, include psychotomimetic 
effects (hallucinations and delirium), nausea, dizziness, 
drowsiness and a dry mouth. S-ketamine may be combined 
with morphine and haloperidol in the same cassette. S-
ketamine is usually administered subcutaneously or 
intravenously, but may also be taken orally. 
The analgesic effect of selective serotonin reuptake inhibitor 
(SSRI) antidepressants is substantially inferior to that of the 
TCAs138, although controlled studies did find SSRIs to be more 
effective than placebo. 139 In any case, the antidepressant 
action of these agents may be useful as it may have a favorable 
effect on some patients by controlling underlying depression. 
The  conclusions, levels of evidence and recommendations for 
the use of adjuvant drugs for the treatment of neuropathic pain 
in patients with cancer are summarized in table 12. 
Table 12: Conclusions, levels of evidence and 
recommendations for the use of adjuvant drugs for the 
treatment of neuropathic pain in patients with cancer  
Conclusion LoE LoR Refs Recommen-
dations 
Remarks 
It is the experts’ 
opinion that tricyclic 
antidepressants 
may be effective in 
management of 
neuropathic pain in 
patients with cancer  
 
D 
 
4 
 Gabapentin or 
pregabalin and 
tricyclic 
antidepressant
s are the first 
choice 
treatments for 
neuropathic 
pain in 
patients with 
cancer. 
In absence of 
comparative trials it is 
not possible to provide 
an evidence-based 
preference for one of 
those drugs.  
It is considered that 
gabapentin 
effectively reduces 
neuropathic pain in 
patients with cancer 
 
A 
C 
 
2 
 
130-
133 
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Table 12: cont     
It is the experts’ 
opinion that 
pregabalin may be 
effective in 
management of 
neuropathic pain in 
patients with cancer 
 
 
 
 
D 
 
 
 
 
4 
 
Tricyclic 
antidepressants 
cannot be used for 
patients with or a 
risk for, cardiac 
problems, 
tendency for 
urinary retention, 
narrow angle 
glaucoma and 
cognitive 
disorders.  
The efficacy of 
gabapentin in 
patients with cancer 
and neuropathic 
pain and the side 
effect profile, 
gabapentin and 
pregabalin are 
preferred over the 
“classic” 
antiepileptics such 
as carbamazepine 
and phenytoin. 
It is the experts’ 
opinion that other 
anti-epileptic drugs 
such as 
carbamazepine and 
phenytoin may be 
effective in 
management of 
neuropathic pain in 
patients with cancer 
 
 
 
 
 
D 
 
 
 
 
 
4 
 
 Opioid treatment 
should be 
considered for the 
treatment of pain 
in patients with 
cancer with a 
nociceptive and a 
neuropathic 
component as first 
choice. or when 
there is insufficient 
result with 
gabapentin or 
pregabalin and/or 
tricyclic 
antidepressants.  
Other 
antidepressants 
and anti-epileptics 
should only be 
used for patients 
with pain and 
cancer by or in 
consultation with 
physicians who 
have an 
experience with 
neuropathic pain. 
It is demonstrated 
that intravenous 
lidocaine is not 
effective for the 
management of 
neuropathic pain in 
patients with cancer 
 
 
 
 
A2 
 
 
 
 
1 
 
 
 
 
140, 
141 
In the seldom 
occurring situation of 
localized 
neuropathic pain a 
local treatment with 
capsaicin or 
lidocain/prilocain 
crème may be 
considered  
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Table 12: cont     
It is considered that 
the local 
administration of 
lidocaine/prolocaine 
is effective in the 
management of 
post-mastectomy 
syndrome 
 
 
 
 
A2 
 
 
 
 
2 
 
 
 
 
142 
Capsaicin and 
lidocain/prilocain 
crème can be 
considered for the 
local treatment of 
pain in patients 
with cancer. The 
use of other drugs 
such as ketamine 
can only be 
considered when 
the other 
treatments failed 
and by physicians 
who have 
experience with 
the use of these 
drugs for the 
treatment of 
neuropathic pain. 
 
It is considered that 
capsaicin cream is 
effective for the 
management of 
neuropathic pain in 
patients with cancer 
 
 
 
A2 
 
 
 
2 
 
 
 
143 
 
There are 
indications that oral 
or intravenous 
ketamine (in 
combination with 
opioids) effectively 
reduce neuropathic 
pain in patients with 
cancer 
 
 
 
 
 
C 
 
 
 
 
 
3 
 
 
 
 
 
144 
 
Considering the 
complexity of 
neuropathic pain, 
the workgroup 
believes that when 
patients do not have 
satisfactory pain 
relief with the 
tricyclic 
antidepressants, 
gabapentin or 
pregabalin and/or 
opioids, the advice 
of a specialist in this 
field should be 
sought.  
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Table 12: cont     
It is the experts’ 
opinion that the 
treatment of anxiety 
in patients with 
cancer may lead to 
a pain reduction or 
a reduction of the 
pain experience 
 
 
 
 
D 
 
 
 
 
4 
 
 
 
 
145, 
146 
  
It is the experts’ 
opinion that the 
treatment of 
depression in 
patients with cancer 
may lead to a pain 
reduction 
 
 
 
 
D 
 
 
 
 
4 
   
It is the experts 
opinion that the 
management of 
sleep disturbances 
in patients with 
cancer may also 
lead to a pain 
reduction and a 
reduction of the 
pain experience 
 
 
 
 
 
D 
 
 
 
 
 
4 
   
It is possible that 
corticosteroids can 
reduce pain in 
patients with cancer 
 
A2 
B 
 
2 
 
147, 
148 
 
It is the experts’ 
opinion that muscle 
relaxants are 
effective to relieve 
muscle pain and 
cramps in patients 
with pain and 
cancer 
 
 
 
D 
 
 
 
4 
 
 
 
149 
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Discussion. 
Guideline composition 
This guideline on the diagnosis and treatment of pain in 
patients with cancer is the first evidence based multidisciplinary 
guideline developed by the scientific societies of medical 
professionals with active participation of patients, thus 
considering the patient’s perspective, and with structural 
support of the National comprehensive cancer institute and the 
national institute for health care evaluation (CBO: www.cbo.nl). 
It was possible to develop this guideline in a period of one year 
starting from a well-prepared analysis of the problems that arise 
with the diagnosis and treatment of pain in patients with cancer 
in the Netherlands. A total of 21 problems could be identified 
and were used as a basis for the delineation of the topics that 
are described in this guideline. The development of this 
guideline was successful because all participants were 
specially trained in the theoretical framework of developing 
guidelines during a dedicated course, and all professionals are 
actively working in the field of researched health care, related to 
pain in patients with cancer. All medical societies, clinically 
active in the field of pain in patients with cancer, delegated a 
mandated professional to this taskforce. This delegated 
professionals were selected on the following criteria: willing to 
succeed in making this multidisciplinary guideline, being 
motivated to follow a training in evidence based medicine 
guideline development, having the capacities to evaluate the 
quality of scientific publications and willing to write down the 
formulated recommendations. Formerly, guidelines were mostly 
developed by consensus of experts and hence were based on 
opinion, experience and less on available evidence. 150 
Nowadays, Evidence Based Medicine recommendations in 
guidelines must be explicitly based on scientific evidence and 
systematic reviews from the literature.151-153   
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The representatives of the patient organizations were fully 
integrated in the development of this guideline to assure that 
patient views, experienced problems and barriers in the 
treatment of pain in cancer were considered and described.154 
Patient integration in the composition of guidelines on cancer 
pain is not usual as shown in other recent guidelines on cancer 
pain. 155, 156 It is however important to diminish the barriers on 
adequate assessment and treatment of cancer related pain.157 
Recently, all European guidelines on the treatment of 
neuropathic pain in patients with cancer were evaluated on their 
quality by the Appraisal of Guidelines for Research and 
Evaluation (AGREE) instrument158. This chapter of the Dutch 
guideline was evaluated as of better quality and reached 
together with 8 other guidelines the minimal scientific level.  
Based on the selected literature and the evidence described in 
this guideline, it is concluded that further research and 
development of new evidence is needed to further adapt this 
guideline and to improve the level of evidence of a lot of 
therapies. 
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Other publications describe parts of this guideline. 7 
Clinical practice algorithm 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Clinical practice algorithm for pharmacologic 
treatment of pain due to cancer  
Patient with cancer 
Tumor is hormone- 
sensitive 
Consider hormone 
treatment 
Moderate pain Peripheral 
analgesics 
Severe pain Strong opioids 
Always prescribe 
laxatives at start of 
opioid treatment 
CNS side-effects (e.g. 
sedation) 
Consider opioid 
rotation 
Decide administration route 
according to patient characteristics 
Always consider combining analgesics and co-
analgesics for neuropathic pain 
Analgesics (opioids) may always be combined with 
treatment that targets mechanisms (hormone therapy 
or bisphosphonates) 
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Addendum 2.   
Formulated clinical questions 
Epidemiology / Etiology  
• What is the incidence and prevalence of pain in patients 
with cancer?  
• What are the expectations for the next 5-10 years?  
Signalization and diagnosis 
• Who should assess pain in patients with cancer and when 
should this be done?  
• How is pain measured in patients with cancer?  
Treatment of pain in patients with cancer: what is the role 
for: 
• Chemotherapy and hormonal therapy  
• Radiotherapy  
• Radionuclides  
• Surgery  
• Bisphosphonates  
• Non-opioids  
• Opioids  
• Adjuvant analgesics 
What are the minimum requirements for the treatment?  
Non-­‐pharmacological	  treatment	  of	  pain	  in	  patients	  with	  
cancer	  
• What is the role of rehabilitation including physiotherapy, 
relaxation therapy?  
• What is the role of psychological guidance?  
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Invasive	  treatment	  of	  pain	  in	  patients	  with	  cancer	  
• What is the role of neuroablative and neurodestructive 
treatments?  
• What is the role of intrathecal and epidural techniques?  
Which patient groups (elderly, patients with renal 
insufficiency, patients in terminal phase) with pain in 
patients with cancer demand special attention?  
Organization	  of	  care	  
• Which caregivers of the 1st and 2nd line are involved in the 
management of the patient with cancer and pain?  
• How are the tasks distributed between the different 
caregivers and between caregivers and the patient?  
• How should a multidisciplinary team for the management of 
patient with pain and cancer be composed? What is the 
minimum expertise required?  
• How can optimal communication be installed between all 
caregivers involved with the patient and between the 
caregivers and the patient and/or his next of kin?  
• What is the role of the patient and his proxies in the care 
process? 
• How can caregivers allow the patient to manage his pain 
as independently as possible?  
• How is the information and education (pain instruction, 
coping with pain) be organized? 
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Chapter 3 
The impact of a national guideline on the 
management of cancer pain on the practice 
of pain assessment and registration.   
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Abstract 
The Dutch clinical practice guideline on the diagnosis and 
management of pain in patients with cancer was published in 
2008 and intensively promoted to health care professionals 
who see patients with cancer. One of the most important 
recommendations is the systematic registering of the pain and 
its intensity. To evaluate in which degree this part of the 
practice guideline is implemented, we analyzed the medical 
records of patients attending the outpatient oncological clinic 
in an academic hospital, a large teaching hospital and two  
smaller peripheral hospitals.  
In none of the participating hospitals the pain was assessed by 
means of a standardized scale. Reference to pain in the 
medical record happened more frequently in the academic 
hospital than in the other hospitals. The frequency of recording 
pain in the medical record in the academic hospital was much 
higher in this study than the one previously reported, whereas 
the findings in the other hospitals were comparable. There 
may be several reasons for the difference in reporting rate of 
pain in patients with cancer. Our findings indicate that the 
clinical practice guideline with regard to pain registration is 
poorly implemented in oncology outpatient departments.  
More efforts should be made to generate the awareness for 
the need of pain registration.  
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Introduction 
In 2009, in the Netherlands about 41,000 patients died from 
cancer and 75,000 patients were diagnosed with cancer. It is 
estimated that in 2015 these figures will be respectively 
45,000 and 95,000. 1, 2 Pain is a highly prevalent and feared 
symptom in patients with cancer. 3 High pain levels decrease 
the patients’ quality of life and strongly interfere with daily 
activities. 4 Prevalence of pain during active oncological 
treatment appeared to be 59%, after recovery from curative 
treatment 33% and 64% in the end stage of cancer. 5 In spite 
of the availability of effective treatments, in a large number of 
patients this pain remains undertreated. 6  
The Dutch Society of Anesthesiologists (NVA) 7, the Society of 
Integrated Cancer Centers (IKNL) 8 and the Quality Institute of 
Healthcare (CBO)9 developed, in collaboration with all relevant 
professional societies and the Dutch Federation of Cancer 
patients (NFK) an evidence-based clinical practice guideline 
on the diagnosis and treatment of pain in patients with cancer. 
2 This multidisciplinary guideline was published in 2008, and 
had the objective to improve diagnosis and treatment of pain 
in patients with cancer, by all professionals involved in cancer 
pain management.  In a comparative study of all European 
clinical practice guidelines that contain information on 
neuropathic pain in patients with cancer, this Dutch guideline 
appeared to have a high quality, as measured with the 
AGREEII instrument. 10  
The Dutch clinical practice guideline shows that thorough pain 
assessment is a key factor for adequate pain management.11-
13 Regular pain assessment with a Numeric Rating Scale 
(NRS) 14, being one of the key recommendations of this 
guideline, should be done every time a patient with cancer 
visits the outpatient department for cancer treatment or 
evaluation. The use of a standardized pain scale simplifies the 
communication about the severity of pain and the evaluation of 
its treatment.15 A pain score ≥ 4 on the NRS makes urgent 
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adaptation of treatment necessary. 16-18 Assessment of pain 
should be obligatory as physicians often underestimate their 
patients’ pain experience 19 and patients hesitate to talk about 
pain, as they are afraid to distract the doctor from the cancer 
treatment. 20 Furthermore, patients want to be “good patients”, 
who do not want to complain about pain. 21-23  
It is unknown whether medical oncologists follow the 
recommendation to systematically assess pain in outpatients 
with cancer. Therefore, we studied how frequently pain was 
registered in medical records of patients with cancer who 
consulted an oncological outpatient clinic for the first time, and 
whether this differs between types of hospitals 
Methods 
Permission for this research was obtained from the Medical 
Ethical Committee and the Committee on Research Involving 
Human Subjects of each of the participating hospitals, protocol 
number 2011/020. 
Design 
We performed a retrospective review of the medical records. 
Study population 
In four hospitals in the Southeastern part of the Netherlands, 
being one academic hospital, one large teaching hospital, and 
two smaller peripheral hospitals, medical records of patients 
with cancer who had visited the outpatient medical oncology 
department in 2010 were studied.  
Data collection 
In 2008 we performed a pilot study to explore if and how we 
could collect data about pain registration in medical records of 
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patients, who were treated in the past and how pain was 
assessed in these medical records. A medical student 
reviewed medical records of patients, who visited the 
outpatient medical oncology and pulmonary oncology 
department in 2007, a year before publication of the Dutch 
practical guideline on cancer pain. We reviewed the medical 
records of the first five new patients of each month.  It 
appeared possible to extract all relevant data about pain 
assessment from these medical records.  
A scoring table was designed from this pilot study to register 
all variables per medical record. These variables included: 1. 
pain registered, according to the guideline recommendation, 
with a numeric rating scale (NRS), visual analogue scale 
(VAS) or visual rating scale (VRS). 2. pain mentioned, 3. 
vague description of complaints possibly related to pain, 4. no 
pain registration at all. We also documented patient’s age and 
gender, type of cancer, and proposed cancer treatment (curative or 
palliative).  
In 2010 and 2011, the medical records of the first three 
patients per calendar month who had visited the outpatient 
medical oncology clinic for the first time and who were 18 
years or older were selected. The medical records of all 
medical oncologists in the participating hospitals were 
included. Patients were only included in the study, when the 
diagnosis cancer was confirmed in the medical record. 
 A medical student, with clinical experience, but not involved in 
the patients’ treatment, extracted the data from the selected 
medical records.  
Statistical analysis 
Data were analyzed with SPSS 20 (SPSS for Windows, 
Version 20.0, Chicago, SPSS Inc. publishers of IBM Corp. in 
Armonk, NY). We used chi-squared and Fishers exact tests to 
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examine differences in pain registration and cancer stage 
between the hospitals.  
Results  
A total of 144 medical records were analyzed: 72 of the 
peripheral hospitals, 36 of the large teaching hospital and 36 
of the academic hospital. In the academic hospital the mean 
age of the patients was 53 years (50-57), in the large teaching 
hospital 60 (57-63) and 64 (62-65) in the peripheral hospitals. 
(p = 0.000) In the peripheral hospitals the majority of patients 
had breast or digestive tract cancer; in the large teaching 
hospital and in the academic hospital patients with different 
types of cancer were included. (Table 1) In the academic 
hospital the treatment of 53% of the patients was considered 
curative and 41% palliative, and not documented in 6%. These 
figures were respectively 46%, 40% and 14% in the large 
teaching hospital and 48%, 32% and 20% in the peripheral 
hospitals.  (Table 1) 
Pain registration significantly differed between the three types 
of hospitals. (p = 0.001) However, in none of the participating 
hospitals the pain was registered with a standardized scale 
(VAS, NRS, VRS). In the pilot test in 2007, in one medical 
record pain was registered on an NRS scale. Pain or the 
absence thereof was documented in words in 50% of the 
medical records in the academic hospital, 28% in the large 
teaching hospital and 21% in the peripheral hospitals. The 
words used to register pain were for example: ‘no pain’, ‘pain 
worsening’, ‘pain interferes with daily activities’, or ‘pain less 
after medication’. A vague description of complaints, possibly 
related to pain, was found in 18% of the medical records in the 
academic hospital, 14% in the large teaching hospital and 
18% in the peripheral hospitals. The words used in this 
respect were for example: ‘no complaints’, ‘going well’, or 
‘sleep disturbed’. No registration at all of pain was observed in 
32% of the medical records in the academic hospital, 57% in 
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the large teaching hospital and 59% in the peripheral 
hospitals. (Table 2)  
In the 2007 pilot study, pain or the absence thereof was 
registered in 67% of the medical records. A vague description 
of complaints possibly related to pain was registered in 15% 
and no mention at all of pain in 16% of the medical records.  
Discussion 
 We were able to analyze pain registration in medical records 
of outpatients with cancer, visiting a medical oncology 
outpatient department for the first time. A standard 
assessment scale to register pain in patients with cancer was 
not used in any of the medical records of all participating 
hospitals in 2010, despite the recommendation of the in 2008 
published Dutch clinical practice guideline that thorough pain 
assessment is the cornerstone of adequate pain treatment. 
This absence of optimal pain registration is in contrast to the 
pan-European survey about cancer-related pain by Breivik et 
al.24 In their study concerning pain prevalence and treatment 
in 12 countries (the Netherlands not included), pain was 
assessed with a pain scale in 15% (Denmark) to 70% (Italy) of 
the cases. Yet, they did not objectively study medical records, 
but they asked patients whether the doctor assessed pain. 
The figures in our study are in accordance with a study of 
Weingart et al 25, who found that pain assessment in 
ambulatory cancer patients was insufficient. Obviously, the 
clinical practice guideline has not been implemented in the 
working method of medical oncologists in the participating 
hospitals.  
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Table 1.Patient characteristics and cancer diagnosis 
 
 
Nijme 
gen    
2007 
N=106 
(%) 
Nijme 
gen 
2010 
N=36 
(%) 
Arn 
hem      
2010 
N=36 
(%) 
Doetin 
chem 
2010 
N=36 (%) 
Winters-
wijk 
2010 
N=36 (%) 
Male 56 
(52.8) 
20 
(55.6) 
20 
(55.6) 
14 (38.9) 16 (44.4) 
Female 50 
(47.2) 
16 
(44.4) 
16 
(44.4) 
22 (61.1) 20 (55,6) 
Mean age (SD) 60 
(10,0) 
52.9 
(14.8) 
62.6 
(11.0) 
60.9 
(12.9) 
65.4 
(12.3) 
Curative treatment 25 
(24.0) 
21 
(41.7) 
18 
(50.0) 
22 (61.1) 27 (75.0) 
Palliative treatment 81 
(76.0) 
15 
(58.3) 
18 
(50.0) 
13 (38.1) 8 (22.2) 
Unknown treatment 
intention 
0 (0.0) 0 (0.0) 0 (0.0) 1 (2.8) 1 (2.8) 
Dermatological tumors 10 (9.4) 1 (2.8) 3 (8.3) 0 (0.0) 0 (0.0) 
Gastrointestinal tumors 20 
(18.9) 
13 
(36.1) 
14 
(38.9) 
14 (38.9) 9 (25.0) 
Gynecological tumors 10 (9.4) 6 (16.7) 1 (2.8) 3 (8.3) 1 (2.8) 
Head/neck tumors 4 (3.8) 1 (2.8) 4 (11.1) 0 (0.0) 1 (2.8) 
Thyroid cancer 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (2.8) 
Lung tumors 46 
(43.4) 
1 (2.8) 0 (0.0) 1 (2.8) 0 (0.0) 
Breast cancer 6 (5.7) 5 (13.7) 8 (22.2) 15 (41.7) 14 (38.9) 
Neuro-oncologic 
tumors 
2 (1,9) 5 (13,9) 1 (2,8) 0 (0) 0 (0) 
Urogenital tumors 4 (3.8) 4 (11.1) 3 (8.3) 2 (5.6) 3 (8.3) 
Osteosarcoma 4 (3.8) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 
Unknown malignancies 0 (0.0) 0 (0.0) 1 (2.8) 0 (0.0) 0 (0.0) 
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Table 2. Pain registration and analgesic treatment. Is the 
existence of pain described in the medical record by the 
oncologist and treatment according to WHO scheme? 
 
 Nijme 
gen 
2007 
N=106 
(%) 
Arn hem     
2010 
N=36 
(%) 
 
Doetin-
chem 
2010 
N=36 
(%) 
Nijme 
gen 
2010 
N=36 
(%) 
Winter-
wijk 
2010 
N=36 
(%) 
Total  
2010 
N=144 
(%) 
Registration of 
anything about pain 
(Wilson 95%CL) 
89 
(84.0) 
19 
(52.7) 
8 (22.2) 23 
(63.8) 
8 (22.2) 58 
(40.3) 
Registration that 
pain is present  
17 
(18.0) 
14 
(38.9) 
7 (19.4) 9 (25.0) 5 (13.9) 35 
(24.3) 
Registration of 
anything about pain 
in words 
Specification of pain 
intensity in words, 
including “no pain” 
69 
(76.2) 
5 (13.9) 1 (2.8) 14 
(38.9) 
3 (8.3) 23 
(16.0) 
Pain measured as a 
VAS/NRS 
(Indicator) 
0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 
No pain medication 
at first referral 
59 
(55.7) 
22 
(61.1) 
27 
(75.0) 
26 
(72,2) 
30 
(83.3) 
105 
(72.9) 
WHO step 1 
Paracetamol and/or 
NSAID 
18 
(17.0) 
3 (8.3) 3 (8.3) 5 (13.9) 5 (13.9) 16 
(11.1) 
WHO step 2 
Step 1 combined 
with a weak opioid 
13 
(12.3) 
2 (5.6) 0 (0.0) 1 (2.8)  0 (0.0) 3 (2.1) 
WHO step 3 
Step 1 combined 
with a strong opioid 
4 (3.7) 3 (8.3) 2 (5.6) 3 (8.3) 1 (2.8) 9 (6.3) 
Adjuvant pain 
medication 
12 
(11.3) 
3 (8.3) 0 (0.0) 0 (0.0) 0 (0.0) 3 (2.1) 
Unknown 
medication or no 
medication noted in 
the record 
12 
(11.3) 
6 (16.7) 4 (11.1) 1 (2.8) 0 (0.0) 11 
(7.6) 
Treatment adapted 6 (5.7) 0 (0.0) 2 (5.6) 1 (2.8) 0 (0.0) 2 (1.4) 
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Pain registration at the first visit of the medical oncology 
outpatient clinic by documenting the intensity in words or by 
using the word ‘pain’ differed significantly between the 
academic hospital (50%), the large teaching hospital (28%) 
and the peripheral hospitals (21%). The lower mean age of the 
patients in the academic hospital might have contributed to 
this difference. Green et al 26 describe that pain interferes 
more with daily life in younger patients at the start of treatment 
and that younger patients have a higher number of pain 
locations. Probably, the higher pain prevalence increased 
discussing pain with the medical oncologist. Besides, younger 
patients might be more assertive, and discuss pain easier than 
older patients. In the large teaching hospital and the peripheral 
hospitals the percentage of patients with breast cancer was 
higher than in the academic hospital. In the pan –European 
survey of Breivik et al. 24 the prevalence of pain in this group of 
patients was 62%, one of the lowest in patients with pain due 
to cancer. This might be another explanation for the lower 
registration of pain assessment in these hospitals. If the 
medical oncologist does not ask for the presence or absence 
of pain, the patient will not mention it, if pain is absent. 
The frequency of pain registration in the academic hospital is 
much higher than the 25% reported by Weber 23  in his study 
on pain registration in medical records, which is in-line with the 
frequency of pain registration the other hospitals participating 
in our study. The academic hospital is the tertiary referral 
center for oncological patients in the region. Patients are often 
referred when the disease in in a later stage, than in the other 
hospitals. Deandrea et al. 27 describe that patients who are 
rated as being more ill, or being in a more advanced stage of 
the disease, will receive better pain treatment.  
In the academic hospital pain registration was worse than in 
the 2007 pilot study. Apparently the introduction of the 
guideline had no positive impact on the way pain was 
assessed in this hospital.  
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Pain assessment as part of the routine measurement of vital 
signs in hospitalized patients or at the outpatient visits will 
certainly improve the frequency of this assessment and pain 
treatment, as was seen in post-operative pain assessment.28 
We studied the frequency of pain registration, not the reason 
why the medical oncologists did not use a structural pain 
assessment scale. In the literature several reasons are 
mentioned, such as poor knowledge of specific clinical 
situations in patients with cancer pain 29 and fear of opioid 
addiction.30 
Strengths and limitations  
Pain registration was studied in departments of medical 
oncology in different types of hospitals (university, large 
peripheral teaching and smaller peripheral ones). This gives a 
reliable overview of the way medical oncologists assess pain 
in their patients.  Standardized pain measurement (VAS, NRS) 
was only found in one of the nearly 500 medical records 
analyzed in this study. 
 Additionally, it was not possible to include a standardized 
sample of medical records in this study that is representative 
for the Dutch population of patients with cancer.  
Conclusions and recommendations 
The evidence-based Dutch national clinical practice guideline 
on the diagnosis and treatment of pain in patients with cancer 
was published in 2008.  All relevant medical professional 
societies, and also the national society of patients with cancer, 
were involved in the development of the guideline. It has been 
disseminated to the medical professionals by their national 
societies. After the introduction of the national guideline, better 
pain registration and evaluation was expected, which could not 
be found in our study. Therefore better implementation plans 
should be developed to improve the evaluation and 
Impact of national guideline on management of  
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registration of pain. The reason(s) why the recommendations 
of the guideline are not followed by the medical oncologists 
should be studied. 31 
Medical oncologists, daily treating patients with cancer, should 
focus not only on the specific treatment of the cancer of their 
patient but also on the assessment of their pain and quality of 
life and should document this in the medical record. 32 Only a 
structured national implementation program can improve the 
assessment, diagnosis and treatment of patients with pain and 
cancer. For that reason, we started a scientific study in which 
the clinical practice guideline was implemented in six regional 
hospitals. 33 Assessment of pain takes time and time has 
become scarcer in medical practice. To overcome this burden, 
dedicated nurses could assess pain before the patient meets 
the medical oncologist. 34 Finally, patient empowerment can 
have an important place in ameliorating the assessment and 
treatment of pain.35, 36 For example, systematic use of a pain 
diary helps to demonstrate to family physicians, medical 
specialists and nurses the existence, intensity and course of 
pain. 37 Information exchange between the patient and 
physician about possibilities and restrictions of pain treatment 
can help to decrease some of the aforementioned barriers. 38, 
39  
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Abstract:  
Background:  Pain assessment and monitoring is a 
prerequisite for its adequate treatment in patients with cancer. 
We performed a feasibility study on the use of Short Message 
Service (SMS) and Interactive Voice Response (IVR) to 
improve pain management in patients with cancer, including 
terminally ill patients.  
Methods: During four weeks, palliative patients received a 
daily IVR asking to provide their pain score on a numeric 
rating scale (NRS) with their mobile phone. If pain was 
moderate or high, the nurse contacted the patient the same 
day and, if required, adapted the treatment.  
Results: Thirteen of the 17 invited patients agreed to 
participate (79%), 4 died during the study period. IVR/SMS 
provides a reliable assessment of the pain intensity. If required 
treatment can be rapidly adapted. All patients were satisfied 
with the intervention. There were no difficulties for the, mainly 
older, patients in handling this communication way on pain 
intensity. The mean pain score decreased from 4.78 to 3.33 
(p=0.07). The pain scale of the EORTC QLQ-C30  (European 
Organization for Research and Treatment of Cancer Quality of 
Life Questionnaire) decreased significantly from 56 to 35 
(p=0.047).   
Discussion: Monitoring and managing pain with IVR/SMS in 
patients with cancer at home appeared acceptable and 
feasible, even in terminally ill patients. The reluctance for 
actively contacting the professional in case of increased pain 
intensity is circumvented in this setting. Further research, 
preferably in a controlled study, is needed to establish the use 
of this intervention in a larger patient population. 
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Introduction  
In recent years cancer has become the leading cause of death 
in the Netherlands. Due to the ageing population more 
patients will be diagnosed with cancer, and patients survive 
longer, which means that the prevalence of cancer will 
increase even more. 1 Pain is the most feared symptom in 
patients with cancer. During the course of the disease and 
also after complete remission, a considerable number of 
patients experience pain. Prevalence of pain was 59% during 
treatment, after curative treatment 33%, and in end stage 
disease 64%.2 Pain strongly interferes with daily activities.3 
Thus, adequate pain treatment is an important factor in 
improving the quality of life.4 A prerequisite for achieving pain 
control is a thorough pain assessment.5 The positive influence 
of pain assessment on diagnosis and treatment of pain is well 
established.6 Particularly in this frail population where cancer 
progresses sometimes very fast, thorough pain assessment, 
and timely adaptation of treatment is of utmost importance if 
the pain increases in intensity or changes in type. 
To improve the quality of pain treatment, a multidisciplinary, 
evidence based guideline on the diagnosis and treatment of 
pain in patients with cancer in the Netherlands was published 
in 2008.7 This guideline was meant to be used by all 
professionals treating patients with cancer, like general 
practitioners, medical oncologists and pain physicians. This 
guideline meets the criteria of Clinical Practice Guidelines 
(CPGs) and appeared of higher quality than most other 
European CPGs. 8 
One of the recommendations in this guideline is to assess pain 
with a Numeric Rating Scale (NRS) or Visual Analogue Scale 
(VAS), each time the patient visits the outpatient clinic.9 Yet, 
medical oncologists mostly do not systematically assess pain 
and the effect and side-effects of its treatment during 
consultations.10 Besides, the course of pain in the period 
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between two consultations is unclear. In a study of Ferrel11 
70% of the patients had a higher pain score at home than 
during hospitalization. Most patients hesitate to consult their 
oncologist or general practitioner outside the planned 
consultations if their pain increases. There are several 
reasons for this hesitation, for example fear of opioid 
addiction, fear of distraction the attention from the causative 
treatment, fear not to behave as a “good” patient.12,13 
To improve pain management at home, registration of pain 
intensity as part of a pain diary appeared effective.14 Yet, such 
a tool is not used consistently by patients. 15 Besides, although 
assessment with a pain diary can give a good view on the 
course of pain, the physician evaluates it retrospectively, 
during the next consultation. This means that treatment 
adaptations are always delayed. The use of modern 
communication tools may be useful to reduce this delay. 
Interactive Voice Response (IVR) is such a tool. This system 
allows a computer database to communicate with a person via 
an automatic telephone call to exchange information. A large 
number of patients can be called at the same time without 
human intervention and data are stored in a database. A 
human voice invites the patient to give information. The patient 
can answer by giving a score with his mobile phone, which is 
sent back to the database. IVR with or without Short Message 
Service (SMS) has been effectively used in health care in the 
treatment of asthma 16,17, diabetes mellitus 18 and anti-
coagulant management.19   
We hypothesized that the use of SMS and IVR is feasible for 
pain management of patients with cancer at home. For that 
reason, we performed a feasibility study of this innovative, 
possible complex intervention. 20 The researched questions 
were: is the use of SMS and IVR feasible and suitable for 
assessment of pain intensity and change of pain treatment 
without delay? Is this intervention acceptable and usable for 
patients receiving palliative treatment? Are mobile phones 
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widely enough used by patients to participate in this 
intervention? Is there a positive effect on pain intensity in 
patients with cancer at home with an intervention using SMS 
and IVR to measure pain intensity and to allow rapid adaption 
of the treatment?  
Methods  
Design.  
To study feasibility of IVR in combination with SMS-alerts, we 
performed an intervention with pre and post measurements. 
(Figure 1)  
 
 
 
 
 
 
 
 
 
 
Figure 1. Study design 
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Patients who visited the outpatient pain clinic between 
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participate. Inclusion criteria were: having any kind of cancer 
together with cancer-related pain; aged 18 years or older; 
having a mobile phone; living at home and having provided 
written informed consent. Exclusion criteria were: having a 
cognitive impairment or not understanding/speaking Dutch. 
(Table 1) 
Table 1. Patient characteristics (N). 
Male 10 
Female 3 
Mean age (range) 58 (27-75) 
Tumor type  
Gasto-intestinal cancer 4 
Lung cancer 4 
Osteosarcoma 1 
Pancreatic cancer 1 
Urogenital cancer 2 
Unknown primary tumor 1 
Metastatic disease 12 
Local disease 1 
Disease stage  
Palliative treatment  
 
12 
Curative treatment 1 
 
Data collection 
All patients were asked for their informed consent. Specific 
information such as tumor type, presence of metastasis (yes 
or no), the oncological treatment intention (palliative or 
curative) and type of pain medication were retrieved from the 
medical record. Next, the researcher (GJ) planned a home 
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visit to explain the intervention. During this visit at home socio-
demographics (age, gender, education) were recorded.   
Pain severity scores were measured with the Numeric Rating 
Scale (NRS), which uses a scale from 0 ( no pain) to 10 (worst 
imaginable pain).21  This scale is considered the most 
workable in clinical practice. 22 This scale is also most 
applicable with the use of SMS. 
Type of pain (stable, episodic, fluctuating), localization and 
possible attributing psycho-social factors were assessed 
before the intervention using the Dutch translation of the 
Wisconsin Brief Pain Questionnaire to assess pain in cancer. 
23 This questionnaire is recommended in the Dutch guideline 
and based on validated questionnaires as the McGill Pain 
Questionnaire (MPQ)24  and the Brief Pain Inventory (BPI).25  
Evaluation with this questionnaire was not repeated at the end 
of the investigation because we estimated, that it would be too 
burdensome for the included patients at the end of their lives.  
The goal of our investigation could be achieved with the 
remaining investigative tools.  
Before and after the intervention period, each patient was 
asked to fill in the EORTC QLC-C30 questionnaire (European 
Organization for Research and Treatment of Cancer Quality of 
Life Questionnaire), which is a validated and reliable tool to 
measure quality of life of patients with cancer.26  
To evaluate satisfaction with the intervention, patients were 
invited to fill out a questionnaire after the intervention period. 
This questionnaire consisted of ten 11-point Likert scales (0 = 
not at all, 10 = very much), such as  ‘I found the SMS-service 
burdensome; time consuming; easy to perform; interfering with 
privacy. Was the given advise on pain treatment satisfactory? 
Was the pain during the investigation period better controlled?’  
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To evaluate the effect of the intervention on pain treatment, 
pain course and treatment adaptations after having reported a 
higher NRS score were studied. 
Each time an SMS/IVR was sent this was recorded in the 
database (Sermos-Line), as well as the response or non-
response of the patient to this IVR. NRS scores were recorded 
per call and day.  
Intervention 
During the home visit, the use of the NRS pain scale and the 
SMS and IVR were explained. During four weeks, from 
Monday to Thursday, twice a day at 8.25 a.m. and 1.55 p.m. 
each patient received an SMS to announce the IVR at 8.30 
and 14.00 hour. The text of the SMS was: ”Dear Mr./Ms./Mrs. 
(family name of the patient). In a couple of minutes you will 
receive a phone call from our computer with the question to 
give a pain score”. The IVR message was a male voice: ”Good 
day, this is an automatic message from the Pain Centre, 
please rate the pain intensity you experience at this moment. 0 
means no pain at all, 10 means the worst pain you can 
imagine”. Next, the voice said: “We thank you for your 
cooperation, and will interrupt the connection”.  
If a pain score was 5 or higher contact between patient and 
nurse was considered necessary, as it is stated in the 
guideline that an NRS score of 5 or higher corresponds with 
an inacceptable pain intensity.27,28 In these cases, the 
researcher automatically received an SMS as well as an e-
mail.  The message contained the identification number of the 
patient and the NRS score. Within one hour the researcher, a 
nurse practitioner who was specialized in pain, called the 
patient and asked the following questions: Has the already 
existing pain worsened? Is this a new type of pain? Which 
actions have you taken to relieve the pain? Is the pain 
bearable? Has the prescribed medication been used? Do you 
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need more help? A personalized advice was given, an 
adaptation of the dose of the prescribed analgesics was made 
or a physician was consulted for advice. 
The effect of the telephone advice or action was evaluated 
with SMS/IVR the following day. If the NRS score again was 5 
or higher, the researcher again contacted the patient for 
additional advice or treatment adaptations.   
Analysis 
Data collected in the Sermos system data were exported to 
SPSS version 17.0. Response rate regarding the SMS/IVR 
was calculated. Mean NRS score of each patient in the pretest 
and in the posttest were calculated and compared with paired 
t-tests.  
The changes of the scores of the EORTC QLC-C30 
questionnaire before and after the intervention were also 
compared with paired t-tests. 
Ethical considerations 
Ethical permission to perform the study was asked from the 
regional Ethical committee. They decided that no ethical 
procedure was required, case number 2009/201.  
Results 
Seventeen patients with cancer and pain were invited to 
participate in the study. Two of them refused to participate as 
they expected the study would be too burdensome; one 
patient could not adequately use a mobile phone and one 
patient was hospitalized for a long time just before inclusion. 
The remaining 13 (79%) patients signed the informed consent. 
The characteristics of the included patients are listed in table 
1.  
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Four patients (31%) were not able to complete the intervention 
period: one patient was hospitalized for a long time and three 
patients died because of the natural course of the disease. 
Therefore, complete data were collected of 9 patients.  
Response to the SMS/IVR  
A mean of 27 SMS/IVR messages per patient were sent, and 
patients responded in a mean of 17 times (62%). There was 
no difference in morning and afternoon response rate.   
Patients’ experience with the SMS/IVR 
All nine patients who completed the intervention returned the 
posttest questionnaire. Patients did not consider the 
intervention as burdensome nor too time-consuming, 
considered it easy to perform and not interfering with their 
privacy. The telephone response and the given therapeutic 
advice by the researcher when the NRS was higher than 5 
was considered useful by 7 of 9 patients (78%).   
Pain scores 
Ten out of 13 patients (77%) at least once had a pain score of 
5 or higher. Of all 213 responses 45 times (21%) an NRS 
higher than 5 was given, which implied that the researcher 
tried to contact the patient by phone. Three out of these 45 
times (7%), the patient did not answer this phone call. Two 
times a patient was hospitalized to treat the pain, in all other 
cases advice or adaptation of the analgesic medication 
according to the guideline was done by phone consultation. 
Ten times (25%) pain intensity was further increased at the 
moment of the next IVR, the next morning. Six times (15%) 
pain intensity remained the same and 24 times (60%) it had 
decreased.  
Chapter 4 
 101 
From the nine patients who completed the four-week study, 
the NRS score at the start and at the end of the study could be 
compared. In one patient the NRS increased (from 1 to 4), in 
two patients the NRS did not change and in six patients the 
NRS decreased between 2 and 5 points. At the start of the 
study four patients considered their pain intensity 
unacceptable; at the end of the study it was acceptable for all 
of them. Mean pain score, as measured with Numeric Rating 
Scales decreased non-significantly from 4.78 to 3.33 (p=0.07); 
on the pain subscale of the EORTC QLQ-C30 the mean pain 
score decreased significantly from 56 to 35 (p= 0.047). Table 
2 
Effects on quality of life 
Overall quality of life increased non-significantly from 48 to 56 
on the EORTC QLQC30 scale, see Table 2. 
Discussion  
Our intervention with SMS and IVR to monitor and manage 
pain of patients with cancer at home appeared acceptable and 
feasible. Most invited patients participated, which is 
noteworthy in a palliative care setting and contrary to the 
findings in other studies, where only a minority of possible 
participants could be included. Inclusion problems in a study in 
palliative care may be attributed to  low physicians referral rate 
28, patients’ believe to have no advantages of participating in a 
scientific study 29, and long distance to the research center.30 
In our study patients were recruited from our own outpatient 
pain department and were already familiar with the nurse 
practitioner who invited the patients to participate. Besides, all 
patients were personally called and visited by him, which 
appeared a strong motivator to participate. 
Three patients died from natural course of their disease before 
completion of the study and one patient was hospitalized for a 
long period and therefore dropped out of the study. Such a 
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high mortality rate was not unexpected and not related to the 
intervention, as all patients were in the palliative stage of their 
disease.  
Mean response rate to the SMS/IVR alerts was high (62%). In 
an Indian study on pain management in palliative care 
patients, also with the help of SMS but without IVR, response 
rate was even higher (93%). 31  
All nine patients who finished the study returned the post-test 
questionnaire. This high response rate was also found in a 
study in which a written pain diary in patients with pain due to 
cancer was evaluated.14  
Most of the patients who had reported a NRS score of 5 or 
higher were satisfied with the phone contact with the nurse 
and the advices. The participants had no difficulties with the 
technical aspect of the intervention, despite their higher age. 
There was no barrier for the patient to contact a medical 
professional because of his or her increased pain as the nurse 
was automatically alarmed by the computer system when the 
pain score was 5 or higher, and he initiated the contact. 
Treatment could be adapted without delay, which is not the 
case when using a pain diary, and which is usually shown to 
nurse or physician at the next planned consultation.14  
The number of included patients was adequate to have an 
impression of the feasibility of our intervention, but not enough 
to provide adequate outcome statistics. For that reason, it was 
not a surprise that we did not find a significant reduction of the 
mean pain score as measured with the NRS, nor of the overall 
quality of life as measured with the EORTC QLQC30 scale. 
On the pain subscale of the EORTC QLQC30 the mean pain 
score decreased from 56 to 35, being only weakly significant 
(p = 0.047). 
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Scoring procedures EORTC QLQ-C30 
The QLQ-C30 is composed of both multi-item scales and single item 
measures. All these scales range in score from 0 to 100. A high 
scale score represents a higher response level. Thus a high 
score for a functional scale represents a high/healthy level of 
functioning; a high score for the global health status/QoL represents 
a high Quality of Life, but a high score for a symptom scale/item 
represents a high level of symptomatology/problems.  
Table 2. Results EORTC QLQ-C30 scale pre- and posttest. 
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 Mean     
Physical 
functioning 57.04 51.85 5.19 31.05 -18.68 29.05 0.63 
Role functioning 37.04 33.33 3.7 24.69 -15.27 22.68 0.67 
Emotional 
functioning 76.85 68.52 8.33 23.2 -9.5 26.17 0.31 
Cognitive 
functioning 75.93 59.26 16.67 28.87 -5.52 38.86 0.12 
Social 
functioning 55.56 48.15 7.41 57.80 -37.02 51.84 0.71 
GHSQOL  48.15 56.48 -8.33 23.20 -26.17 9.5 0.31 
Fatigue 45.68 43.21 2.47 19.86 -12.80 17.73 0.72 
Nausea 9.26 25.93 -16.67 30.05 -39.76 6.43 0.14 
Pain 55.56 35.18 20.37 26.06 0.34 40.40 0.05 
Dyspnea 22.22 22.22 0.00 33.33 -25.62 25.62 1 
Insomnia 22.22 29.63 -7.41 40.06 -38.20 23.39 0.59 
Appetite 40.74 25.93 14.81 29.40 -7.78 37.41 0.17 
Constipation 11.11 25.93 -14.81 37.68 -43.78 14.15 0.27 
Diarrhea 3.70 14.81 -11.11 23.57 -29.23 7.00 0.20 
Financial 
difficulties 25.93 11.11 14.81 37.68 -14.15 43.78 0,27 
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Strengths and limitations 
In our study modern communication tools were used to 
monitor and manage pain intensity in patients with pain due to 
cancer. No special electronic devices for pain measurement 
for the patients were necessary as they could use their own 
mobile phone. 
The low threshold to get professional help could solve the 
hesitation of many patients to ask for professional assistance 
in pain treatment.   
Our study also had limitations. Home visits, consultations by 
phone and treatment advices were provided by one person, a 
highly motivated, experienced nurse practitioner. This 
personal contact with the patients certainly has contributed to 
a more confidential relation, which probably has positively 
influenced inclusion rates and results. Particularly the home 
visit at the start of the intervention was time-consuming and 
not realistic in daily practice. 
The study population included ten males and three females. In 
the study period obviously more males than females visited 
our outpatient department. Because of the limited time to 
include patients, it was not possible to collect a more balanced 
study population. In a follow up study with a larger population 
a more equal number of males and females has to be 
included.  
The SMS/IVR notification was done two times per day during 
four days per week. This meant that patients were reminded 
quite often of the possibility of feeling pain and having a life 
threatening disease. Further research should be done to 
assess the optimal frequency of the SMS/IVR calls to make 
pain treatment adaptation possible as soon as needed without 
unnecessary disturbing the patient. 
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The questionnaire to study the feasibility of the intervention 
was especially developed for this study and not validated.  
Conclusions 
The use of SMS/IVR calls gives a reliable assessment of pain 
intensity and the possibility of an immediate intervention if the 
pain needs urgent treatment. There appears to be no barrier to 
the use of this novel intervention in patients with pain and 
cancer in the palliative phase of their disease. In the majority 
of the patients pain decreased after the first intervention or the 
patient was acutely hospitalized, although this result was not 
significant as measured with the NRS pain scale. 
Increase in quality of life on the EORTC QLQ-C30 scale was 
not significant, but all patients were satisfied with this way of 
pain monitoring and treatment adaptation. 
The use of a computerized system might reduce time 
investment of professionals in monitoring severity of pain and 
treatment adaptation in patients with cancer. Professional 
contact and advice is only required when increased pain 
severity requires treatment adaptation, like in this study. 
Regularly phone calls for pain monitoring are not required. A 
mobile phone is so widely used, that there is no restriction and 
no financial investment on the side of the patients with cancer 
for the use of SMS/IVR notification in the assessment of their 
pain. The effects of IVR and SMS for pain management 
should be studied in a randomized controlled trial.  
Implementation in a larger patient population will need a 
financial investment for the acquisition of a modern 
communication system, that on the other hand has also been 
used in the assessment of post-operative pain in ambulatory 
patients and in the treatment of asthma 16,17, diabetes mellitus 
18, and oral coagulation management.19 More patients will 
mean a higher number of pain notifications that need an 
intervention. An adequate number of well-educated 
professionals must be available to meet this care.  
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Abstract 
Pain in patients with cancer can be refractory to pharmacological 
treatment or intolerable side effects of pharmacological treatment 
may seriously disturb patients’ quality of life. Specific interventional 
pain management techniques can be an effective alternative for 
those patients. The appropriate application of these interventional 
techniques provides better pain control, allows the reduction of 
analgesics and hence improves quality of life. Until recently the 
majority of these techniques were considered to be a fourth 
consecutive step following the World Health organization’s pain 
treatment ladder. However, in cancer patients, earlier application of 
interventional pain management techniques can be recommended 
even before considering the use of strong opioids.  
Epidural and intrathecal medication administration allows the 
reduction of the daily oral or transdermal opioid dose while 
maintaining or even improving the pain relief and reducing the side 
effects. 
Cervical cordotomy may be considered for patients suffering 
unilateral pain at the level below the dermatome C5.This technique 
can only be applicated in patients with a life expectancy of less than 
1 year. 
Plexus coeliacus block or nervus splanchnicus block are 
recommended for the management of upper abdominal pain due to 
cancer. Pelvic pain due to cancer can be managed with plexus 
hypogastricus block and the saddle or lower end block may be a last 
resort for patients suffering perineal pain.  
Back pain due to vertebral compression fractures with or without 
pathological tumor invasion may be managed with percutaneous 
vertebroplasty or kyphoplasty. All these interventional techniques 
should be part of a multidisciplinary patient program. 
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Introduction 
This review on interventional treatment of pain in patients with 
cancer is part of the series “Evidence-based Interventional 
Pain Medicine according to clinical diagnoses”. 
Recommendations formulated in this chapter are based on 
“Grading strength of recommendations and quality of evidence 
in clinical guidelines” described by Guyatt et al.1, and adapted 
by van Kleef et al. in the editorial accompanying the first article 
of this series.2 (Table 1). The latest literature update was 
performed in October 2010. 
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Table 1: Summary of evidence scores and implications for 
recommendation:  
Score Description Implication 
1 A+ Effectiveness demonstrated in various 
RCTs of good quality. The benefits 
clearly outweigh risk and burdens 
Positive 
recommendation 
1 B + One RCT or more RCTs with 
methodological weaknesses, 
demonstrate effectiveness. The benefits 
clearly outweigh risk and burdens 
2 B+ One or more RCTs with methodological 
weaknesses, demonstrate 
effectiveness. Benefits closely balanced 
with risk and burdens 
2 B± Multiple RCTs, with methodological 
weaknesses, yield contradictory results 
better or worse than the control 
treatment. Benefits closely balanced 
with risk and burdens, or uncertainty in 
the estimates of benefits, risk and 
burdens. 
Considered, 
preferably 
study-related 
2 C+ Effectiveness only demonstrated in 
observational studies. Given that there 
is no conclusive evidence of the effect, 
benefits closely balanced with risk and 
burdens 
 
0 There is no literature or there are case 
reports available, but these are 
insufficient to prove effectiveness and/or 
safety. These treatments should only be 
applied in relation to studies.  
Only study-
related 
2 C- Observational studies indicate no or too 
short-lived effectiveness. Given that 
there is no positive clinical effect, risk 
and burdens outweigh the benefit 
Negative 
recommendation 
2 B- One or more RCTs with methodological 
weaknesses, or large observational 
studies that do not indicate any 
superiority to the control treatment. 
Given that there is no positive clinical 
effect, risk and burdens outweigh the 
benefit  
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The treatment of pain in patients with cancer is a delicate 
balance, affected by a range of interfering factors, such as: the 
patient’s general condition, the co-medication and the nature 
of the pain, which is usually a mixture of nociceptive and 
neuropathic pain. Interventional pain management techniques 
have a specific role in the treatment of pain in patients with 
cancer.3 Until recently, mainly because of potential 
complications and the special requirements of aftercare and 
the need for specific devices, these techniques have mostly 
been used as a last resort among the arsenal of pain 
treatment options in patients with cancer. Several recent 
publications, however, as well as the new guidelines on the 
management of pain in patients with cancer of the Dutch 
association of anesthesiologists (NVA), the society of Dutch 
comprehensive cancer centers VIKC and the Dutch Institute 
for Health Care Improvement (CBO), have recommended the 
use of certain interventional techniques at earlier stages, 
possibly even at the stage where opioid treatment is first being 
considered.4 Preserving the use of these techniques for the 
last few days of life is certainly not a good idea. All 
interventional pain management techniques impose a certain 
burden on the patient, which must be taken into account when 
considering these treatment options. In addition, correct 
performance of these techniques requires one or more days of 
hospitalization. This information must be communicated to the 
patient to allow an informed decision-making.  
The interventional pain management techniques can be 
classified into two main categories: 
1) Intrathecal / epidural administration of medication, used 
to treat pain refractory to oral and transdermal 
pharmacologic therapy. 
2) Specific targeted nerve blocks; in this article the 
following techniques will be discussed: cervical 
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cordotomy, plexus coeliac block, nervus splanchnicus 
block, plexus hypogastricus block and lower end block.  
Another treatment modality that is becoming more popular is 
spinal cord and peripheral nerve stimulation, which, however, 
does not (or at least not yet) play an important role in 
oncologic pain management.  
A. Epidural and Intrathecal administration of 
analgesics 
Epidural and intrathecal administration of analgesics directly 
targets the receptors or pain transmission pathways in the 
spinal cord. The use of these techniques is mainly proposed in 
situations where oral or transdermal analgesics have 
insufficient effect or produce unacceptable side effects. 
Central administration of the analgesics is then expected to 
increase the analgesic effect and reduce the risk of side 
effects. In addition, this administration route allows 
simultaneous administration of other analgesics, such as 
bupivacaine and clonidine. The analgesic is administered via a 
catheter into the cerebrospinal fluid (intrathecal or spinal) or 
outside the dura mater (epidural).  
The use of epidural and intrathecal drug administration has not 
increased, despite considerable progress in our understanding 
of the safety, effectiveness and side effects of epidural and 
intrathecal opioid administration techniques, and further 
optimization of the logistics that allow its use in the home 
situation. This may be attributed to the fact that various new 
opioids have become available, and average individual 
dosages have increased, allowing the switch to epidural and 
intrathecal opioids to be postponed. The increasing use of 
subcutaneous opioids at patients’ homes has also reduced the 
use of intrathecal and epidural administration. There is still an 
indication for intrathecal and epidural analgesics, however, 
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provided that optimal use has been made of all options for oral 
and transdermal opioids. 4 
A. I. DIAGNOSIS 
A.I.A History  
There are two major reasons to switch to epidural or 
intrathecal analgesia, when the pain cannot be sufficiently 
relieved despite suitable dosages of opioids and where 
indicated co-analgesics, and when side-effects prove 
intolerable despite aggressive treatment. 
A. I.B Physical examination  
Physical examination of patients who are suffering pain that is 
refractory to oral or transdermal analgesics and for whom 
intrathecal or epidural analgesia is being considered should 
focus on:  
- Inspecting the painful area, concentrating on local 
problems of infection, skin abnormalities or open 
wounds, as well as on possible causes of the pain, 
such as a tumor compressing a nerve tract. It is 
important to estimate the consequences of the 
presence of such a tumor. 
- Detailed neurologic examination and tests of skin 
sensitivity by means of pinprick, ice cube or cold roller 
and ether test, to allow the difference in response to be 
evaluated after the catheter has been placed and local 
analgesics and opioids have been delivered. 
- Inspection of the entire spinal column, focusing on the 
sites where the catheter is to be inserted and tunneled. 
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- Clinical examination of mobility and motor function of 
the patient’s lower limbs, which might be affected by 
the use of the spinal or epidural catheter. 
- Consulting with patient and nurse to decide on the best 
exit site for the catheter in terms of nursing 
convenience, and the advantages and disadvantages 
of the treatment.  
A.I.C Indications for the use of an epidural or intrathecal catheter  
1. Pain resistant to very high dosages of oral, transdermal 
or systemic opioids. 
2. Pain that is responsive to systemic opioids but 
accompanied by intolerable side effects like nausea, 
vomiting, constipation or allergic reactions. 
3. Pain that cannot be treated with other modalities such 
as neurolytic blocks, cordotomy or other neuroablative 
of neuromodulatory techniques. 
4. Refractory pain of oncologic origin occurring in a 
localized and well-defined area. 
A.I.D Contraindications for the use of a epidural or intrathecal 
catheter  
1. Elevated intracranial pressure. 
2. Generalized or localized infections at the spinal level 
corresponding to the painful area. 
3. Suspected tumor mass at the level of the insertion site. 
4. Hemorrhagic diatheses 
5. Allergic reaction to the epidural or intrathecal agents to 
be used. 
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6. Agitation or cognitive disorders that may induce the 
patient to unexpectedly pull out the catheter and which 
are not expected to subside after the administration of 
locoregional analgesics. 
7. Expected problems in nursing the exit or insertion site 
of the catheter or exchanging the medication supply. 
A.II. A  Epidural and spinal drug delivery  
In a 2005 Cochrane review, Ballantyne was only able to 
include 1 RCT comparing intrathecal morphine delivery and 
conventional (oral and transdermal) administration of opioids 
in patients with pain due to cancer. 5 The clinical success rates 
were 85% and 71%, respectively. The group receiving 
intrathecal morphine reported less pain and fewer side effects, 
and survived longer. The other studies included in the review 
were cohort studies of patients exclusively treated with 
epidural or intrathecal opioids. The effectiveness of epidural 
opioids has been reported on by 31 uncontrolled studies 
involving a total of 1343 patients. Intrathecal opioid delivery 
was studied in 28 cohort studies involving a total of 722 
patients, the most frequently used opioid being morphine. 
Good to excellent analgesic effect was achieved in 87% and 
89% of the intrathecal and epidural groups, respectively.  
Addition of a local anesthetic has been most extensively 
studied using bupivacaine. One RCT and several cohort 
studies found that the addition of bupivacaine is effective for 
those patients who fail to achieve sufficient pain relief with 
intrathecal and epidural morphine.  
 A prospective observational study on the effect of intrathecal 
morphine and levobupivacaine, included 55 cancer patients 
who were highly opioid tolerant. Complete data with adequate 
follow-up until death were available for 45 patients. The initial 
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morphine dose was calculated from the previous opioid 
consumption. During treatment the doses of morphine and 
levobupivacaine were adjusted according to the clinical needs 
and balanced with adverse effects. Statistical significant 
difference in pain intensity was noted at all time intervals until 
death. Significant improvement in drowsiness and confusion 
were found until 1 month after starting intrathecal therapy. The 
daily morphine dose was 3-fold increased at the time of 
hospital discharge. Subsequent dose increases were not 
significant. The use of systemic opioids decreased significantly 
until death. 6 
Administration of clonidine has been investigated in one RCT 
and several cohort studies. Clonidine proved more effective 
than placebo (56% and 5%, respectively) especially for 
patients with neuropathic pain.4  
For an audit in a tertiary center medical records of 29 patients 
who received intrathecal drug administration were reviewed. 
Eighty six percent of those patients had metastatic cancer. 
The main reason for intrathecal drug administration was poor 
pain control. The pain intensity decreased significantly at the 
time of hospital discharge. The number of opioid side effects 
decreased. 7 Epidural	  and	  intrathecal	  medication	  
The most frequently used types of medication for epidural or 
intrathecal delivery are morphine, hydromorphone, fentanyl, 
bupivacaine, ropivacaine and clonidine. These drugs are often 
mixed; a commonly used mixture consists of morphine 1 
mg/ml and bupivacaine 2-3 mg/ml. Intrathecal delivery starts at 
a continuous rate of 0.5-2 ml/h, with a bolus option of 0.1-0.3 
ml/ 20 minutes. If the infusion rate is below 0.5 ml/h, the 
concentration of the morphine and bupivacaine solution must 
be adjusted. When using morphine, it is important to 
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remember that this compound is metabolized to morphine-6 
glucuronide and morphine-3 glucuronide. There is a limit to the 
amount of the latter that can be processed in long-term spinal 
administration (maximum 16 mg intrathecal morphine a day), 
and excess administration may cause opioid-induced 
hyperalgesia.  
Higher doses of local anesthetics may induce motor weakness 
and sensory deficiencies. In addition, urinary retention may 
occur, as well as transient arterial hypotension. There are no 
literature reports on toxic effects on the nervous system in 
case of long-term administration of local anesthetics on nerve 
tracts.  
Intrathecal clonidine can be added to the opioids and/or local 
anesthetics if required, at doses of 150 - 600 µg/ day. 
Ziconotide, the synthetic analog of the omega-conotoxin, has 
been used in both chronic non-malignant pain and in pain due 
to cancer. A randomized controlled trial found intrathecal 
ziconotide to be effective in relieving pain in patients with 
cancer or AIDS at a short follow-up period. 8 In the recently 
published Italian registry, ziconotide was used for the 
management of chronic pain, in general. In those patients with 
cancer a significant improvement in pain intensity was 
achieved faster than in non-cancer patients. 9 
In the US, in refractory cases the use of intrathecal ziconotide 
starting at low dose 1-2 mcg/day with a slow titration up to 8-
10 mcg/daily or higher seemed successful in several cases. 
However, the side effects are the major limitation of this drug. 
A.II.B Additional considerations 
The choice between implantable drug delivery systems and 
external pumps depends mainly on the patient’s life 
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expectancy. When the patient’s condition and life expectancy 
justifies the use of an implantable pump, because of the 
complexity and dynamic state of cancer pain, preference 
should be given to a programmable pump that allows patient 
controlled bolus administration. 10 A cost-effectiveness 
analysis has shown that implantable systems are to be 
preferred over external pumps if the patient has a life 
expectancy of at least 3 months. 11  
Epidural delivery will be preferred if the treatment goal is focal 
analgesia and a short treatment period is expected. The 
catheter tip is then inserted at the level of the vertebra 
corresponding to the dermatome where analgesia is required. 
Intrathecal delivery will be preferred if the painful area to be 
treated is large, if a disorder of the epidural space precludes 
the insertion of a catheter, or if the patient has a life 
expectancy of more than a few weeks. 12  
A.II.C Side-effects and complications 
Side effects like nausea, urinary retention, pruritus and 
headaches are common in the start-up phase of intrathecal 
treatment. A study found that infections occurred in 1% 
(epidural) or 2% (intrathecal) of cases. In the epidural group, 
16% of the patients had to have their catheter exchanged or 
removed because of catheter-related complications (such as 
fibrosis). The corresponding figure in the intrathecal group was 
5%. Other catheter-related complications, like infections and 
mechanical obstruction, have been reported with varying 
incidence rates (1-44%). 13 
A recent study into safety and complications found a relation 
between the occurrence of an inflammatory mass around an 
intrathecal catheter and the concentrations and dosages of 
morphine used. 14 Previously, a relation had been found 
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between high dosages of intrathecal morphine and the 
occurrence of myoclonias and hyperpathy. Long-term 
intrathecal morphine administration also results in hormonal 
changes: hypogonadotropic hypogonadism and hypocorticism. 
15 
A systematic review and meta-analysis investigated the 
infection rates associated with epidural catheters in place for 
at least 7 days. Of the 12 studies, 9 were published after 1990. 
Eight were retrospective (3893 patients) and 4 studies were 
prospective (735 patients). There were 6.1% catheter related 
infections, 4.6% superficial and 1.2% deep infections. The 
incidence of catheter related infections was calculated to be 
0.4 per 1000 catheter days. 16 
Another systematic review and meta-analyses on the serious 
complications with external intrathecal catheters identified 10 
articles, including a total of 821 patients. Twenty catheter-
related infections, 10 superficial and 10 deep infections were 
noted. The risk for bleeding was calculated to be 0.9% and for 
neurological injury 0.4%. The authors concluded that the risk 
of serious complications is rare in both hospitalized and 
homebound patients with intrathecal catheters. 16  Aprili et al in 
their meta-analysis on the related topic specifically looking at 
tunneled intrathecal catheters found a rate of superficial 
infection of 2.3%, with deep infection rate of 1.4%, with 
bleeding at 0.9%, and neurological injury 0.4%.  They further 
calculated that every 71st patient would get an infection after 
54 days of therapy through statistical means.17   
A.II.D Other therapeutic options  
Spinal drug delivery is usually considered as a final option, 
when all other treatment modalities produce insufficient 
results. If spinal drug delivery is contraindicated or impossible 
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for a particular patient, treatment will consist of a combination 
of therapeutic modalities involving subcutaneous or 
intravenous administration of analgesics. If a patient in the 
terminal stages is suffering from a refractory pain syndrome, 
palliative sedation can be considered, in consultation with the 
patient and their caregivers.   
A.II.E Evidence for epidural and intrathecal medication 
delivery for cancer pain relief  
The evidence for epidural and intrathecal medication delivery 
for cancer pain is listed in table 2. 
Table 2: Summary of the evidence for epidural and intrathecal 
medication delivery 
Technique Evaluation 
Intrathecal medication delivery 2 B+ 
Epidural medication delivery 2 C+ 
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A.III. Recommendations 
Use of intrathecal medication delivery is recommended for 
patients with refractory pain due to cancer especially when 
they have a significant neuropathic pain component. To this 
end, morphine should preferably be combined with a local 
anesthetic. Epidural delivery may be considered for short 
treatments or for a quick assessment of the required dosage; 
in all other circumstances, intrathecal delivery is to be 
preferred.    
 In some locations in the US, home catheter care is 
virtually unavailable, and an implanted pump can be used with 
a 40 cc reservoir, and maximal medication concentration fill 
prior to sending a patient to a home hospice situation with a 
remote geographical location.  Often, this reservoir will outlast 
the patient’s life expectancy with fair certainty.  Also, in many 
practices, the patient therapy manager device (PTM) with the 
Medtronic implanted pump will allow the patient to deliver as 
needed boluses, simplifying the home care programming 
needs significantly. 
A.III.A  Technique Preparing	  the	  patient:	  	  
1. Discuss the method and the consequences of placing 
an epidural or intrathecal catheter with the patient and 
their family or caregivers.  
2. Ensure that a suitable treatment facility is available, 
equipped with all the materials required for normal 
anesthesia, resuscitation and sterile procedures. If the 
patient is to be given anesthesia, he will need to be 
fasted. Note that with some tumors of the 
gastrointestinal tract, the patient can never be regarded 
as fasted. 
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3. Ensure the availability of a radiographic image 
intensifier to check the specific position of the catheter 
or to inspect the cause of unexpectedly difficult 
insertion, especially when inserting an epidural or 
intrathecal catheter near the tumor or extensive 
metastases.  
4. Evaluate the patient’s physical condition to determine 
the most suitable position for the treatment: cervical 
and thoracic catheters are best inserted with the patient 
sitting upright, unless the physical condition does not 
allow this or extensive sedation or anesthesia is 
required. Lumbar catheters are preferably inserted with 
the patient in lateral recumbent position, unless the 
patient is unable to lie down due to, e.g., extreme 
dyspnea.  Preparation	  for	  the	  intervention	  	  
The insertion site for the needle should be 10 to 15 cm from 
the intended catheter tip position. In the case of epidural 
analgesia, the following levels should be chosen for the 
following types of pain:   
a. lumbar insertion (Th12-L5) for sub-diaphragmatic pains 
and pains in the pelvis and lower limbs; 
b. low thoracic approach (Th8-Th12) for patients with 
lymphedema of the lower half of the body, previous 
lower back surgery, a tumor in the lumbar spine, 
presence of pyelostomy catheters or high upper 
abdominal tumors; 
c. mid-thoracic approach (Th4-Th8) for patients with 
thoracic pain due to tumors of the thorax (rib 
metastases, oncologic rib fractures, mesotheliomas or 
pulmonary tumors); 
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d. high thoracic approach (Th1-Th4) for patients with a 
pancoast tumor, severe neuropathic pain from 
mammary tumors or brachial plexopathy (due to tumor 
infiltration or radiotherapy) and refractory angina 
pectoris;  
e. A spinal catheter should always be inserted at the 
lumbar level, below the level of the presumed lower 
end of the conus medullaris (L1-L2). Inserting	  the	  needle	  and	  introducing	  the	  catheter	  
1. Apply local anesthesia to the skin and underlying 
subcutaneous tissues at the insertion site of the 
epidural or spinal needle and along the tunneling 
pathway. If required, the patient may also be sedated 
using propofol, ketamine or other agents.  
2. Place a 17G Tuohy needle preferably on the midline, 
as a paramedian approach is associated with a greater 
risk of accidental puncture of epidural blood vessels, 
paresthesias or radicular pain. Use the “loss of 
resistance” technique with a specially adapted syringe 
to detect the epidural space.  
3. For epidural pain control, the epidural catheter can now 
be introduced, ensuring that the catheter tip ends up at 
the intended level for effective pain relief. 
4. For spinal pain control, the Tuohy needle is placed 
transversely and inserted until CSF reflux is obtained. 
Although the “dural click” can be felt in some cases, 
this is frequently not the case, and the surgeon should 
check regularly whether CSF is flowing from the 
needle. Since patients who have only been given local 
anesthesia are usually well able to indicate when the 
spinal space has been accessed, their reactions should 
be observed. When CSF flows from the needle 
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(positive glucose test) the catheter is advanced through 
the spinal space to the required level, guided by the 
patient’s reactions. Avoid excessive CSF leakage. 
Initial insertion of the catheter through the spinal space 
may be somewhat difficult. If necessary, check the 
position of the spinal catheter radiographically with a 
contrast medium.  
5. Check whether CSF is flowing from the catheter, 
preferably by allowing the catheter to hang downward 
and letting any fluid drain out by gravity. 
6. Withdraw the Tuohy needle by 1-2 cm, but do not 
remove it until an incision has been made and the first 
tunneling device has been introduced (see below). 
7. Delivering a bolus of morphine and/or a local 
anesthetic after the catheter has been inserted may 
result in rapid pain relief. 
8. Tunneling the epidural / intrathecal catheter:  
9. Make a 4 to 6 mm incision down to the fascia around 
the Tuohy needle, to free the needle from the 
surrounding skin. 
10. If tunneling cannot be completed in one movement, 
make incisions along the intended course of the 
tunneled catheter, except at the exit site (to prevent 
any CSF leakage along the catheter). 
11. If patients prefer to have a full immersion bath, apply 
paravertrebral tunneling across the shoulder to the 
ipsilateral parasternal area. 
12. If the paravertebral route is contraindicated, for 
instance due to paravertebral metastases, extensive 
tumor growth or skin damage due to radiotherapy along 
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the intended course of the catheter, abdominal 
tunneling in a ventral direction may be used. 
13. Ensure that the catheter is not accidentally retracted 
during the tunneling procedure; in case of doubt, check 
by means of radiography. 
14. Use a second Tuohy needle or a special tunneling 
needle to guide the catheter subcutaneously. The 
tunneling device should always be inserted from 
peripheral to central. 
15. With each manipulation of the catheter, check whether 
CSF is still spontaneously flowing from the end of the 
catheter when this is held below the insertion site. 
16. Finally, connect the catheter to the special connector 
and fasten the connector onto the skin to prevent the 
catheter being dislocated and accidentally withdrawn 
from the spinal space.  
17. The catheter may also be connected to a system, 
which is fastened subcutaneously over a hard 
substrate. This requires a pocket to be made on the 
fascia of the thoracic wall. 
18. Check whether the catheter is sufficiently embedded in 
the subcutaneous adipose tissue at all incision sites, to 
avoid fistula formation. 
19. Cover all incision sites with aseptic bandaging, while 
covering the catheter exit site with separate bandaging 
for easy nursing access. Connect a micropore filter and 
connect this to a medication pump from which all air 
has been removed. Ensure that the catheter is free of 
air from the point where it leaves the pump to the 
micropore filter.  
EBM interventional pain medicine in patients with cancer 
 126
20. Try to avoid traction on the catheter by providing extra 
loops on the skin or in the tunneling channel, as this 
reduces the risk of dislocation. 
21. After the incisions have healed and a semipermeable 
bandage has been applied to the catheter exit site, the 
patient will be able to take a shower or use a hipbath. 
22. If a subcutaneous Port-a-cath is used, the needle 
insertion should always be checked. Instructions	  	  
1. To the patient about the correct way to use the pump 
(possible bolus option).  
2. To the patient’s family about the care required by the 
patient and any special concerns. 
3. To the nursing staff about programming, exchanging 
batteries and medication cassettes, pain assessment 
and advice for correct usage. Instructions should 
preferably be given in writing or by referring to printed 
guidelines for this treatment available at the clinic. 
4. To the patient’s family doctor and other medical staff 
involved, about preferred dosage, possible side effects, 
aspects to be observed and possible adjustments.  Observation	  
After an epidural or spinal catheter has been installed, the 
patient should be observed at the postoperative care 
department for a few hours, after which they should stay on a 
hospital ward for further observation for at least two to three 
days, which time can be used  
• to teach the patient how to use the pump correctly; 
• to find the correct dosage for optimum pain relief; 
• to identify and treat possible side-effects; 
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• to dress the wounds correctly. 
For permanent implantable pumps specific surgical techniques 
are used.  
B. Unilateral pain with limited life expectancy  
Introduction  
Unilateral oncologic pains situated below the shoulder or 
dermatome C5, such as may occur with pancoast, pleural 
mesothelioma or invasion of the brachial or lumbar plexus, 
may be eligible for treatment with cordotomy, if they prove 
refractory to other techniques.  
Cordotomy involves creating a lesion of the spinothalamic tract 
at the C1-C2 level of the spinal cord with the aim of relieving 
unilaterally localized pain below the level of dermatome C5. 
The technique was first described by Mullan in 1963. 18 
Although the treatment was originally applied for non-
oncologic pain, because of the potential side effects, it is now 
mainly reserved for the management of patients with refractory 
pain due to cancer whose maximum life expectancy is 1 year. 
19, 20  
B. I. DIAGNOSIS 
B.  I.A  History  
Unilateral refractory pains due to cancer located under the 
dermatome C5 are eligible for treatment with cordotomy. The  
best results are obtained for the treatment of neuropathic pain 
and incident pain,  occurring by some form of strain. Visceral 
pain, especially abdominal pain, is not an indication for 
cordotomy. It is also important to assess whether pain 
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elsewhere in the body is well controlled. The patient must be 
informed that successful cordotomy may unmask other pain. 
B. I.B Physical examination 
Clinical neurologic examination results obtained before and 
after treatment should be compared to identify any neurologic 
deficits. This includes pain perception and/or temperature 
perception on both sides, as well as motor function. 
B.I.C Additional tests  
The referring doctor must have completed the technical 
examination that is required to accurately identify the causes 
of the pain, in order to provide a detailed picture of the 
situation before any interventional pain management 
techniques are applied.  
B. I.D  Differential diagnosis 
All causes of unilateral pain of non-oncologic, neurologic, 
osteogenic or myofascial origin must be excluded.  
B. II Treatment options 
B. II.A  Cordotomy 
The effects of cordotomy on patients have been described in 
one non-randomized study and a number of observational 
studies. A study comparing cordotomy with subarachnoid 
phenolization found that both techniques yielded similar pain 
control at lower opioid dosages. 21 Seven of the 10 cordotomy 
patients developed pain on the contralateral side of the body, 
while 4 of the 10 patients developed complications, which 
resulted in functional deterioration. Since 1990, 6 case series 
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have been described in which a total of 677 patients with 
cancer were treated with unilateral cordotomy. 22-27 The 
authors reported considerable or even complete pain reduction 
in 82-98% of the patients, while opioid consumption was 
reduced by 50%. The best results were obtained in the 
treatment of unilateral pain.  
A number of patients (31-88%) experience recurrence of the 
pain, which can usually be effectively treated with opioids. Two 
studies described 3 patients who survived for considerably 
longer than 2 years. 23, 27 These patients did not develop 
neuropathic pain as a result of the procedure. However, this 
number is too small to allow conclusions about the long-term 
safety of cordotomy. A recent report describes a patient who 
survived 5 years after right-sided cervical cordotomy. Sensory 
dysfunction was observed in the left side of the body, but no 
motor neuron or autonomic dysfunction was observed. There 
was limited influence on the patient’s daily activities. 28 
Cordotomy is only used for cancer patients suffering severe 
pain, which is refractory to pharmacologic treatment. The 
Dutch CBO guidelines for the treatment of pain from cancer 
recommend that these therapeutic options should only be 
considered for patients with a limited life expectancy (1 year). 4  
The immediate results of the treatment are evaluated by 
applying the pinprick test to the patient’s thorax. We 
recommend regular evaluation of the pain (at least weekly). In 
view of the complexity of the pain syndrome and the risk of 
other (masked) pains becoming manifest, we recommend that 
the pharmacologic treatment be adjusted on the basis of the 
patient’s complaints.  
There have been contradictory reports about the value of 
bilateral cordotomy to relieve pain due to cancer. Amano et al. 
22 found that 95% of the 60 patients who had a bilateral 
EBM interventional pain medicine in patients with cancer 
 130
cordotomy reported (virtually) complete pain reduction, versus 
82% of the patients who had had a unilateral cordotomy. In 
this study, however, both groups were suffering from bilateral 
pain. By contrast, Sanders et al. 25 found no advantage of 
bilateral cordotomy, whereas the risk of complications 
appeared greater. 
Computer tomography-guided radiofrequency treatment was 
also described for ablation of the upper spinal cord pain 
pathways. Of a series of 55 patients, 42 underwent a unilateral 
cervical cordotomy. Patients reported initial and 6 months pain 
relief of 98% and 80% respectively. 29 
Another series of 207 patients treated with CT-guided 
cordotomy over 20 years reports an initial success rate of 
92.5%. The success rate was higher in patients suffering pain 
due to malignancies. In this group cordotomy was achieved in 
83%. Bilateral cordotomy was successfully applied in12 cases. 
30 
B. II.B  Side-effects and complications 
The localization of the tractus spinothalamicus lateralis and the 
size of the thermo lesion relative to the spinal cord, explain the 
risk of damage to adjoining nerve tracts. Reported 
complications include pareses (up to 10%), bladder 
dysfunction (up to 15%) and respiratory depression (up to 10 
%), 31 as well as head and neck pain and dysesthesias. These 
side effects proved to be permanent in a number of cases. 25 
In addition, there is a risk of other, previously masked pains 
becoming manifest, or of developing “mirror pain”, that is, pain 
on the contralateral side. The incidence of such pain 
syndromes is between 9 and 63%. 31 Interestingly, none of the 
studies reported neuropathic pain due to the treatment. The 
risk of major complications is larger with bilateral cordotomy. 25 
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B. II.C  Other treatment options 
If patients are not eligible for cordotomy, epidural or intrathecal 
analgesics may be considered. Surgical neuroablation 
techniques have been abandoned because they were 
insufficiently selective.  
B. II.D  Evidence for cordotomy 
The evidence for cervical cordotomy is given in table 3.  
Table 3: Summary of the evidence for cordotomy 
Technique Evaluation 
Cervical cordotomy  2 C + 
B. III .A Recommendations for cordotomy  
Cordotomy may be considered for patients with unilaterally 
localized refractory oncologic pain below the level of 
dermatome C5, with a maximum life expectancy of 1 year, 
who obtain insufficient relief from conventional treatment.  
Cordotomy should only be carried out at centers where staff 
has extensive experience with this treatment.  
B. III.B Technique for fluoroscopy guided cordotomy 
Cordotomy is applied at cervical level, between C1 and C2, 
where the fibers of the tractus spinothalamicus lateralis run 
close together in the anterolateral quadrant. The fibers are 
somatotopic, with the most cervical fibers in the most anterior 
position and the most sacral fibers in the most posterior 
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position. The treatment is applied on the contralateral side of 
the pain. (Figure 1) 
All aspects of the procedure should be thoroughly discussed 
with the patient beforehand, including the fixation of the head, 
the unpleasant effects that may be caused by stimulating the 
spinal cord and the potentially lengthy duration of the 
procedure. During the intervention, a nurse should always be 
at hand to reassure the patient if necessary. The patient will 
need to cooperate to check the correct placement of the 
electrode in the spinal cord.  
The radiofrequency treatment is performed using a 
thermocouple cordotomy electrode (e.g. Levin) with a 2 mm 
non-insulated tip. The patient is placed in supine position and 
the head firmly fixed.  
The arch of C1 is projected as a line in lateral fluoroscopy. The 
angles of the jaw and the meatus acousticus externus must 
also be projected over it as a reference. This ensures the best 
visibility of the space between C1 and C2, which is projected 
as an arrow shape with its tip pointing ventrally. 
Treatment is carried out under sedation while monitoring ECG 
and blood pressure. It starts with a 20G spinal needle being 
inserted into the subarachnoid space between the first and 
second cervical vertebrae. The direction should be as ventral 
as possible. Its position should be checked by means of lateral 
fluoroscopy. As soon as the CSF is reached, a mini-
myelogram is made, using emulsified contrast medium (lipiodol 
with NaCl 0.9% 2:6, or with CSF 1:1 after very thorough 
shaking) to visualize “3 lines”: the ventral side of the spinal 
cord, the ligamentum denticulatum and the posterior surface of 
the dural sac. (Figure 2) 
Depending on the position of the needle, a second spinal 
needle may be introduced. This should be inserted, using a 
stylet, 1-2 mm ventral to the ligamentum denticulatum, at a 
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right angle to the spinal cord, where the tractus 
spinothalamicus lateralis is situated.  
 
Figure 1: Anatomic representation of cordotomy: a: needle placement 
between C1 and C2. b: location of the tractus spinothalamicus lateralis in the 
anterolateral part of the spinal cord c: maximum extent of the area where 
pain can be treated by left-sided cordotomy.  
  
Figure 2: Needle placement for cordotomy: 
note the myelogram at the level of the 
ligamentum denticulatum. 	  
Figure 3: Definitive needle position 
for percutaneous cordotomy: note the 
increase in impedance as the needle 
is advanced into the spinal cord. 
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The (Levin) thermocouple electrode is inserted after the stylet 
has been removed. It is connected to the radiofrequency 
generator, after which the tip of the electrode is inserted into 
the spinal cord with the free hand while measuring the 
impedance. Impedance suddenly rises from 150-300 Ω in the 
CSF to 1200-1500 Ω in the spinal cord. (Figure 3) The needle 
often encounters a rubbery kind of resistance at this point. 
Sedation can now be terminated. 
Stimulation at a frequency of 50 Hz causes a contralateral 
heat sensation (hot or burning sensation or chill) at stimulation 
thresholds < 0.1 V. These sensations should be perceived in 
or above the area to be treated. The patient should preferably 
not feel any stimulation responses of the ipsilateral musculus 
trapezius and neck muscles (due to stimulation of the anterior 
horn) or the arms and legs (tractus corticospinalis) at a 
frequency of 2 Hz at 0,5-2 V, as this could result in paresis if 
the lesion is made. If these conditions are met, the needle has 
been correctly inserted in the anterolateral quadrant at a safe 
distance from the tractus corticospinalis.  
RF treatment is applied for 10 sec at a temperature of between 
80 and 90°C, after which the contralateral analgesia is 
checked by means of pinprick. Muscle force in the ipsilateral 
arm and leg should also be checked after each lesion. The 
procedure should be repeated one or two times, depending on 
the size and intensity of the analgesic area.  
Edema development in the spinal cord may result in side 
effects, including persistence or increase of the pain, so 
regularly checking the patient’s pain level is a precondition for 
optimum treatment. In view of the complexity of the pain 
syndrome, and the risk that previously masked pains may 
become manifest, we recommend adjusting the pharmacologic 
treatment on the basis of the patient’s complaints. Special care 
should be taken with patients who are being treated with high 
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opioid dosages, for whom rapid adjustment of the dosage is 
often required to prevent respiratory depression.  
B. III.C Technique for CT- guided cordotomy 
For a description of this technique we refer to Kanpolat et al.30 
C. Upper abdominal pain due to cancer of the 
pancreas / stomach  
Introduction 
Pancreatic carcinoma usually leads to death within a relatively 
short time, as the diagnosis is often established at a time when 
the cancer is already in an advanced stage, where tumor 
resection is no longer an option. Patients often first present 
with upper abdominal pain, although in the advanced stages 
they also frequently complain of back pain. Cancer of the 
pancreas is also associated with anorexia, loss of appetite, 
sleeping problems and weight loss.  
Upper abdominal pain may also be caused by metastases of 
stomach cancer.  
The plexus coeliacus is the network of orthosympathetic nerve 
fibers located in front of the aorta at the level of the truncus 
coeliacus. The plexus is formed from the nervi splanchnici, 
which arise from the thoracic truncus sympathicus. Plexus 
coeliacus block was first described by Cappis in 1914 for the 
treatment of upper abdominal pain after abdominal surgery. It 
is currently mostly applied in patients with cancer, usually due 
to pancreatic carcinoma. 
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C. I. Diagnosis 
C. I.A  History taking and clinical symptoms 
If a patient presents with severe upper abdominal pain and 
also complains of loss of appetite, sleeping problems and 
unexplained weight loss, the doctor should first seek to confirm 
the cause of the pain.  
The pain is worse when the patient lies down and subsides as 
he or she sits up or bends forward. 
Patients will report indistinctly localized, deep-seated pain, 
which resembles pinching, cramps or colic. Other symptoms 
include referred pain such as shoulder pain, which occurs as 
the tumor invades the diaphragm, and is caused by stretching, 
compression or invasion of visceral structures. 
C. I.B Physical examination  
Although physical examination is irrelevant to the pain 
syndrome, it is important to ascertain whether the pain is 
indeed situated in the upper abdomen. Additional radiation of 
the pain to the lower abdomen or the back due to a primary 
upper abdominal process is no contraindication for a nervus 
splanchnicus blockade/neurolysis. Patients should also be 
checked for local anatomic abnormalities (severe scoliosis) 
and infections at the level of the intended puncture site. In 
addition, the patient must be able to lie in prone position for 
the duration of the procedure. 
C.I.C Additional testing (multidimensional) 
Basic additional examination includes medical imaging, 
whether or not followed by laparoscopic examination, during 
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which any obstructive symptoms can be treated. The technical 
examination required for accurate assessment of the cause of 
the pain should have been completed by the referring doctor. 
The examination should yield an accurate understanding of 
the situation before interventional pain control techniques are 
applied.  
C.I.D Differential diagnosis 
Pain related to non-oncologic problems are not eligible for 
neurolytic plexus coeliacus block.  
C. II TREATMENT OPTIONS 
C. II.A  Interventional management 
A meta-analysis of 24 studies assessing the effectiveness of 
plexus coeliacus block among a total of 1145 patients with 
various types of cancer was published in 1995. 32 This analysis 
showed that 89% of the patients report reduced pain after 2 
weeks, with complete relief reported by 58% of the patients. 
The corresponding figures after 3 months were 90% and 56%, 
respectively. Later publications based on double blind RCTs 
have confirmed the conclusions of the meta-analysis that 
plexus coeliacus block leads to reduced pain scores and/or 
reduced opioid consumption. Reported effects on quality of life 
have been variable. A meta-analysis evaluating the effect size 
of the treatment showed that plexus coeliacus block reduces 
the pain but does not remove the need for opioids. 33 It 
concluded that plexus coeliacus block is no substitute for 
pharmacologic treatment.  
A double blind randomized controlled trial compared the 
efficacy of conventional analgesic treatment and sham 
intervention with plexus coeliacus block and analgesic 
treatment. Pain reduction was greater in the group receiving 
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active plexus coeliacus block at 1 week and over time. Opioid 
consumption and quality of life were not significantly different 
between groups. One year after randomization 16% of patients 
in the plexus coeliacus block group were still alive compared 
to 6 % in the conventional treatment group, this difference was 
however not significant. 34 
The efficacy of CT guided neurolytic plexus coeliacus block 
was compared with pharmacological treatment of pain due to 
pancreatic cancer. In the short term (1 to 14 days after the 
intervention) the VAS score of patients in the group having 
received a neurolytic block were significantly lower than in the 
group receiving pharmacological treatment. In the longer term 
up to 90 days after randomization the difference in VAS pain 
score disappeared. The opioid consumption however 
remained significantly lower in the neurolytic block group over 
the complete follow-up period. There were no differences in 
quality of life between the two groups. 35 
An open randomized comparison of clinical effectiveness of 
protocol-driven opioid analgesia, plexus coeliacus block or 
thoracoscopic splanchnicectomy in patients with pancreatic 
and other abdominal malignancies showed no differences in 
outcome between the 3 groups at 2 month follow-up.36 
The results of this latter study differ from previous findings. 
The reported mortality rate within the 2 months follow-up 
suggests that the population studied consists of patients 
whose cancer is in a far advanced stage.  
A comparative study found that ethanolization of the nervus 
splanchnicus was superior to plexus coeliacus block in terms 
of pain relief and quality of life in patients with a pancreatic 
tumor. 37 This technique may therefore be considered, 
although further research is required to confirm the results.  
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C. II.B  Complications 
Although there have been reports of transient hypotension or 
diarrhoea, as well as local pain, percutaneous plexus 
coeliacus block appears to be a relatively safe technique. 
There have been only a few reports of serious complications 
like pareses, paresthesias (1%), hematuria, pneumothorax 
and shoulder pain (1%).32 There are case reports of paraplegia 
due to plexus coeliacus block. 38-40  
A recently published case report described hemorrhagic 
gastritis and duodenitis following plexus coeliacus neurolysis. 
The patient had a known history of gastritis and duodenitis and 
developed severe upper GI bleeding immediately following the 
plexus coeliacus neurolysis. It was speculated that inhibition of 
the sympathetic tone caused increased blood flow to the GI 
system, which resulted in active bleeding from previously 
indolent hemorrhaging gastritis and duodenitis. 41 
Relieving abdominal pain may cause other pains to become 
manifest. Although this means that it is often not possible to 
completely terminate analgesic treatment, considerable 
dosage reductions may be achieved.  
Contraindications for plexus coeliacus or nervus  splanchnicus 
block: 
• hemorrhagic diatheses 
• local infections 
• patient’s inability to lie in prone position 
• tumor invasion into the insertion site of the needles 
C.II.C  Other treatment options 
Initial treatment of upper abdominal pain due to pancreatic 
carcinoma consists of analgesics like non-steroidal anti-
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inflammatory drugs and opioids, which may be administered in 
various forms.  
C.II.D Evidence for interventional management 
The evidence for interventional management of upper 
abdominal pain due to cancer is summarized in table 4. 
Table 4: Summary of evidence for upper abdominal pain  
Technique Evaluation 
Neurolytic plexus coeliacus block  
Neurolytic nervus splanchnicus block 
2 A ± 
2 B + 
 
C. III  Recommendations  
We recommend the use of plexus coeliacus block or nervus 
splanchnicus block to reduce pain or opioid use in patients 
with upper abdominal pain due to malignancy. This treatment 
may be considered as soon as opioid treatment is started. 
Plexus coeliacus or nervus splanchnicus block may be 
repeated if necessary. The choice between these two 
techniques depends on the preferences and experience of the 
attending physician.  
C. III.A Technique Plexus	  coeliacus	  block	  
Various techniques to approach the plexus coeliacus have 
been described. Literature reports do not indicate one to be 
superior to the others, although the results of nervus 
splanchnicus block at the Th11 level appear to be better than 
those of the trans aortal approach. 37 The sections below 
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discuss the posterior trans aortal, paravertebral (retrocrural) 
and transdiscal techniques for plexus coeliacus block and 
nervus splanchnicus block. 
Plexus coeliacus plexus block can also be implemented 
surgically and endoscopically (by a gastro-enterologist), but 
these techniques are beyond the scope of this article.  Also, 
there is a growing experience with anterior, ultrasound-guided 
techniques.  Posterior	  transaortal	  technique	  	  	  	  
The patient is lying in prone position, with support under the 
abdomen to achieve thoracolumbar kyphotic position. This 
increases the distance between the ribs and the crista iliaca 
and between the processus transversus of the adjoining 
vertebral bodies. For the sake of comfort, the patient’s head is 
turned sideways with the arms hanging down along the body 
or placed above the head.  
It may be useful to mark the following reference points on the 
skin with a marker pen: the crista iliaca, the 12th rib, the dorsal 
midline, the vertebral bodies and the lateral limit of the 
paraspinal muscles. It is also useful to mark the intersection of 
the 12th rib and the lateral border of the paraspinal muscles on 
the left side (which usually corresponds to the L2 level). A 
steel ruler can then be used to draw bilateral lines parallel to 
the lower edge of the 12th rib. These lines, which cross the L1 
vertebral body, serve to indicate the direction of the needle. 
The surgery site is prepared and covered with sterile drapes. 
The skin, subcutaneous tissues and muscles are anesthetized 
with a local anesthetic at the site where the needles will be 
inserted. For the sake of patient comfort, spinal anesthesia 
with a short-acting local anesthetic may be considered.  
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A 20 or 22G, 15 cm stylet needle is inserted from the left. The 
needle is initially oriented at an angle of 45° to the midline and 
about 15° cranially in order to make contact with the L1 
vertebral body. As soon as the needle touches the bone, its 
depth of insertion is noted, after which the needle is retracted 
to the subcutaneous tissue. It is then repositioned slightly 
laterally (at about 60° to the midline) to pass along the lateral 
surface of the L1 vertebral body. All this is done under 
fluoroscopic guidance. The needle is now cautiously advanced 
until aortic pulsations are felt in the needle. The stylet is then 
removed from the needle, and the needle is advanced so as to 
perforate the aortic wall. Blood emerging from the needle 
indicates it is in intra-aortic position. The needle is advanced 
until no more blood emerges, indicating that the needle tip is in 
pre-aortic position. A “click” may be felt as the needle 
perforates the aortic wall. It is important to use anteroposterior 
as well as lateral views to ensure correct needle placement.  
After the needle has reached its correct position, the stylet is 
removed and the hub is checked for blood and CSF, lymph 
fluid and urine. A small amount of contrast medium is then 
injected bilaterally and its distribution pattern is checked with 
the help of the C-arm. If the contrast medium shows 
insufficient dispersion, it may be necessary to introduce 
another needle from the right side for the instillation of the 
neurolytic agent. 
In the anteroposterior view, the contrast medium should show 
up in the midline, concentrated around the Th12–L1 vertebral 
bodies. The contrast medium should not spread beyond the 
contours of the vertebral bodies on the fluoroscopic image. 
The lateral view of the vertebral body should show a smooth 
posterior outline. The contrast medium should not spread 
dorsally towards the nerve roots. 
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Alternatively, if the procedure is done under CT guidance, the 
contrast medium should show up laterally and behind the 
aorta. If the contrast medium shows up only in the retrocrural 
space, the needles should be advanced deeper, to reduce the 
risk of the local anesthetic or the neurolytic agent spreading to 
the somatic nerves.  Paravertebral	  (retrocrural)	  approach	  	  
The Th12 vertebral body is identified in a posteroanterior view 
and marked. The C-arm is then rotated to an oblique position 
(about 45°) on the side where the needle is to be inserted. The 
image should show the side of the diaphragm lateral to the 
vertebral body. Observe the diaphragm movements as the 
patient breathes in and out. If the diaphragm obscures the 
Th12 vertebra and rib, identify the Th11 rib. For both levels, 
the needle insertion site on the skin is located at the point 
where the connection between rib and vertebral body cross 
each other.   
After the skin at this site has been anesthetized, a 14G, 5 cm 
extracath is inserted under fluoroscopic guidance, in such a 
way that the catheter moves toward the target like the head of 
a needle. After the extracath has been inserted for two thirds 
of its length, the stylet is removed and replaced by a 20 or 
22G, 15 cm stylet needle. The C-arm is kept in oblique 
position. An extension tube is connected to the needle. The 
needle tip is advanced anteriorly in short (0.5 cm) pushes, with 
the needle tip continuing to slide along the vertebral body. 
Both needles are advanced further, under fluoroscopic 
guidance, past the Th12 – L1 vertebral body. Check for blood 
or CSF by means of aspiration. The final needle location is 
checked on lateral views. After the contrast medium has been 
injected, the lateral view should show it in prevertebral 
position, while the anteroposterior view should show it within 
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the contours of the spine. (figures 4,5 and 6) A neurolytic 
agent can now be gradually injected (see below).  Transdiscal	  technique	  	  
This approach was first described by R. Plancarte,42 but needs 
to be further assessed for efficacy and safety.  
The transdiscal procedure is also carried out under 
fluoroscopic or CT guidance. The patient lies in prone position 
with a support underneath the iliac crest in order to widen the 
access to the intradiscal space. Fluoroscopy is used to identify 
the Th12-L1 level. The C-arm is then rotated obliquely to the 
left at an angle of 15 to 20°. It is important to align the inferior 
endplates using a cranio-caudal projection. The needle 
insertion site is 5 to 7 cm from the midline. After the skin and 
subcutaneous tissues have been locally anesthetized, the 
needle is advanced under tunnel vision to the inferior aspect of 
the facet joint. After the disc has been penetrated, 0.5 ml 
contrast medium (Omnipaque) is injected to check the position 
of the needle in the disc. The needle is then advanced until 
“loss of resistance” is perceived, indicating that the needle has 
exited the Th12-L1 disc. After the final needle position has 
been checked with the help of contrast medium, 10 ml phenol 
in 10% saline (or 10% phenol in glycerin) is injected, followed 
by injection of 2 to 3 ml of air to prevent intradiscal leakage of 
the neurolytic agent. 
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Figure 4: Neurolytic 
plexus coeliacus block: 
needle position in 
anteroposterior view. The 
needles enter at the L2 
level and point obliquely 
upward toward L1 (a stent 
is present in the ductus 
choledochus). 
Figure 5: Neurolytic 
plexus coeliacus block: 
lateral view showing 
dispersion of contrast 
medium around Th12-L1, 
both pre- and retro-aortic. 
 
Figure 6: Neurolytic 
plexus coeliacus block: 
anteroposterior view 
showing dispersion of 
contrast medium within the 
spinal contours. Note the 
characteristic vacuole-like 
bright areas indicating 
correct placement 
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Diagnostic prognostic blocks with the retrocrural technique are 
carried out by injecting 12 to 15 ml lidocaine 1% or 0.25% 
ropivacaine with both needles.  
Most researchers recommend carrying out therapeutic blocks 
by first injecting 10 to 16 ml of local anesthetic, followed by 10 
to 16 ml of 96% ethyl alcohol or a 10% solution of phenol in 
telebrix (10% phenol in glycerin in US) with both needles. 
Many researchers have simultaneously injected a contrast 
medium to check the dispersion of the neurolytic agent. Before 
injecting the neurolytic solution, the area around the needle 
should be covered with wet gauze, followed by fractionated 
injection of the solution in 1 ml portions. This prevents the 
neurolytic agent from spreading to surrounding structures, and 
thus reduces the risk of complications. We recommend the 
use of 10% phenol in telebrix or in glycerin as a reference. 
After the neurolytic agent has been injected, each needle 
should be flushed with saline or a local anesthetic to prevent 
fistula formation. Nervus	  splanchnicus	  block	  	  
An alternative to the paravertebral (retrocrural) approach is the 
nervus splanchnicus block technique proposed by Abram and 
Boas. 43 This blocks the nervi splanchnici, branches of the 
thoracic truncus sympathicus and the nerve supply to the 
plexus coeliacus. 
The patient is lying in prone position with support under the 
abdomen to achieve thoracolumbar kyphotic position. The 
Th11 vertebral body is identified, after which the C-arm is 
rotated from the anteroposterior orientation in a caudal and 
lateral direction, allowing the concave mid-portion of the 
vertebral body to be visualized without being obscured by ribs 
or the processus transversus. 
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A 20 or 22G, 15 cm needle is inserted paravertebrally, under 
tunnel vision, in the direction of the concave mid-portion of the 
vertebral body. Try to make contact with the vertebral body. 
Under lateral fluoroscopy, the needle is advanced to the 
anterolateral aspect of the Th11 vertebral body. Radiographic 
imaging should show the tip of the needle just within the 
contours of the Th11 body in an anteroposterior view, and just 
at the anterior border of the Th11 vertebra in a lateral view. A 
small volume of contrast medium is injected to check 
dispersion along the anterolateral aspect of the vertebral body. 
Before the neurolytic agent is injected (as described above) 
the area around the needle is covered with wet gauze, after 
which the neurolytic solution can be injected in fractions, 
preferably together with contrast medium. The same 
procedure is repeated on the other side. The needles then 
have to be flushed with saline, or a local anesthetic. Aftercare	  
After the procedure, patients may experience pain at the 
insertion site, (orthostatic) hypotension or diarrhoea. Patients 
should therefore be sufficiently hydrated and hospitalized for a 
night to check for signs of hypotension. 
D. Visceral pain due to pelvic tumors 
Introduction 
Patients with extensive tumors in the small pelvis often 
perceive little benefit from oral or parenteral painkillers, or may 
experience intolerable side effects at the required dosages. 
This may necessitate a plexus hypogastricus block. Pain relief 
in the small pelvis is possible because afferent tracts 
innervating the organs in the small pelvis run along the 
sympathetic nerves, bundles and ganglia, making them easily 
accessible to neurolytic blocks. Since visceral pain is often a 
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major component of the pain due to tumors in the small pelvis, 
these neurolytic techniques deserve to be more commonly 
used for patients in the advanced stages of cancer in the small 
pelvis. The superior plexus hypogastricus is located bilaterally 
in the retroperitoneum, along the third to fifth lumbar vertebrae, 
often extending to the upper third part of the first sacral 
vertebra.   
D. I Diagnosis 
D. I.A History taking and clinical symptoms 
Plexus hypogastricus block may be considered for patients 
with a tumor in the small pelvis and pain in the lower 
abdomen. Patients with mostly visceral pain report ill-defined, 
dull, indistinctly localized pain.  
D.I.B Physical examination 
Examination should concentrate on the anatomy of the lower 
back and the sacrum, and try to detect signs of infection and 
superficial tumor growth. Areas to which the pain radiates 
should be assessed in order to identify secondary and primary 
pains. The examiner should also assess whether the patient is 
able to lie in prone position for the duration of the treatment 
without the risk of collapse.  
D. I.C Additional testing 
The location of the pain must be very carefully identified. If the 
patient suffers from radicular pain or very extensive painful 
zones in the lower abdomen or lower body, the preferred 
treatment option is epidural or intrathecal pain control. Pain in 
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the higher parts of the upper abdomen should preferably be 
treated with plexus coeliacus block.  
The technical examination requires accurate assessment of 
the cause of the pain and should have been completed by the 
referring doctor. This examination should yield an accurate 
understanding of the situation before interventional pain 
control techniques are applied.  
Before deciding to carry out a neurolytic block, the physician 
should apply a diagnostic block with a local anesthetic, which 
should produce a 50% reduction of the pain for the normal 
duration of action of the anesthetic.  
D. I.D Contraindications 
• Hemorrhagic diatheses 
• Serious infections in the area where the needle is to be 
inserted 
• Extensive tumor invasion in the area where the needle 
is to be inserted 
D. I.E  Differential diagnosis 
Any pains related to non-oncologic problems are not eligible 
for treatment with plexus hypogastricus block. 
D. II Treatment options 
D. II.A  Interventional management Plexus	  hypogastricus	  block	  
Plexus hypogastricus block has only been evaluated in 
observational studies. The study with the largest number of 
patients was that by Plancarte et al. 44 Of the 277 patients 
included in their study, 51% reported satisfactory pain relief. 
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One study compared the effects of plexus hypogastricus block 
with those of pharmacologic treatment, 45 and found a 
favorable effect of plexus hypogastricus block on both pain 
and opioid consumption. The data provided, however, do not 
allow the specific effectiveness of plexus hypogastricus block 
to be evaluated.  
All studies involving more than 10 patients reported at least 
60% of patients showing considerable pain reduction. 4  
D. II.B Complications 
Plexus hypogastricus block is a relatively safe technique 
provided it is carried out under X-ray or CT guidance. 
Neurolysis of somatic nerves or intravascular injection of 
neurolytic agent is possible. 
Bilateral superior plexus hypogastricus block can cause sexual 
dysfunction in men. 46 There are several cases of lumbar 
plexopathy with hip flexor weakness (unpublished) due to 
injection into the musculus psoas major laterally, and the 
operator must be careful to inject the neurolytic solution 
medially enough to avoid the psoas compartment. 
D. II.C  Evidence for interventional management 
The evidence for interventional management of visceral pain 
due to cancer is summarized in table 5. 
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Table 5: Summary of the evidence for plexus hypogastricus block 
Technique Evaluation 
Neurolytic plexus hypogastricus block  
 
2 B+ 
D. III Recommendations  
We recommend the use of plexus hypogastricus block for 
patients with visceral pain due to pelvic tumors.  
D. III.A Technique 
The patient is lying in prone position on a radio transparent 
table, with a support underneath the pelvis to reduce lumbar 
lordosis. It might be useful to apply lumbar spinal or epidural 
anesthesia before starting the plexus hypogastricus block 
procedure, to reduce the discomfort caused by the puncture. 
Alternatively, the deep paravertebral muscles may be 
infiltrated with local anesthetics.  
The X-ray device is positioned in such a way as to allow the 
promontory or the concave mid-portion of the L5 vertebral 
body to be seen under tunnel vision from the needle insertion 
point 5-7 cm lateral of the midline, at the L4 level. This means 
that the tube has to be angulated by about 45°, both in 
anteroposterior and cranial view.  
A 20 or 22G, 15 cm needle is positioned at the front of the L5-
S1 intervertebral space, under radiographic guidance (tunnel 
vision). Use aspiration to check its position, in order to avoid 
injecting into the iliac blood vessels. The radiographic images 
should show the tip of the needle paravertebrally at the level of 
the L5-S1 intervertebral space in anteroposterior view, while a 
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lateral view should show the tip just touching the anterior 
border of the L5-S1 vertebra. (Figures 7, 8, and 9) At this 
point, it is useful to inject a water-soluble contrast agent to 
confirm the correct position of the needle and avoid 
intravascular injection. The contrast medium should not 
disperse beyond the lateral confines of the L5 vertebral body, 
nor in a dorsal direction toward the nerve roots. A diagnostic 
plexus hypogastricus block can be carried out using 6 to 8 ml 
bupivacaine 0.25–0.5%. A therapeutic block is carried out 
using 6 to 8 ml 10% phenol solution in telebrix (in glycerin in 
US) on each side of the vertebra. The safety of the procedure 
can be improved by fractionated injection, with continuous 
monitoring of the dispersion of the phenol by means of 
contrast medium.  Please take care to avoid the psoas 
compartment laterally at L5-S1 level. 
 
 
 
 
Figure 7: Needle position 
for plexus hypogastricus 
block: oblique view 
Figure 8: Needle position for 
plexus hypogastricus block: 
anteroposterior view 
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Figure 9: Plexus hypogastricus 
block: lateral view 	  
 
E. Perineal pain due to pelvic tumors  
Introduction 
Perineal pain caused by tumors may be treated with 
intrathecal phenolization of the lower sacral roots of the cauda 
equina (lower end block or saddle block). Physicians have 
hesitated to use this technique, however, because of the risk 
of permanent damage to the nerves controlling the bladder 
and rectum function, with potentially serious consequences. 
This is why the technique is usually considered only as a last 
resort, after all other forms of oral or parenteral pain control 
have been tried and either proved ineffective or cause 
intolerable side-effects.  
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E. I Diagnosis 
E. I.A History taking and clinical symptoms 
Lower end block may be considered for patients with perineal 
pain due to tumors of the small pelvis. The technique is often 
considered only after the anus has already been surgically 
removed and the patient has been fitted with a stoma and a 
permanent bladder catheter.  
E. I.B Physical examination 
The lower back and sacral zone must be carefully inspected to 
check for any infections or tumor invasion. Check whether the 
patient is able to sit up during the procedure and is 
cooperative. The patients must be able to accurately report 
sensory perceptions in the lower limbs.  
E. I.C Additional testing 
Perineal pain should be of mainly somatic origin, and no other 
suitable therapy should be available. A precondition for the 
use of this technique is existing urinary and fecal incontinence 
or the presence of a bladder catheter and an artificial anus. 
E. II Treatment options 
E. II.A  Interventional management 
Although lower end block is described in textbooks, 47, 48 no 
high-quality studies on the subject have been published in the 
past 20 years. Three recent case reports included a limited 
number of patients. The results in these reports were variable: 
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the median duration of the effect was 3 months, but opioid 
dosages could be reduced to 60%. 49-51 
E. II.B Complications  
• Loss of sensory function, sometimes with dysesthesias 
of the lower limbs and/or the buttocks 
• Loss of urinary or anal sphincter function, 
• Muscle weakness  
E. II.C Contraindications 
• Life expectancy > 6 months 
• Blood coagulation deficiencies 
• Extensive tumor invasion  
• Extensive infection in the needle insertion area 
E. II.D  Evidence for interventional management 
The evidence for interventional management of perineal pain 
due to pelvic tumors is summarized in table 6 
Table 6: Summary of the evidence for lower end block 
Technique Evaluation 
Intrathecal phenolization of lower sacral 
roots of cauda equina  
0 
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E. III Recommendations  
 
A lower end block should only be considered for the treatment 
of cancer patients who experience pain in the small pelvis and 
have lost normal bladder or rectal function. Since there have 
been no formal studies of the effectiveness of the treatment 
and the duration of the effect, we recommend using this 
technique only in the context of an experimental study or in 
cases of compassionate use with no other available forms of 
effective pain relief available with good informed consent.  
E. III.A Technique 
The patient should be able to respond normally when being 
spoken to or asked questions during the procedure. There 
should be enough nursing staff present to place and hold the 
patient in the correct position and to change the patient’s 
position during the procedure. All regulations for implementing 
aseptic procedures must be strictly observed. An intravenous 
line must be inserted to allow medication to be administered, 
and precautions for resuscitation must be in place.  
The lower lumbar spinal segments must be in kyphotic position 
so as to achieve maximum curvature. A large area should be 
disinfected and covered with a sterile surgical drape with an 
opening. The skin is anesthetized. A 22G spinal needle is 
inserted in the L5-S1 intervertebral space at median level, and 
carefully advanced until CSF flows out. The phenol solution 
(6% in glycerin) is then freshly drawn into a 2 ml syringe with 
accurate volume graduation lines. The phenol syringe is 
connected to the spinal needle. The patient’s position must 
now be adjusted. The patient is asked (assisted by the nursing 
staff) to lean backward at an angle of 45°, so that the back is 
at a 45° angle to horizontal. This requires considerable effort 
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on the part of the nursing staff. Phenol is now injected in 0.2 
ml portions into the intrathecal space, to a total volume of 1 ml 
over a period of 5 minutes. Infiltration should be immediately 
stopped if the patient indicates sensory changes in the lower 
limbs or the buttocks. In some cases, injection must be 
continued to a maximum total volume of 1.5 ml. The spinal 
needle is then removed and the patient should remain seated 
at a backward angle of 45° for the next 6 hours. Their blood 
pressure must be regularly checked, and some fluid 
replacement may be required.  
Changes in pain perception should be checked by monitoring 
the VAS score for pain. Oral or parenteral analgesics should 
only be gradually reduced in the course of the following days, 
if the treatment has an analgesic effect. It is rarely possible to 
end analgesics use completely, as successful treatment often 
causes other pains to become manifest.    
F. Spinal pain related to vertebral compression 
fracture (with or without pathologic tumor 
invasion) 
Introduction 
Many cancer patients suffer morbidity due to skeletal 
metastasis, pain, and vertebral compression fractures. 
Skeletal complications are very common in multiple myeloma 
regardless of stage, and in metastatic breast, prostate, and 
other solid tumors. 
Extradural metastases account for some 95% of secondary 
spinal tumors. The primary sources of metastatic neoplasms to 
the spinal axis vary among the published series with 65% 
coming from carcinoma of the breast, lung, and prostate. 
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Renal cell carcinoma and myeloma also occur and together 
account for 10% of spinal metastases. 52  
F.I Diagnosis 
F. I.A History taking and clinical symptoms 
Patients with cancer who develop significant axial spinal pain 
merit imaging studies via their oncologist to rule out metastatic 
disease or pathological fracture.  Focal spinal pain in a cancer 
patient nearly always mandates some sort of radiological 
workup.  Vertebral compression fracture pain is typically 
incidental, and non-radiating.  Patients with neurological 
deficit, band-like pain, or any loss of bowel and bladder control 
may have spinal cord compression and merit an immediate 
neurosurgical evaluation to include imaging studies.   
F. I.B Physical examination 
Patients with cancer related vertebral fracture should have a 
complete neurological exam to ensure that the spinal cord is 
not compromised prior to consideration of these techniques.  
Furthermore, the pain should be concordant with the level of 
pathology.    
F. II Treatment options 
F. II.A  Interventional management 
Pathologic spinal involvement without fracture is usually 
treated with conventional radiotherapy.  A spinal vertebral 
compression fracture with tumor is often treated the same 
way, but the mechanical pain can be refractory to the radiation 
therapy.  In these cases, percutaneous vertebroplasty (PV) or 
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kyphoplasty can be helpful.  In cases involving neurological 
compromise or significant epidural disease, open surgical 
treatment may be indicated.   
Percutaneous vertebroplasty and kyphoplasty 
Indications for PV have expanded to include osteoporotic 
compression fractures and painful vertebral metastasis.  
Percutaneous kyphoplasty (PK) is a modification of PV; it 
involves the percutaneous placement of balloons (called 
“tamps”) into the vertebral body with an inflation/deflation 
sequence to create a cavity prior to the cement injection.  
Percutaneous kyphoplasty (PK) may restore vertebral height 
and reduce the kyphotic angulation of the compression 
fracture prior to bone cement injection.53, 54 A recent 
prospective trial in non-cancer VCF’s shows good efficacy, 
with significant reduction in pain and improved function. 55.  
Several smaller case series show good pain improvement with 
these procedures.56  
F. II.B Complications  
Complications are rare, but can be serious and the exact 
incidence is unknown.  Most case series report asymptomatic 
Polymethyl Methacrylate (PMMA) extravasation rates of 
around 10-15%. 54, 57 The Society for Interventional Radiology 
(SIR) divides up complications for these techniques into minor 
and major. Minor complications are those considered to 
require no therapy and having no consequence, such as 
PMMA extravasation into the disc.  Major complications are 
those requiring therapy, including an unplanned increase in 
the level of care needed, or having ongoing permanent 
sequelae (i.e.- PMMA into the spinal canal with neurological 
deficit).  SIR noted published complication rates for major 
complications to be less than 1%, except in those with 
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neoplastic involvement of the vertebrae, where the reported 
level of major complications is less than 5%.58, 59    Indications/	  Relative	  and	  Absolute	  Contraindications	  
The indications and contraindications are summarized in table 
7. This table is based on the different guidelines from the SIR 
and Cardiovascular and Interventional Radiological Society of 
Europe. First published by McGraw et al. 58 and updated by 
Gangi et al. 59.   
Table 7: Indications and contraindications for percutaneous 
vertebroplasty 
INDICATIONS: 
1. Painful osteoporotic vertebral compression fracture refractory to 3 
weeks of analgesic therapy. 
2. Painful vertebrae due to benign or malignant primary or secondary 
bone tumors. 
3. Painful vertebral compression fracture with osteonecrosis 
(Kummel’s disease) 
4. Reinforcement of vertebral body prior to surgical procedure.* 
5. Chronic traumatic vertebral compression fracture with nonunion.* 
ABSOLUTE CONTRAINDICATIONS: 
1. Asymptomatic vertebral compression fracture 
2. Patient Improving on Medical Therapy 
3. Ongoing Infection 
4. Prophylaxis in Osteoporotic Patient 
5. Uncorrectable coagulopathy 
6. Myelopathy due to retropulsion of bone/canal compromise 
7. Allergy to PMMA or opacification agent 
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RELATIVE CONTRAINDICATIONS: 
1. Radicular pain 
2. VCF > 70% height loss* 
3. Severe spinal stenosis, asymptomatic retropulsion of bony fragment 
4. Tumor extension into canal/epidural space 
5. Lack of surgical backup.* 
 
Modified from McGraw et al. 58 and updated by Gangi et al. 59. 
Recommendations from the more recent update (Gangi 2006 are 
marked with *) 
F. II.C  Evidence for Vertebroplasty or Kyphoplasty 
Recent reviews and editorials have called for a more critical 
evaluation of these procedures in view of some recent studies 
questioning the efficacy of these procedures in non-cancer situations. 
Table 8 summarizes the level of evidence  
 
Table 8: Summary of the evidence for vertebroplasy and kyphoplasty 
in the management of vertebral compression fractures with or without 
pathologic tumor invasion 
Technique Evaluation 
Vertebroplasty 2B + 
Kyphoplasty 2B + 
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F. III Recommendations for Vertebroplasty or Kyphoplasty 
In summary, we view PV/PK as valuable adjunctive therapies 
for cancer patients with painful vertebral compression fractures 
from all etiologies.  The overall complication rate is low and 
efficacy acceptable.   
F. III.A Technique 
The technique of both vertebroplasty and balloon kyphoplasty 
has been described in Peh et al. 53 
Summary 
Interventional pain management techniques in the treatment of 
refractory oncologic pain syndromes are indicated if oral or 
parenteral analgesics cause such severe side effects that a 
satisfactory quality of life and satisfactory pain relief cannot be 
reached.  
All of the techniques described in this article should only be 
considered in a specific multidisciplinary pain center, with all 
capacities of a thorough clinical follow-up.  
These interventional techniques require high attention, great 
care and thorough specialist knowledge as well as extensive 
expertise. The clinical center needs to meet all requirements 
for the safe implementation of interventional techniques.  
Effective nursing assistance, a specially equipped operating 
area and effective aftercare are required to satisfy all safety 
regulations.  
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Abstract: 
 
The management of chronic pain still remains a challenge, because of 
its complexity and the unpredictable response to the pharmacological 
treatment. In addition, accurate pain management may be hindered by 
the prejudice of physicians and patients that strong opioids, classified 
as step 3 medications in the WHO ladder for cancer pain 
management, are reserved for the end stage of life. Recent 
information indicates the potential value of strong opioids in the 
treatment of chronic non-malignant pain. There are, up till now 
insufficient data to provide indications about which opioid to use for the 
start of the treatment and at which dose it should be used for any 
specific pain syndrome. The strong inter-patient variability in opioid 
receptor response and in the pharmacokinetic and pharmacodynamic 
behavior of strong opioids justifies an individual selection of the 
appropriate opioid and step-wise dose titration. Clinical experience 
shows that switching from one opioid to another may optimize pain 
control while maintaining an acceptable side effect profile or even 
improving the side effects. This treatment strategy, described as opioid 
rotation or switch, requires a dose calculation for the newly started 
opioid. Currently, conversion tables and equianalgesic doses are 
provided, mainly by the drug manufacturing companies. However, 
those recommendations are often based on data derived from studies 
designed to evaluate acute pain relief, and sometimes on single dose 
studies, which reduces this information to the level of an indication. In 
daily practice, the clinician needs to titrate the optimal dose during the 
opioid rotation from a reduced calculated dose, based on the clinical 
response of the patient. Further research and studies are needed to 
optimize the equianalgesic dosing tables. 
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Introduction 
Chronic pain represents a major burden for the patient, his 
environment and society. Whereas acute pain is mainly 
attributed to an identifiable cause, chronic pain syndromes are 
usually complex and the underlying mechanisms often remain 
unknown. Pain is defined by the International Association for the 
Study of Pain (IASP) as an unpleasant sensory and emotional 
experience associated with actual or potential tissue damage or 
described in terms of such damage 1. Chronic pain mostly 
persists for more than 3-6 months, far beyond the normal 
healing time 2. Even though medicine has made considerable 
progress, the management of chronic pain still remains difficult 
3,4. In a proportion of patients, no clear etiological diagnosis can 
support the presentation of pain. Chronic low back pain for 
example is commonly divided into disease specific and atypical 
low back pain. The latter group is estimated to be approximately 
90% of patients suffering low back pain.5 Moreover, 
pharmacological and somatic treatments fail to provide 
prolonged pain relief 6, which result in misinterpretations and 
difficulties with reference to medical judgment in the case of 
chronic pain patients 7. 
A classical, merely anatomical, understanding of the disorder 
cannot explain why some, but not all, people are disabled by 
pain in the absence of a specific organic cause 8. Since the 
introduction of the biopsychosocial model of chronic pain, its 
treatment has become multimodal and directed towards a 
maximum of pain reduction and a better quality of life, 
independency and mobility 9-12.  
Pharmacological treatment is still a cornerstone of the 
management of patients suffering chronic pain.  
Aim of this review 
Opioids are generally considered to be efficient drugs for the 
management of chronic cancer and non-cancer pain. Achieving 
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optimal therapeutic effect by increasing the opioid dose may 
however be hindered by serious side effects. Opioid rotation or 
switch is a technique used to optimize the analgesic effect of 
opioids while keeping side effects at a tolerable level. This 
article aims at reviewing the available information regarding 
opioid rotation or switch in cancer and non-cancer pain.   
Methods 
A search in PubMed using the abstract words “opioid” and 
“rotation” or “switch” was performed. The abstracts were 
reviewed by the authors and the full papers of those articles 
reporting clinical trials (retrospective, prospective and 
controlled) as well as the first reviews were retrieved for further 
analysis.  
The management of chronic pain: a step-wise 
pharmacological approach 
The World Health Organization (WHO) established guidelines 
for the management of cancer pain 13 represented in the well-
known three-step pain ladder, whereby treatment is initiated 
with non-opioid analgesics (step 1) potentially combined with 
co-analgesics. When these products are used at correct doses 
and in the right administration schedule without providing 
sufficient pain relief, or provoking intolerable side effects, weak 
opioids (step 2) will be added and if necessary combined with 
co-analgesics. Finally, if pain persists, weak opioids will be 
replaced by strong opioids (step 3) potentially with or without co-
analgesics 13.  
Comparable pharmacological guidelines can be useful for the 
management of chronic non-malignant pain 14,15. One should 
however always consider that in order to treat the multimodal 
character of chronic pain the pharmacological treatment must 
be combined with psychological, social, physical rehabilitation 
interventional techniques 16.  
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The role of opioids for the management of cancer 
pain 
Studies report that 33 % of patients receiving active cancer 
treatment experience severe cancer-related pain 17. Despite the 
recognition that cancer pain seriously interferes with the 
patient’s quality of life and all efforts to stimulate adequate pain 
management, estimates indicate that approximately 30 % of the 
cancer patients do not receive appropriate pharmacological pain 
treatment 18. Several factors contribute to this under treatment 
such as patient’s reluctance to report increasing pain intensity 
out of fear that this means disease progression and patients’ 
and physicians’ deficient knowledge of opioid therapy, 
overestimating the risk for addiction and side effects. Long-
acting opioid preparations form the cornerstone of cancer pain 
management and short-acting opioids will be used for 
breakthrough pain. The newer administration forms and 
molecules have provided physicians with a greater range of 
analgesic options. In clinical practice, opioid pharmacotherapy 
for cancer and non-malignant pain hinges on finding “a 
satisfactory balance between analgesia and side effects” 19.  
The role of opioids for the management of non-
malignant pain 
While over 80% of the cancer patients use WHO step 3 
analgesics health care providers remain reluctant to initiate a 
prolonged opioid treatment for non-malignant pain 20. Chronic 
pain management should initially focus on treating the 
underlying cause, such as infection or fracture. In a substantial 
proportion of patients, which can be as high as 90% no 
etiological diagnosis can support the presentation of pain, 
leaving a symptomatic pain control as the main treatment. 
Recent research demonstrates that opioids can have an 
additive value in the management of chronic pain 14.  
Opioid rotation 
 172
Prescribing opioids 
The WHO recommendations for the management of cancer 
pain, suggesting the use of long acting opioid preparations on a 
fixed time dosing schedule, should also be pursued when 
treating chronic pain of non-malignant origin. Evidence on the 
efficacy and safety of chronic opioid use in non-cancer patients 
is progressively becoming available. However, more information 
is still needed regarding the effect of long-acting versus short-
acting opioids and differences in efficacy and safety between 
the available µ-receptor agonists needs clarification. 21 Recently 
published guidelines provide suggestions for correct prescription 
of opioids. 22. The chronic use of opioids is safe when they are 
correctly prescribed and monitored, minimizing the risk of 
substance dependency and abuse 23. Opioid treatment should 
be considered for both continuous neuropathic and nociceptive 
pain if other therapies fail to provide adequate analgesia within 
a reasonable timeframe 14. This treatment approach has the 
objective to reduce pain as much as possible and to improve the 
patients’ quality of life, while keeping the side effects and risks 
at a minimal level. Both of these objectives should be assessed 
during a specific well-defined trial period. The first weeks to first 
months of opioid treatment in non-cancer patients are 
considered as a starting titration period which requires strict 
medical supervision in order to find an adequate dose of opioid 
until satisfactory pain relief is achieved and the severity of side 
effects can be judged. This screening period can vary in length 
for each individual patient depending on the pharmacological 
response.22Those patients demonstrating a good clinical 
response to the use of opioids during this trial period can 
continue their opioid treatment chronically. During the initial trial 
period, selection of a specific opioid should be done based on 
criteria such as efficacy, tolerability, safety, and ease of use. 
Chronic opioid treatment is initiated at a low dose that is 
gradually increased based on careful monitoring of the pain 
reduction and the side effects 22. Possibly, several long-acting 
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opioids will have to be tested before the optimal management 
scheme is reached. This means that the patient experiences an 
adequate pain relief during the whole day, with a minimum of 
side effects. Short-acting opioid preparations are reserved for 
the treatment of pain attacks (breakthrough pain) or as a help in 
the dose titration phase. 
Chronic pain management should be individualized. 
Preferentially, the proposed treatment scheme is the result of 
consent between the pain patient and the physician. This 
consent is useful for clarifying patient expectations and defining 
limitations of therapy. Patients must be fully informed about the 
nature of their treatment and its possible benefits as well as 
harmful effects. A contract should be agreed between both 
parties, illustrating the patient is committed to the aims of the 
treatment and is understanding that receiving opioid therapy 
entails responsibilities. The patient agrees to inform his 
physician about his medical treatments, other medications and 
the occasional use of centrally acting substances such as 
alcohol or drugs. He commits to use only those analgesics 
prescribed by his treating physician and not to ask prescriptions 
from other doctors. This contract should also allow performing 
random blood and urine sampling for drug testing. Especially, 
for patients with a history of drug abuse and aberrant drug-
related behaviors, strict follow-up is mandatory to allow timely 
identification of potential abuse and addiction .18,22 
Factors influencing the failure of opioid treatment 
The most frequent reason for opioid treatment failure is that a 
dose increase necessary to control pain, is limited by intolerable 
side effects. The pharmacological tolerance refers to the 
diminishment of opioid effects caused by repeated exposure to 
the drug. There may be many reasons for the induction of opioid 
tolerance. First, chronic use of alcohol and barbiturates induce 
an increased metabolization of other medication (increasing 
Opioid rotation 
 174
activity of cytochrome P450), resulting in a reduced 
pharmacological effect.24 Second, chronic receptor activation 
induces adaptation of the neuronal systems by the expression 
of compensating mechanisms, whereby the receptor has a 
reduced sensitivity for the agonist. 25Third, some metabolites 
may also induce receptor activation. 26 
Finally, pain intensity for an individual patient does not remain 
constant, making adequate dose titration of the strong opioid 
difficult. Because of the diversity of the factors contributing to 
opioid tolerance it is a difficult to study subject27.  
Opioid-induced hyperalgesia (OIH), a clinical entity in which 
patients experience worsening of pain and abnormal symptoms 
such as allodynia, despite increasing doses of opioid, is now 
accepted as a clinical reality and should be differentiated from 
opioid tolerance 28. OIH is thought to be caused by the 
simultaneous development of a pronociceptive process along 
with a desensitization process, though the relative contribution 
of each is not yet clear 29. Cross-tolerance is the tolerance to 
one opioid that develops as the result of the continued use of 
another substance with similar pharmacological action. Not all 
WHO step 3 strong opioids have a comparable pharmacological 
response in the same pathology. Intrinsic opioid receptor activity 
can vary significantly between the different strong opioids. 
Genetic factors are another cause for differences in opioid 
responsiveness 30. Differences between strong opioids in the 
potential induction of tolerance and dependence have been 
attributed to differences in receptor affinity, potency, efficacy, 
bioavailability and half-life, constituting the relative activity of the 
particular opioid µ-receptor agonist. Opioids are µ-receptor 
agonists, this means that coupled to the µ-receptor, the complex 
‘receptor-receptor agonist’ induces a signal transduction.  The 
quality and quantity of signaling by µ-receptor agonists is 
determined by a variety of properties leading to receptor 
activation “RA” and/or endocytosis and resensitization “VE”. 
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Because ligand activity and the degree of endocytosis is not 
always linear each opioid has an particular Relative Activity 
Versus Endocytosis ‘RAVE’. The differences in RAVE are 
considered to be one explanation for differences in the potential 
for developing tolerance and/or dependence 25.  
For these reasons switching from one opioid to another is useful 
to improve the individual responsiveness 31. 
Opioid rotation or opioid switch 
After a correct initiation and titration of the opioid, the initial 
clinical efficacy may wean off gradually 14. Patients may 
experience breakthrough pain regardless of an adequate 
adherence to therapy, which justifies a titration of the treatment 
regimen to higher doses. When these higher doses provoke 
unwanted side effects opioid administration route conversion 
and/or opioid rotation may be considered. 
Conversion from oral or transdermal administration route to 
parenteral administration results more rapidly in adequate 
analgesia 32. In two prospective non-randomized studies in 
cancer patients 33,34 it was shown that changing to the 
parenteral administration route was successful in 75-95% of the 
patients 35.  
Intrathecal opioid administration has been practiced since the 
discovery of the opioid receptors in the neural tissue. 
Administration of the opioid agonist close to the receptor results 
in the need of lower doses to achieve comparable analgesia. 
When switching from oral morphine or hydromorphone to the 
intrathecal administration the daily dose can be reduced by a 
factor 300 36. There is little information on the reduction in side 
effects when switching from oral to intrathecal drug 
administration. Evidence on the efficacy of intrathecal drug 
delivery is predominantly acquired in patients suffering cancer 
pain, where effective pain relief was demonstrated 37. The 
Opioid rotation 
 176
implantable drug delivery systems facilitate the chronic 
intrathecal drug administration. A review of more than 20 years 
use of intrathecal opioid application with implantable pumps the 
efficacy and safety of this treatment option in chronic non-
cancer pain concluded that an improvement in pain and 
functioning was observed 38. There is however a lack of 
comparative data with other treatments.  
Opioid rotation is a therapeutic strategy whereby the first opioid 
is stopped and replaced by a different opioid. The success of 
opioid rotation is based upon the incomplete cross-tolerance 
between opioid analgesics implying a distinctly different 
pharmacodynamic and receptor interaction between opioids. A 
systematic review of 67 publications related to opioid rotation for 
reducing side effects in patients suffering cancer pain found 
regain of satisfactory pain control and/or reduced side effects in 
50 to 70 % of patients 39.  At present, there are no evidence-
based guidelines for opioid choices with rotation. Changing from 
one opioid to another is not easy. Many physicians do not feel at 
ease with this technique, because of the challenge to provide a 
safe adequate pain relief during this period.  
The rational for opioid choice for rotation are listed in table 1. 
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Table 1:  Rationale for opioid choice during rotation 
 
Rational choices for opioid rotation involve consideration of 
differences in: 
 The MOR receptor binding (fentanyl and methadone) 
Opioid receptor type, other than MOR (KOR for oxycodone, 
DOR for methadone and levorphanol, ORL-1 for buprenorphine) 
Affinity for opioid receptors 
Affinity for non-opioid receptors involved in analgesia 
(NMDA receptor antagonist and monoamine reuptake 
inhibitors such as methadone and levorphanol) 
The ability to influence opioid receptor adaptation and intrinsic 
efficacy (sufentanil, fentanyl and methadone) 
MOR= Mu-opioid receptor; KOR = Kappa-opioid receptor; DOR= Delta-opioid 
receptor; NMDA = N-methyl D-aspartate 
Opioid tolerance inversely relates to opioid intrinsic efficacy, 
which significantly changes equivalents at higher doses. 
Intrinsic efficacy accounts for differences in dose response and 
dose equivalence between opioids, and is partly the cause for 
asymmetrical cross-tolerance between opioids.40 Therefore 
choices for rotation can be from a narrow to broad-spectrum 
opioid binding profile or from low to high intrinsic efficacy or 
both.  
Equianalgesic tables 
Equianalgesic tables can guide physicians to estimate the 
optimal dose for a patient of a new opioid that should replace 
the opioid to which the patient has started to develop tolerance. 
They provide only broad guidelines for selecting the dose of an 
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opioid because of differences between the populations studied 
to define the equivalent dose, with those patients requiring 
opioid rotation. As stated above, there are large individual 
pharmacokinetic and even larger pharmacodynamic differences 
in opioid pharmacology. 
The calculations of equianalgesic doses often give the highest 
dose for comparable analgesic effects. However, these 
conversion tables have no scientific evidence 41. They are often 
based on results of older clinical trials that had the objective to 
compare the efficacy of two opioids in a short time frame. Some 
of these trials describe single medication administrations 42,43. 
The treating physician should be well aware of the limitations of 
equianalgesic tables.  
“Ongoing diligent patient assessment is the most important step 
in the equianalgesic conversion process. The conversion must 
take into account individual patient characteristics such as age, 
renal function, side effects and the patient’s pain syndrome. In 
addition, if the opioid dose is not adequate to begin with, the 
conversion dose is less likely to be effective. In all situations, 
once the patient is converted, liberal titration and adjustment of 
individualized doses for each patient are required to ensure that 
the conversion transition is smooth and provides the patient with 
the analgesia needed to adequately manage the pain.” 43 
So, the proposed opioid dose should be based on a theoretical 
dose calculation and titrated in accordance with the observed 
clinical efficacy and the patients’ individual characteristics such 
as, age, renal function, side effects and type of pain syndrome.  
It is important to realize that conversion ratio’s can differ 
according to the patient population and the sensitivity of the 
underlying etiologies. Different pain syndromes, such as 
osteoarticular diseases, neuropathic pain or oncologic pain 
states may demonstrate a variable and highly unpredictable 
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clinical response, which devaluates the importance of 
conversion tables 44. Besides, in both chronic non-cancer and 
cancer patients considerable interindividual differences exist in 
the pharmacokinetic and pharmacodynamic behavior of different 
opioids, making an individual dose titration mandatory 22,39,45,46 
Safety of equianalgesic tables 
The majority of patients needs a lower dosing of the new opioid, 
than the dose theoretically calculated with an equianalgesic 
table 43,47,48. Because of an incomplete cross-tolerance, it is 
recommended to reduce the calculated dose by 33 %. For 
safety reasons the new opioid will be initiated at the lowest 
dose, that, if necessary can be gradually increased to achieve 
adequate analgesia 35,43,45. 
Reference works such as the Textbook of Pain (Wall and 
Melzack, 5th Edition) 49 provide conversion tables whereby 
parenteral morphine 10 mg is used as the unique comparator to 
calculate all other opioid doses in single patients. A recently 
published evidence based guideline for the management of 
cancer pain offers a conversion table based on the literature 50 
(see table 2). Based on a retrospective cohort study in patients 
with cancer and noncancer pain the equipotency ratio of 
transdermal buprenorphine to oral morphine is established at 
1:110 to 1:115. 51 The available conversion tables mainly report 
on the formulation(s) available in the country where the study is 
performed, unfortunately the formulations may differ from one 
country to another, and though they may have proven 
bioequivalence, the method to produce the controlled release 
formulation may be different. 
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Evidence on opioid rotation 
 
Table 2: Conversion ratios for opioid rotation 
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30 10 15 7.5 12 4 
60 20 30 15 25 8 
120 40 60 30 50 16 
180 60 90 45 75 24 
240 80 120 60 100 32 
360 120 180 90 150 48 
480 120 240 120 200 64 
 
Buprenorphine was not included in the source guidelines. 
Mercadante et al. 32 identified a ratio of 70:1 for oral morphine: 
transdermal buprenorphine and 0.6:0.8 for transdermal fentanyl: 
transdermal buprenorphine.   
Opioid rotation or opioid switch is frequently done in the 
management of cancer pain. Retrospective studies indicate that 
in 21-44% of the patients opioid rotation is used 52-56. In 
prospective studies those percentages are 12% 57 and 25% 58. 
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There are no randomized controlled trials investigating the 
efficacy of opioid rotation. A Cochrane review based on articles 
published until January 2003; found 52 publications: 14 
uncontrolled prospective trials, 15 retrospective trials and 23 
case reports 41. Since then more information has become 
available. Published studies are often based on retrospective 
chart reviews but prospective studies have also been conducted 
52,57. Almost all trials demonstrated that opioid rotation results in 
a better pain relief and/or less side effects. More recently, the 
results of prospective trials have become available. Three 
papers report on the switch from high dose morphine to fentanyl 
(transdermal n=9 and parenteral n=11) in delirious cancer 
patients 59; transdermal buprenorphine (n= 42) 60 and oral 
oxycodone (n =27) 61. The reason for opioid rotation in these 
studies was inadequate analgesia due to intolerable side effects 
that prevented dose increase. After switching from morphine to 
the alternative opioid the dose-equivalent could be increased, 
resulting in better pain control, without increasing the burden of 
intolerable side effects. Another prospective trial reports on the 
rotation to sustained-release hydromorphone (n=50). Patients 
were switched from oral morphine, transdermal fentanyl, 
tramadol, oxycodone or sublingual buprenorphine 62.   
Opioid rotation to methadone 
Methadone, which is less expensive than other sustained-
release opioid formulations, has a unique multiple receptor 
agonist profile, which differs from other strong opioids. 
Methadone is a opioid receptor agonist, a NMDA antagonist and 
a strong inhibitor of serotonin and norepinephrine reuptake. This 
unique pharmacodynamic profile can be beneficial in the 
treatment of chronic pain states. Its non-linear 
pharmacokinetics, the large inter individual differences in drug 
clearance, time-dependent clearance and different intrinsic 
efficacy compared with morphine, makes it impossible to 
accurately predict equianalgesia to other opioids. Fatal 
Opioid rotation 
 182
arrhythmias with methadone treatment have been described. 63 
Most doctors fear delayed toxicity and therefore are reluctant to 
consider methadone as a first line opioid or an option in opioid 
rotation. However, dosing strategies are published in 
retrospective and prospective trials.  
Methadone potency is much higher than previously published in 
older conversion tables dating from in the 1980s and early 
1990s. Recent studies have found methadones’ relative potency 
increases with the dose of morphine at the time of rotation 64 65. 
This is also true for hydromorphone 66. Hence, opioid ratios will 
change with total opioid dose prior to methadone rotation. A 
systematic review of opioid-methadone conversion ratios found 
22 clinical studies and 19 case reports or series on 730 patients 
in total. Methadone was most commonly used in cancer patients 
(88.9%). The most common reasons for switching to methadone 
was a combination of inadequate analgesia and adverse effects. 
This review highlights the wide variation in ratios of dosing 
between the prerotation opioid and methadone. In general a 
ratio of 4:1 was used for patients who received < 90 mg daily 
oral morphine equivalent; a ratio of 5:1 was used for < 400 mg 
daily oral morphine equivalent and 10:1 for > 400 mg daily of 
oral morphine equivalent. The percent of success ranged from 
46% to 89% 67. 
The rotation to methadone reported in trials can be summarized 
in two strategies. A 3-day overlap rotation schedule utilizes a 
morphine or morphine equivalent reduced by 30-50 % per day, 
while simultaneously adding methadone. Respiratory 
depression was reported in two trials utilizing this strategy, and 
the time to achieve satisfactory analgesia and reduction of side 
effects may be prolonged, making this method less attractive. 68 
Another rotation strategy includes a “stop-start” method with 
every 8 hours dosing using a linear dose ratio based upon pre-
rotation morphine doses or an every 3hours “as needed” dose 
strategy in which initial methadone doses are 1/10 the of the 
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total morphine or equivalent dose. Responses with these dosing 
methods are seen in 80 % of the patients. Moreover, dose 
requirements do not appear to be related to age, gender or type 
of pain.  
Conclusion 
Opioid rotation should be considered as an option when 
insufficient pain control and/or intolerable side effects are 
reported with a given opioid therapy or when the initially well-
balanced and effective treatment no longer provides the desired 
results. Equianalgesic tables can be used as a guide for safe 
opioid rotation. Those equianalgesic tables should however only 
be considered as a first guide to obtain an indication of the dose 
of a new opioid. Since these tables are often based on studies 
that had as objective to demonstrate analgesic properties, they 
do not take into account the individual pharmacological needs of 
the patients, which justify prudence. It is recommended to 
reduce the dose calculated with the equianalgesic tables by 1/3 
to 2/3. This is justified by a possible incomplete cross-tolerance 
and difference in receptor affinity of the opioids used. The 
consideration of the above-mentioned principles improves 
adequate pain control and reduces the risk of opioid overdosing 
with possible negative consequences.  
Opioid rotation can result in a better analgesic effect at a lower 
equipotent dose. Therefore, appropriate dose titration will result 
in a more optimal use of pharmacological substances. 
Methadone has a specific pharmacodynamic and 
pharmacokinetic profile. The different receptor agonist and 
antagonist activity renders this molecule attractive. However the 
unpredictable pharmacokinetics and inter individual variation in 
drug clearance call for careful monitoring of the patient who is 
switched from another opioid to this drug.  
In those patients in whom insufficient analgesia and/or 
intolerable side effects are noted, opioid rotation can result in 
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better pain control and a reduction of side effects. Clinical 
observations provide evidence that the affinity of different 
opioids for their receptors is not identical. Switching from one 
opioid to another can lead to better pain control with less side 
effects resulting in an improvement of the individual’s overall 
quality of life. Recently, several strong long acting opioids 
became available necessitating further studies to improve opioid 
rotation ratios and equianalgesic tables. Because of the weak 
scientific evidence, pharmacoeconomic decisions cannot be 
based on the present available equianalgesic conversion tables. 
Opioid treatment requires meticulous monitoring, with individual 
dose titration based on the specific clinical condition. Although 
further research is needed to address equianalgesic doses, 
opioid rotation may be considered in patients suffering chronic 
cancer or non-cancer pain that is refractory to the initially used 
opioid.  
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Abstract 
Background 
In 2008 the evidence-based, multidisciplinary Dutch guideline on the diagnosis 
and treatment of pain in patients with cancer was published.  
Objectives 
To study the knowledge of and the adherence to the Dutch guideline on cancer 
pain treatment.  
Setting 
Dutch anesthesiologists/pain specialists 
Methods 
The study was performed with the help of a case vignette. This case vignette 
concerned the treatment of pain and related problems of a patient with inoperable 
pancreatic cancer. The questions of the case vignette reflected the core 
recommendations of the guideline. The anesthesiologists/pain specialists were 
approached by e-mail.  
Results 
The results show that the majority of the Dutch anesthesiologists/pain specialists 
follow the recommendations of the guideline on the pharmacological  (99%) and 
invasive treatment (95%) in the several stages of the disease. The 
recommendations to use a one-dimensional pain scale to evaluate the effect of 
pain treatment or a multidimensional pain assessment in a deteriorating situation 
of the patient with pain were only followed by a minority of the respondents (23% 
in the earlier, 15% in the later stage of the disease). 
Limitations 
As response rate was low (27%), the results should be interpreted with caution 
and cannot be generalized to the entire population of pain specialists in the 
Netherlands. The case vignette was built on the recommendations of the 
guideline; the participants might react differently in daily practice. 
Conclusions 
We conclude that Dutch anesthesiologists/pain specialists treat patients with 
cancer pain according to the standard given by the evidence-based guideline. Yet, 
only a minority of the pain specialists performs structural pain assessment of the 
patient with cancer pain as recommended in the guideline. We recommend that, 
in the next update of the guideline and in implementation programs, more 
attention is given to thorough assessment of the patient with pain and 
cancer. 
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Introduction  
Many patients with cancer suffer from pain,1,2 which is often under-
diagnosed and under-treated.3 Clinical practice guidelines are 
developed to assist practitioners and patients in making decisions 
about appropriate health care for specific clinical situations.4 Their 
implementation should improve the quality of care. The use of a 
guideline decreases the variation between physicians in 
diagnosing and treating diseases by providing the most recent 
evidence-based diagnostic and therapeutic options. 5  
To improve pain treatment in cancer patients in the Netherlands, 
the Dutch Society of Anesthesiologists (NVA), in cooperation with 
the society of integrated cancer centers (IKNL), and with the 
Quality Institute for health care (CBO), initiated the development of 
a multidisciplinary, evidence-based guideline on the diagnosis and 
treatment of pain in patients with cancer, which was published in 
2008. 6,7 A multidisciplinary team of experts of medical and 
paramedical specialists, all involved in the treatment of patients 
with cancer, as well as representatives of the national society of 
patients with cancer (NFK) participated in the development of the 
guideline. The printed version of the guideline was sent to all 
anesthesiologists/ pain specialists in the Netherlands. The 
guideline was also accessible on a national website. In a 
comparative study of all European cancer pain guidelines with 
information on neuropathic pain in patients with cancer, this 
guideline appeared to have a high quality as measured with the 
AGREE II instrument.8 
Yet, developing and disseminating such a guideline does not 
guarantee that the recommendations will be systematically read 
and followed by all health care professionals.9 Therefore, assessing 
the knowledge of and the intention to use a guideline in everyday 
clinical practice is a prerequisite to fine-tune implementation 
activities. Several methods have been described and are used to 
assess whether clinicians are familiar with a guideline and follow its 
recommendations. A first method is self-reporting which can be 
used on a large scale, but overestimates guideline adherence. 10 A 
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second method is retrospective, individual medical record review, 
which is very time-consuming and labor-intensive; in ambulatory 
settings this is also impractical and unreliable, as accuracy and 
completeness in record keeping vary widely.11 Thirdly 
unannounced standardized patients can be used, this is also very 
expensive and time-consuming.12 A fourth method is direct 
observation in normal practice which is inefficient, and potentially 
subject to the Hawthorne effect, meaning that practitioners perform 
better when observed.13 To overcome all these different restrictions 
a case vignette seems an acceptable alternative.14  This is a brief, 
written case history of a fictitious patient, based on a realistic 
clinical situation accompanied by questions exploring what the 
physician intents to do if confronted with this case. A vignette 
should create the normal sequence of events in an actual patient 
visit: taking the patient history, performing physical examination, 
ordering adjuvant tests, making a diagnosis and administering a 
treatment plan. Vignettes provided better insights in the quality of 
clinical care than did medical record review.15 Besides, using a 
case vignette appeared to be comparable with using standardized 
patients to assess the use of a clinical practice guideline, but 
appear to be much cheaper.14 Therefore, we created a case 
vignette study to explore practical knowledge of the Dutch 
evidence based guideline on the diagnosis and treatment of 
patients with pain and cancer in a population of Dutch certified 
anesthesiologists/ pain specialists. The Dutch National guideline 
on the diagnosis and treatment of pain in cancer patients of 2008 
was used as the standard reference.7  
Method  
Participants  
All 350 Dutch anesthesiologists/ pain specialists  
Survey Mailings 
E-mail by the Dutch Society of Anesthesiology 
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The case vignette 
A case vignette was developed by the chairman (KV) and co-
chairman (KB) of the Dutch ‘pain in cancer patients’ guideline 
committee. The format was based on prior surveys regarding 
physician knowledge, communication and attitudes with respect to 
patients with cancer.9,16 In the vignette fourteen questions were 
formulated regarding each relevant topic of the Dutch guideline 
concerning pain assessment, pharmacological and invasive 
treatment and assessment of psychosocial problems related to the 
pain and its treatment.  
This case vignette concerned a relatively young woman with an 
inoperable pancreatic cancer with a fast disease progression. In 
this situation the physician is forced to adapt the assessment and 
treatment of pain in a short period of time according to the illness 
progression and its impact on the patient’s suffering. The case 
vignette was divided in four stages of the disease in which pain 
increased and became more complex. Per part, questions were 
asked about diagnostic and therapeutic issues. The first part dealt 
with the initial assessment and treatment of pain in patients with 
cancer. The second part contained the first adaptations of 
treatment in worsened pain. The third part explored how the 
respondent dealt with multidimensionality such as psychosocial 
and spiritual problems of the patient when having advanced 
cancer. The last part covered more invasive pain treatment in the 
case of insufficient pain relief with regular, conservative treatment 
of pain due to cancer. The case vignette can be found as 
appendix 1.   
The questions of the case vignette were asked in such a way, that 
they reflected the core recommendations in the guideline. (Table 
1) 
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Validation and pre-test 
The use of the vignette was pilot-tested in an academic 
multidisciplinary pain and palliative medicine center, recognized as 
a European Society of Medical Oncology (ESMO) center for 
integrated oncological and palliative care. In this ESMO center 
medical oncologists, trained specialists in palliative care and 
certified anesthesiologists/ pain specialists (all fellows in 
interventional pain practice, FIPP) treat patients with pain and 
cancer in advanced stages. Besides, all clinicians teach pain and 
palliative medicine at the medical faculty. Five of these staff 
members, with different medical specialist background, completed 
the case vignette, which took them 12-15 minutes and gave 
feedback. After adaptation, the case vignette was, with the 
approval of the board, sent by e-mail to all 350 certified members 
of the pain chapter of the Dutch society of anesthesiologists (NVA). 
In the Netherlands, anesthesiologists are not automatically pain 
specialists. Registration in the pain specialist index by the board of 
the Society of Anesthesiologists is done if the requirements of 
education, postgraduate courses and clinical experience are met. 
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Table 1: Summary of the Dutch guideline on the diagnosis and 
treatment of patients with cancer in relation to the questions from 
the case vignette study. The references are the pages in the 
guideline. The question numbers refer to the questions in the 
vignette relevant to this topic. 
Item Recommendation Ref Question(s) 
Pain diagnosis Thorough history and physical 
examination; further investigation on 
indication 
p 27 1,3,11 
Pain 
assessment 
One dimensional scale or 
multidimensional questionnaire in 
persistent pain 
p 26 1,3,8,11 
Paracetamol First line treatment p 69 2,4 
NSAID Given in combination with 
paracetamol or strong opioids if these 
have insufficient effect 
p 73 2,4 
Weak opioids No indication in the treatment of pain 
due to cancer 
p 79 2 
Strong opioids If pain persists with 
paracetamol/NSAID. No preferential 
drug; titration necessary  
p 85 2,4,12,14 
Opioid route Oral or transdermal; subcutaneous or 
intravenous 2nd line 
p 95, 
96 
2,4,12,14 
Spinal opioid 
route 
In opioid resistant, localized pain p 144 6,13,14 
Opioid rotation In opioid resistant pain despite 
thorough titration or intractable side 
effects 
p 96 12 
Constipation Prophylactic laxative mandatory p 105 5 
Nausea Anti-emetic drug in persistent nausea p 104 5 
Sedation Methylphenidate or modafinil in 
persistent sedation and impossibility 
of opioid dose reduction 
p 107 9 
Sleeplessness Benzodiazepine; tricyclic 
antidepressant 
p 25 9 
Nerve blocks Cordotomy; celiac plexus block; 
splanchnic nerve block; lower end 
block; all on specific indication  
p 147, 
150, 
151 
6,13 
Psychological 
evaluation 
Indicated by the multidimensional 
pain questionnaire; in anxiety and/or 
depression  
p 139,, 
140 
7,8,10 
Social 
assessment 
Indicated by multidimensional pain 
questionnaire, spiritual and existential 
questions 
p 139, 
173 
7,10 
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The Dutch anesthesiologists/ pain specialists were the first group 
of medical specialists to be studied with this case vignette as the 
Dutch Society of Anesthesiologists was one of the initiators for the 
development of the Dutch National Evidence based Guideline on 
the Diagnosis and Treatment of patients with cancer. 
Statistics 
Statistical analysis was performed with SPSS 20.0 (IBM, New 
York, NY, USA) and consisted of descriptive statistics: proportions, 
medians and range. 
Per question, frequencies of each answering option were made, as 
well as the percentages of the correct option or combination of 
options. (Table 2)   
Results  
Demographic data 
Ninety-three anesthesiologists/pain specialists completed the 
questionnaire (27%). All questions were completed by all 
respondents, except for the age, which was not answered by 
one participant. Median age of the participants was 48 years 
(range 32-62), and 76 respondents were male (82%). The 
responses on each question of the case vignette are listed in 
appendix 1. 
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Table 2. Case vignette: management of pain in a patient with 
pancreatic cancer by anesthesiologists/ pain specialists in the 
Netherlands 
Number and proportion of Dutch anesthesiologists/pain 
specialists who followed the Dutch guideline on 
diagnosis and treatment of patients with cancer 
 
N (%) 
Initial pain management  
Strategy of pain management (Question 1)     68 (73) 
Treatment of pain (Question 2)     87 (94) 
Adaptation of pain management  
Strategy of pain management (Question 3)     21 (23) 
Treatment of pain (Question 4)     92 (99) 
Prevention of side effects of strong opioids (Question 5)     91 (98) 
Choice of invasive treatment (Question 6)     88 (95) 
Management of pain and environment  
Mourning management (Question 7)     79 (85) 
Strategy of sleeplessness (Question 8)     34 (37) 
Treatment of sleeplessness (Question9)     56 (60) 
Strategy of depression management (Question 10)     90 (97) 
Further adaptation in pain treatment in advanced disease  
Strategy of pain management (Question 11)      14 (15) 
Pharmacologic adaptation of pain treatment (Question 12)      60 (65) 
Choice of invasive pain treatment (Question 13)      48 (52) 
Choice of pain treatment in end stage disease (Question 14)      68 (73) 
 
Number and proportion of Dutch anesthesiologists/pain 
specialists who followed the Dutch guideline on diagnosis and 
treatment of patients with cancer 
Table 2 gives an overview of the results, as compared to the 
recommendation in the Dutch guideline. 
Per part guideline follow up 
In part I, checking the initial management of a patient with pain 
due to cancer, 27% of the respondents failed to perform structural 
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pain assessment. In this stage, almost all respondents (94%) 
treated the pain as recommended.    
Regarding part II of the case vignette, about adapting pain 
treatment when the pain due to pancreatic carcinoma progresses, 
the guideline recommends structural pain assessment together 
with adaptation of pharmacological treatment and consideration of 
invasive pain treatment. Twenty-three percent of the respondents 
combined these three recommendations. In the following questions 
in which adaptation of treatment was asked on separate topics, like 
pharmacological treatment, prevention of side effects and invasive 
treatment, 99% followed the guideline. In accordance with the 
guideline, nobody prescribed codeine and everybody prescribed a 
laxative to prevent constipation due to the use of strong opioids. 
In part III of the case vignette, 22% of the respondents followed 
the recommendation to use a multidimensional pain assessment 
scale to explore problems in daily functioning of patients. 
Nevertheless, the majority of the respondents would also consult 
non-medical professionals to give advice to the patient on topics as 
coping with the deteriorating situation of the patient and her 
children and furthermore talking about the end of life decisions.  
Part IV dealt with disease progression and treatment adaptations. 
Again, the recommendation to do a structural pain assessment 
was hardly followed (15%) in this deteriorating disease state. The 
other recommendations for pharmacological (65%) and invasive 
treatment  (52%) were followed by the majority of the respondents.  
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Discussion 
With the help of the questions from a case vignette we studied the 
practical adherence of Dutch anesthesiologists/pain specialists to 
the Dutch guideline on the diagnosis and treatment of pain in 
patients with cancer. The participants followed the 
recommendations from the guideline on the treatment of cancer 
pain from 65-99% in the relevant questions. The recommendations 
on the assessment of pain were only followed by 15-23%.  
In part I of the vignette, questions were asked about the first visit 
of the patient with the treating physician. As the primary reason of 
referral of patients with cancer to anesthesiologists/ pain 
specialists is pain, it seems logical that the different aspects of pain 
in these patients need careful structural assessment, as is 
recommended in chapter two of the guideline. Yet, still one out of 
four respondents did not use a one- or multidimensional pain scale 
at the first outpatient clinic visit of the patient, which was also the 
case in the French vignette study.17 Almost all respondents 
followed the recommendation on the pharmacological treatment of 
pain, like in the French study. The participants of the French study 
were not only anesthesiologists, but different medical specialists or 
general practitioners who all followed a two year advanced training 
in pain treatment. The French respondents would use more often a 
multidimensional pain assessment scale than the Dutch. This can 
be explained by the fact that part of the respondents in France was 
general practitioner/pain specialist, who are trained in exploring 
multidimensional pain causes and are often responsible for the 
overall treatment of the patient. In the Netherlands, all respondents 
were pain specialists/anesthesiologists. They are consulted for 
their specific expertise in pharmacology of analgesics and in 
invasive techniques and not the primary responsible physician of a 
specific patient. Also the strong emphasis in the Dutch guideline on 
the treatment of cancer pain and less to the assessment of pain, 
which is only mentioned in a short chapter, might have contributed 
to this difference in pain assessment between the Dutch and the 
French respondents. In the Dutch guideline the use of weak 
opioids in the treatment of pain due to cancer is not advised any 
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more. 18 All participants consistently followed this recommendation. 
The Dutch guideline led obviously to a successful de-
implementation of the previous advice on the use of weak opioids.   
In the French study, still 35% of the participants considered the use 
of weak opioids. 
Part II of the vignette covered the adaptation of treatment in 
progression of the disease. The Dutch guideline recommends 
considering, early in the course of the illness, together with the 
necessity to start strong opioids, the performance of a neurolytic 
nerve block in patients with pain due to a pancreatic carcinoma. 
Such a celiac plexus or splanchnic nerve block was chosen as 
often by the Dutch as by the French respondents, but by no more 
than half of the respondents. This is a substantial deviation from 
the guideline. A possible explanation could be the fact, that other 
invasive pain treatments are considered only after starting oral or 
transdermal opioid therapy. Early in the course of the illness spinal 
administration of opioids is not recommended in the Dutch 
guideline. Most Dutch respondents and approximately half of the 
French pain specialists answered in accordance with this 
recommendation. Apparently, this intervention is considered earlier 
in the course of the illness in France than in the Netherlands. The 
other recommendations of the guideline about adaptation of 
pharmacological treatment and coping with side effects of opioids 
were followed by almost all respondents. 
In part III of the vignette attention is given to problems of coping 
with a fatal disease by the patient and her family. The guideline 
gives not very precise recommendations on these topics. The 
majority of the respondents followed common medical practice in 
the Netherlands, but neglected more precise assessment of these 
problems by a multidimensional questionnaire.  
Part IV contained the treatment of pain in advanced disease. In the 
further deteriorating situation of the patient in the case vignette the 
participants followed the guideline on the pharmacologic and 
invasive treatment, again with mostly neglecting accurate 
assessment of the pain. A one- or multidimensional pain 
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assessment scale was used by 79% of the Dutch pain specialists 
at the first visit of the patient. Only 27% of them considered this 
step in an advanced stage of the disease, in which problems with 
coping with suffering and the nearing death can be more 
pronounced. Therefore it is possible, that not directly tumor-related 
factors, which can play an important role in the severity of the pain, 
are insufficiently diagnosed and treated.19  
In progressive pancreatic disease with pain spread over the upper 
abdomen, there can be an indication for spinal administration of 
opioids. The same proportion of Dutch and French respondents 
considered the use of this invasive technique according to the 
guideline. At the end of life, when the oral route to take medication 
is not suitable, almost all Dutch respondents (73%) choose the 
subcutaneous route for opioid administration. Being acquainted 
with the intravenous route of opioid administration as 
anesthesiologists/pain specialists are, it is remarkable that almost 
all of them correctly advice the subcutaneous route at home. They 
are obviously aware of the difficulty of maintaining the intravenous 
route outside the hospital. The intravenous route is preferred by 
53% of the French pain specialists and the subcutaneous route by 
23%. In France therefore it seems more customary to maintain an 
intravenous route than in the Netherlands.     
Strengths and limitations   
This is the first evaluation of the adherence to the national 
guideline of the Dutch anesthesiologists/pain specialists. The 
results can be used for the future revision of the guideline as well 
as for specific implementation activities and training of pain 
specialists. Next, the case vignette was sent to all 
anesthesiologists/pain specialists in the Netherlands.  
Although the response rate was quite low (27%), it was equal to 
the response rate of a similar case vignette study in France, 17 and 
slightly lower than the response rate of medical oncologists (32%) 
on a case vignette study on cancer pain in the United States.20 Yet, 
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because of this low response rate, the study results should be 
interpreted with caution and cannot be generalized to the entire 
Dutch pain specialist population. As we expect that respondents 
were more familiar with and interested in cancer pain than non-
respondents, adherence to the guideline probably will be lower in 
the entire population of pain specialists. 
The case vignette was created on the recommendations of the 
guideline with questions about problems, which a physician can 
really meet in patient care. However, the answers are given from 
behind the writing desk and not in real confrontation with a patient. 
This certainly will have influenced the answers as intended 
behavior differs from real behavior. 21 
Finally, a critical note should be placed on the presentation and 
building of a case vignette study in the interpretation of study 
results. Since such a case is artificially built based on the ideal 
recommendations of a guideline, and care is not always possible to 
standardize, participants might have answered differently than in 
real-time situations.  
Conclusions 
The recommendations of the Dutch guideline on the diagnosis and 
treatment of pain in patients with cancer are followed by the 
majority of the Dutch anesthesiologists/pain specialists with 
respect to the pharmacological and invasive treatment of pain in 
the several stages of the disease. Structural assessment of pain 
with a one-dimensional scale or a multidimensional questionnaire 
is only done by a minority of the respondents and mostly at the 
start of the treatment. As in progressive disease not only the size 
of the tumor, but also the suffering of a patient determines the 
severity of pain, careful assessment of the different aspects of pain 
is necessary. Therefore, in the future revisions of the national 
guideline more attention should be paid to structural pain 
assessment. Also more attention should be paid to the question 
how the behavior of medical specialists can be influenced to 
accomplish a better adherence to the recommendations of clinical 
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practice guidelines. The Theory of Planned Behavior (TPB) could 
be used to make an inventory of the barriers to follow a guideline 
and to advice how to change the behavior of physicians.22    
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Appendix 1  
Case vignette 
In parentheses the number and percentage of participants who 
choose for a specific answer  
I. Initial pain management in cancer 
Mrs. A is 45-year old. She is married and has got 2 children (12 
and 15 years old). After the discovery of a silent jaundice, a non-
operable pancreatic carcinoma was diagnosed. The family is 
informed about the bad prognosis. The bile secretion is secured 
with a stent in the bile duct. The patient is in good condition and 
has a good appetite. Mrs. A receives chemotherapy on her 
demand. 
Few weeks after leaving the hospital she consults you because 
she has pain in the upper abdomen. The pain is not constant 
present and differs in severity. 
1. You decide the following strategy (more than one answer 
possible): 
A. Pharmacological treatment                         (88; 94,6%) 
B. Pain measurement with a one-dimensional scale (only 
the intensity of the pain                               (25; 26,9%) 
C. Pain measurement with a multidimensional scale (pain 
intensity and other dimensions as social, psychological 
and quality of life impairment)                     (49; 52,7%) 
D. Further investigation for diagnosis, precise:   
                (21; 22,6%) 
• Answers recommended in the Dutch Guideline on 
Cancer Pain (DGCP); A in combination with B or C. 
  
Chapter 7 
 207 
•  
2. The pharmacological treatment includes (more than one 
answer possible): 
A. Paracetamol                                                (87; 93,5%)     
B. Codeine                                                       (  0;      0%)       
C. NSAID                                                         (67; 72,0%) 
D. Strong opioid                                               (61; 66,3%) 
E. Other, precise: (18; 19,4%) 
• Answers recommended in the DGCP: A, 
combination with C or D acceptable. 
 
II. Adaptation in pain management in cancer. 
The pain is acceptable during a couple of weeks.  Then the pain 
increases. Mrs. A experiences pain in the upper abdomen, 
especially during the night and she wakes up early in the 
morning. 
3. You decide the following strategy (more than one answer 
possible): 
A. Adaptation of the pharmacological treatment  (85; 91,4%)   
B. Ask for constipation                                          (59; 63,4%) 
C. Pain measurement with a one dimensional scale  
                                                                         (29; 31,2%) 
D. Pain measurement with a multidimensional scale    
                                                                         (22; 23,7%) 
E. Invasive pain treatment                                    (46; 49,5%) 
F. Otherwise, precise:                                          ( 4;     4,3%) 
•  Answers recommended in the DGCP: A, in combination 
with C or D; E can be considered.    
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•  
4. The adaptation of the pharmacological treatment includes: 
A. Add paracetamol                                       (  2;   2,2%) 
B. Add NSAID                                                (  4;   4,3%)  
C. Add or increase codeine                            (  0;      0%)  
D. Add or increase strong opioid                    (92; 98,9%) 
• Answers recommended in the DGCP: D. 
 
5. To treat or avoid possible side effects of strong opioids you 
prescribe systematically the following medication: 
• A. A laxative                                                         (93;  100%)      
• B. An anti-emetic                                                  (34; 36,6%) 
• C. A treat to avoid sedation                                  (  2;   2,2%)  
• Answers  recommended in the DGCP: A.  
 
6. An invasive pain treatment in this situation can be: 
A. Cordotomy                                                  ( 0;       0%) 
B. Celiac plexus block                                     (76; 81,7%) 
C. Splanchnic nerve block                              (12; 12,9%)   
D. Hypogastric nerve block                              ( 0;      0%) 
E. Lower end block                                          ( 0;      0%)   
F. Spinal catheter                                            ( 2;      2%) 
G. Other, precise                                             ( 3;      2%)   
• Answers recommended in the DGCP: B or C.                                                                                      
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III. Management of patients psychosocial problems and other 
distressing factors. 
• Mrs. A worries about her children’s reaction concerning her 
future death. 
 
7. In addition to consulting her doctor additional help can be 
provided by: 
A. Foundation “de Einder”( the Horizon)         ( 6;     6,5%)  
B. Foundation “Achter de Regenboog” 
( behind the Rainbow)                                          (11; 11,8%) 
C. A psychologist                                             (53; 57,0%) 
D. A social worker                                            (61; 65,6%) 
E. A pastoral assistant or past                         (27; 29,0%)   
F. Other, precise:                                             (16; 17,2%)  
• Answers recommended in the DGCP: all possible, 
except A. 
 
• The pain decreases after your treatment, but the 
problem of sleeplessness continues. 
 
8. You decide to the next strategy: 
A. Adaptation of pharmacological treatment   (87; 93,5%)  
B. Pain measurement with an one dimensional scale  
                                                                    (12; 12,9%) 
C. Pain measurement with a multidimensional scale    
                                                                    (20; 21,5%) 
D. Psychological consultation                          (28; 30,1%) 
• Answers recommended in the DGCP: A in 
combination with B or C. 
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•  
9. The adaptation of pharmacological treatment includes: 
A. Add a benzodiazepine                               (57; 61,3%)    
B. Add a antidepressant drug                        (44; 47,3%)       
C. Add methylphenidate                                 ( 1;    1,1%) 
D. Other, precise:                                           (10; 10,8%)  
• Answers recommended in the DGCP: A or B.  
Mrs. A still suffers sleeplessness after your treatment and tells you 
she is afraid of the possible suffering in the future. 
10. You decide the next strategy: 
A. Discussion of her case in your multidisciplinary team 
meeting  
                                                                   (69; 74,2%) 
B. Referral to a clinical psychologist               (45; 48,4%)   
C. To meet pastoral assistance                      (11; 11,8%)         
D. Referral to a nurse specialized in the care of cancer 
patients                                                      (20; 21,5%)  
E. Prescribe an antidepressant drug              (24; 25,8%)  
F. Other, precise:                                           (10; 10,8%) 
• Answers recommended in the DGCP: A or B. 
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IV. Further adaptation of pain treatment in advanced disease 
• After a short period of time the pain worsens and is localized 
in the whole abdomen. The status of the patient deteriorates 
and the chemotherapy must be stopped, because of illness 
progression. 
 
11. You decide to the next strategy (more than one answer 
possible): 
A. Adaptation of the pharmacological treatment         
                                                                  (66; 71,0%) 
B. Pain measurement with an one dimensional scale 
                                                                  (16; 17,2%) 
C. Pain measurement with a multidimensional scale  
                                                                  (18; 19,4%) 
D. Invasive pain treatment                             (73; 78,5%) 
E. Other, precise:                                           ( 5;    5,4%)  
•  Answers recommended in the DGCP: A in 
combination with B or C; D can be considered.       
 
12. Despite optimal titration of the used strong opioid the pain 
further increases; which adaptation of the pharmacological 
treatment can be proposed? 
A. Further increase of the opioid dose           (21; 22,6%)  
B. Opioid rotation                                           (34; 36,6%)  
C. Parenteral administration of opioids          (26; 28,0%)        
D. Other, precise:                                           (12; 12,9%)  
• Answers recommended in the DGCP:  B or C.       
 
13. An invasive treatment in this situation can be: 
A. Cordotomy                                                  (  0;      0%) 
B. Celiac plexus block                                     (34; 36,6%)     
C. Splanchnic nerve block                               (11; 11,8%) 
D. Hypogastric nerve block                              (  0;     0%) 
E. Lower end block                                          (  0;     0%)  
F. Spinal catheter                                            (48; 51,6%)   
• Answers recommended in the DGCP:  F.     
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The patient doesn’t want an invasive treatment anymore. The 
disease is complicated by a pelvic venous thrombosis, which is 
treated with acenocoumarol. After a few weeks patient’s situation 
further deteriorates. She is very tired en it is impossible for her to 
take food. Drinking fluids is an effort. The patient can’t swallow the 
strong opioid tablets.  Life expectancy is estimated one to two 
weeks. 
14. What is in this situation the most suitable way of giving 
strong opioids at home? 
A. Intraspinal                                              (11; 11,8%)      
B. Subcutaneous                                        (68; 73,1%)    
C. Transdermal                                           (  7;   7,5%)  
D. Intravenous                                            (  7;   7,5%) 
• Answers recommended in the DGCP:  B. 
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Pain is one of the most prevalent and feared symptoms in 
patients with cancer. As the number of patients with cancer will 
increase in the coming years, the number of patients with 
cancer and pain will also increase. Despite the efforts of 
researchers, patients and physicians during the last decades, 
the assessment and treatment of pain in these patients is still 
insufficient in many cases.  
Pain in patients with cancer has many dimensions, from local 
tissue and/or nerve damage (nociception and/or neuropathy) 
to the central cognition and modulation of the incoming 
stimulus, and thereafter the several possibilities and 
restrictions of treatment. A limited number of items of these 
overwhelming quantity of aspects of pain was studied in more 
detail as the basis of this thesis.  
In this thesis I explored (1) barriers in the assessment and 
treatment of patients in pain due to cancer, (2) the possibilities 
to reduce the suffering of the patients and (3) how to facilitate 
and improve the approach of physicians to these problems. In 
this discussion, I will present my findings as a reply to the 
specific research questions, formulated in chapter 1.  
1. It is possible to create a multidisciplinary evidence 
based clinical practice guideline (CPG) including 
recommendations on the diagnosis and treatment of 
pain in patients with cancer, including an active 
patient participation model. 
The publication of the Dutch guideline: “Diagnosis and 
treatment of pain in patients with cancer.” confirms 
the statement from this research question. This 
guideline has a very high score on the quality 
assessment with the AGREE II instrument 1 and the 
conclusions and recommendations are in 
concordance with the “Content development for 
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European guidelines” from the European Palliative 
Research Collaborative (EPCRC).2  As a result of 
active patient participation, this  CPG contains 
chapters on information and education, and on the 
organization of care in which items with prominent 
importance for adequate patient care are outlined. 
These patient-centered topics are absent in many 
other guidelines on the treatment of cancer pain, 
which are restricted to the pharmacological treatment 
of pain in patients with cancer.3, 4 
The lowest score on the AGREE II instrument 
concerns the applicability of the guideline.1 The Dutch 
CPG does not specifically describe potential problems 
regarding the implementation of the recommendations 
of the guideline; the possible implementation costs 
and the way the effectiveness of the implementation 
will be monitored. 
Further research needs to be developed to study the 
implementation of the guideline in daily practice of 
pain treatment in patients with cancer.  
In the guideline extensive attention was given to the 
pharmacologic treatment of pain in patients with 
cancer as this is the foundation of cancer pain 
management.5 A historical turning point in the 
management of cancer pain was the publication of the 
World Health Organization three-step analgesic 
ladder in 1986, in which analgesics are prescribed in 
a step-wise manner from non-opioids over weak 
opioids to strong opioids.6 Recent research has 
shown however, that switching immediately from step 
1 to step 3, the use of strong opioids, leads to faster 
pain relief and fewer dosage adjustments.7, 8 An 
important recommendation in the guideline advises 
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therefore to abandon step 2 from the WHO ladder. 
The recent availability of oral transmucosal fentanyl 
citrate (OTFC) has changed the treatment of 
breakthrough pain. The latter is a transient flare of 
more intense pain occurring in a patient with a 
background pain that is otherwise well controlled and 
tolerated. It is considered, that OTFC is more effective 
than short acting morphine in the treatment of 
breakthrough pain in patients with cancer. 9, 10 In our 
experience the use of OTFC nowadays is sometimes 
not restricted to the treatment of breakthrough pain, 
but it is used for the treatment of insufficient relieved 
background pain, for which it is not suited. This leads 
to unnecessary suffering of patients with pain due to 
cancer and prolongs the time till sufficient pain relief is 
established. 
2. Medical specialists need to improve assessment of 
pain of patients with cancer, and registration of pain in 
the medical records, as recommended in the Dutch 
CPG on pain in patients with cancer. 
Our analysis of the medical records of outpatients 
with cancer, visiting a medical oncology outpatient 
clinic for the first time, showed that pain registration 
with a standard scale (Numeric Rating Scale (NRS), 
Visual Analogue Scale (VAS) or Verbal Rating Scale 
(VRS)) was never used, although this is one of the 
recommendations in the Dutch guideline. In part of 
the medical records, the existence or absence of pain 
was registered in an alternative way. For example, 
intensity of pain was documented as ‘more pain than 
before’, or the medical record only contained the word 
‘pain’ or the words ‘no problems’. The mere mention 
of the presence or absence of pain was highest in the 
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visits at the academic hospital (67.9%) and lowest in 
one of the peripheral hospitals (21.1%). 
 As thorough pain assessment is a key factor for 
adequate pain management, it is obvious, that an 
important opportunity to optimize the treatment of pain 
in patients with cancer is missed. 
In this study, we only checked pain registration during 
the first consultation at the medical oncology 
outpatient clinic. During the first consultation with a 
medical oncologist the emphasis will be on the 
diagnosis and causal treatment of the tumor, which 
might have contributed to our findings.11 Yet, in a later 
study on this topic we also checked pain 
documentation at the second and third visit to the 
outpatient clinic. We found no pain documentation in 
the recommended way.12  
These findings are in accordance with figures from 
Nordic countries as Denmark, Finland and Norway, in 
which countries health care providers also do not 
systematically explore pain during consultations. 13 
Yet, this pan-European study showed that in other 
European countries as Italy, Ireland and Romania 
pain is assessed at almost every visit of the patient to 
the physician. 
The use of a standardized pain scale, like an NRS or 
VAS is easy and simplifies the communication about 
pain between the patient and the medical specialist.14, 
15 Besides, the need for adaptation of the treatment of 
pain in patients with cancer and the effects of this 
adaptation are more reliably registered with the use a 
standardized pain scale.16 
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Further research is needed to find a way to widely 
implement the use of standardized pain scales by 
medical specialists in the treatment of patients with 
cancer. 
3. Telemedicine is feasible to improve patient pain 
monitoring and pain management. 
In our pilot study on the feasibility of the use of Short 
Message Service (SMS) and Interactive Voice 
Response (IVR) in the assessment and treatment of 
pain in outpatients with cancer thirteen from the 
invited seventeen patients could be included. Being in 
the palliative stage of their disease two patients found 
it too burdensome to join the study, one could no 
more use a mobile phone and one was hospitalized 
for a long time. From the studied thirteen patients 
three died during the study due to advanced disease 
and one was hospitalized until the end of the study, 
so eventually eight patients completed the study. The 
low number of included patients is in accordance with 
other studies on patients in the palliative stage of their 
disease and can be caused by low referral rate17, 
patients’ belief that there is no advantage in 
participating in a scientific study 18 and long distance 
to the research center 19. 
Our study showed, that in patients with pain and 
cancer, the use of SMS and IVR calls gives a reliable 
assessment of pain intensity and the possibility of an 
immediate intervention if the pain needs urgent 
treatment adaptation. The invitation of patients to 
assess and report the intensity of their pain as well as 
a message to the nurse if the pain intensity of the 
patient is above a certain level, are done 
automatically with the help of ICT. As long as pain is 
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absent or the intensity of pain low, no action of the 
professional is asked for. As soon as a patient reports 
a higher pain intensity level, the nurse is automatically 
informed and invited to contact the patient by phone.  
This was the first study in which the feasibility of this 
innovative, person-centered ICT-tool to monitor pain 
was studied. As we only included a limited number of 
patients in this pilot study, the results must be 
interpreted with caution. Besides, the study was 
performed by one very dedicated pain nurse. The 
dedication of this nurse, who personally invited all 
participants to take part in the study, and who visited 
all participants at home to inform them about the 
project and to collect the baseline questionnaires, 
certainly will have contributed to the successful 
patient recruitment and high satisfaction of the 
participants. 
This intervention can only be implemented for a larger 
number of patients if enough educated professionals 
are available to adequately react on a warning that a 
patient has an increased pain level.  
The use of SMS in the treatment of long term 
illnesses was reviewed by the Cochrane 
Collaboration.20  They found 4 Randomized Controlled 
Trials (RCT) on this subject involving 182 participants. 
These studies were on the use of SMS in the 
treatment of diabetes mellitus 21, 22, hypertension, 23  
and asthma.24 They concluded that the use of SMS 
had only a small direct impact on health outcomes 
related to the management of these chronic 
conditions. The studies gave little information about 
long-term effectiveness, risks and limitations, and 
consumer satisfaction with the intervention. They 
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found no studies on the use of SMS in the 
assessment and treatment of pain.  In a large patient 
population (202 patients) and during a long study 
period (12 months) Johns studied the use of 
telemedicine in the treatment of depression and pain 
in patients with cancer. He found good adherence to 
the intervention by telemedicine by the patients of 
whom 87.2% were satisfied with the provided care.25 
The development of telemedicine is much faster than 
for instance the development of new analgesics in the 
treatment of cancer pain. Recently studies were 
published on the communication on Internet of cancer 
patients’ symptoms 26, and an iPhone application for 
multidimensional pain assessment.27 Further research 
is this field should learn us the future possibilities that 
can be provided by telemedicine at the treatment of 
patients with pain and cancer. The short and long 
term effects, the risks and acceptability of 
telemedicine should be the focus at which these 
research should be directed. 
 
4. Medical specialists should be aware that not all 
opioids can be administered unlimited for the 
treatment of pain in patients with cancer.  
We found that opioid rotation should be considered as 
an option when insufficient pain control and/or 
intolerable side effects are reported with a given 
opioid therapy or when the initially well-balanced and 
effective treatment no longer provides the desired 
results. (Chapter 4) The prescription of opioids are the 
mainstay in the treatment of patients with moderate to 
severe pain due to cancer.28 Dose escalation of the 
chosen opioid because of insufficient pain relief can 
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give rise to increase of side effects and even increase 
of the pain in the case of opioid induced 
hyperalgesia.29 The phenomenon of incomplete cross 
tolerance between opioids provides us the tool of 
opioid rotation to optimize patient’s pain treatment.30 
A drawback in opioid rotation is the limited evidence 
of the conversion ratio’s between opioids.31 At the 
start of opioid rotation inadequate dose replacement 
can therefore lead to because of time restrictions, 
increase of pain or side effects. Nevertheless opioid 
rotation is an important tool in the treatment of pain in 
patients with cancer and is also approved in the last 
recommendations at the use of opioids in the 
treatment of cancer pain by the European Association 
of Palliative Care (EAPC).32 Further research is 
necessary to reveal the pharmacologic differences 
between the opioids and pharmacogenetic differences 
between human beings, which are the basis of opioid 
rotation. More research is needed to explore and built 
more evidence on the conversion ratio’s between the 
opioids.  
5. Advanced (interventional) techniques should be 
implemented to ameliorate the treatment of pain in 
patients with cancer and avoid important side effects 
and complications of conservative treatment. 
Interventional pain management techniques in the 
treatment of refractory oncologic pain syndromes are 
indicated if oral or parenteral analgesics cause such 
severe side effects that a satisfactory quality of life or 
pain relief cannot be reached. In some malignancies 
as for example pancreatic carcinoma and lung cancer 
with involvement of the brachial plexus adequate pain 
relief is very difficult to obtain. It is important for 
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patients and physicians to be aware that invasive pain 
treatment is available in these cases with apparently 
intractable pain to diminish the ongoing suffering.33 
The application of invasive pain treatments 
challenges the patient to endure yet another invasive 
procedure after often awful periods of burdensome 
oncologic or surgical treatments. Therefore the 
procedure should be timely and proactively planned in 
the course of the disease of the patient, so that they 
are able to accept the burden of an interventional pain 
technique and that the result of this treatment can be 
expected to be optimal. We should be aware that 
invasive pain treatment can relieve local generated 
nociceptive and/or neuropathic pain, but is not the 
panacea for the overall suffering of patients. 
As the number of patients who can benefit from 
invasive pain treatment in cancer pain is limited, these 
procedures should be centralized in hospitals in which 
there is and will stay enough experience to 
accomplish these sometimes complex procedures 
including their follow-up and after care. 
Our recommendations are in agreement with the 
recent review of the treatment of cancer pain in the 
Lancet.28 Physicians treating patients with pain and 
cancer should thus be aware of the possible 
beneficial effects of invasive pain treatment in these 
patients and assure a timely consultation of a 
specialist in this procedures.   
Further research is necessary to collect more 
evidence of invasive pain treatment in patients with 
cancer and to refine the indications and performance 
of the procedures.  
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6. Medical specialists partly know the recommendations 
of the national multidisciplinary evidence based 
guideline ‘pain in patients with cancer’, and how to 
apply them in their daily practice. Evaluating the 
practical knowledge of this multidisciplinary guideline 
by a vignette case study is possible and useful.     
According to our case vignette study the majority of 
the Dutch anesthesiologists/pain specialists, who 
participated in the study, follow the recommendations 
of the Dutch clinical practice guideline regarding the 
diagnosis and treatment of patients with pain and 
cancer as long as these recommendations concern 
the pharmacological and invasive treatment of pain 
due to cancer. These recommendations seem to be 
incorporated in the daily practice of these medical 
specialists. Almost all respondents (95%) timely 
choose invasive pain treatment, which is a much 
higher adherence rate than in a similar French study, 
where only 44% of the pain doctors did. 34 This 
indicates that the Dutch anesthesiologists/pain 
specialists are more aware of the possibility of and 
how to refer a patient for interventional pain 
treatment. 
 As only 27% of the Dutch anesthesiologists/ pain 
specialists responded to the invitation to participate in 
this case vignette study, we cannot be sure that these 
recommendations are followed nationwide. The 
response rate in our study corresponds with the 
response rate in other case vignette studies 34, 35, but 
is far less than for example in another study in the 
Netherlands on palliative sedation, where the 
response rate of medical specialists and physicians 
was 69.3%.36 
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Besides, a case vignette is a representation of reality, 
showing the intention to act in a certain manner. As 
theories on changing behavior show, the intention 
given to perform a behavior is often higher than the 
behavior itself.37 Unfortunately, specific 
recommendations of the Dutch National guideline 
such as the regular and structural assessment of pain 
with a one dimensional pain scale or a 
multidimensional pain questionnaire in the case of 
difficult to treat pain, are only followed by a minority of 
Dutch anesthesiologists/ pain specialists. This 
outcome is in accordance with a study of Weingart, 38 
who also found that pure somatic items in patient care 
are more considered than a regular assessment of 
pain in patients with cancer. This implies that pain will 
often remain under diagnosed. 
In order to improve pain management for patients with 
cancer, further research is needed on how to improve 
the awareness of medical specialists on the 
multimodal aspects of pain in patients with cancer and 
how they can learn to incorporate the required 
assessments of the pain of their patients in their daily 
practice. 39 
General conclusion and recommendations 
Introduction 
In 1978 on the International Symposium on Pain of Advanced 
Cancer John J. Bonica, the founder of the IASP held the 
opening lecture titled “The Importance of the Problem” (of 
cancer pain). 40 There are two main reasons according to 
Bonica for the inadequate relief of pain in patients with cancer. 
The first is that there are voids in our knowledge of the basic 
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mechanisms and pathophysiology of cancer pain. The study of 
the basic mechanisms of cancer pain is a continuous, long-
term process in which only gradual progression is made. 41, 42 
The second reason he mentioned, is the improper or 
inadequate application of the knowledge currently available for 
the care of cancer patients.40 
The improvement of the application of available knowledge 
seems easier to perform. After all, the basic and advanced 
knowledge on how to deal with pain in patients with cancer 
already is present and ‘only’ needs to be disseminated, 
adopted and implemented. However, 46 years after this 
lecture of Bonica, we still did not succeed in motivating 
medical specialists to adhere to the developed and widely 
available guidelines. Even though these guidelines were 
developed with special attention to simplify the medical 
practice of medical specialists in assessing and treating 
patients with pain and cancer.35 In the development of 
guidelines more importance should be paid to ensure that 
targeted physicians believe that the guideline is applicable to 
situations they face. Health behavior change theories can 
address the issue of relevancy and applicability by identifying 
and measuring pertinent personal, social and environmental 
factors influencing the physicians’ behavior.37 This information 
can then be incorporated into the guideline to address the 
barriers.43  
   In 1978 the emphasis of the Congress on Cancer Pain was 
on medical and psychological assessment and treatment. Until 
recently, the developed guidelines still had an identical 
structure and basis as 35 years ago.3, 44 Participants of 
national and international congresses on pain in cancer 
patients and the dedicated taskforces developing guidelines 
on cancer pain are almost exclusively health care and 
methodological trained quality of health professionals.44 
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However, in the 21th century the opinion of patients concerning 
the treatment of such an important topic in the treatment of 
their life threatening disease can no longer be neglected. In 
the ‘Dutch evidence based guideline on the diagnosis and 
treatment of pain in patients with cancer’ 45 representatives of 
patient federations were actively involved in the whole 
development process. Their opinions played an important role 
in special items on arrangement of care, medical information 
for patients, education and how to organize optimal pain care.  
The role of medical specialists 
As one of the recommendations to improve the treatment of 
pain in patients with cancer, in 1978 Bonica advised to make 
better information sources about the possibilities of different 
pain treatments in patients with cancer available. In the 
Netherlands, the publication of the Dutch evidence based 
guideline on the diagnosis and treatment of pain in patients 
with cancer in 2008 can be considered to be a delayed result 
of Bonica’s recommendation. In 2010, two years after the 
publication and start of implementation of our national 
guideline, we studied whether and how pain or its absence is 
registered in the medical records of patients with cancer who 
visited the medical oncology outpatient clinic for the first time. 
It appeared that the recommendation, as described in the 
guideline, to assess and document pain with a numeric rating 
scale (NRS) or a visual analogue scale (VAS) was never 
followed. (chapter 3)   
As the structural assessment of pain in these patients with 
cancer is neglected by otherwise very dedicated medical 
specialists the question arises: is assessment of pain 
necessary and does it contribute to the well-being of our 
patients? In a review on the under-treatment of cancer pain, 
Deandrea46 found a discrepancy between the physician’s and 
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patient’s estimate of the severity of pain in four of five studies. 
In this review it appeared that patients who were rated less ill 
and at an early stage of the disease were more likely to 
receive inadequate analgesia. 
The way physicians and patients look at pain seems to be 
different. An explanation for this could be given from 
anthropology. Already in 1978 Kleinman47 and his associates 
offered a conceptual distinction between disease and illness. 
In this conception a disease is defined as an abnormality in the 
function or structure of the body, the malfunction of certain 
biologic processes in the body. In contrast, illness is construed 
as the patient’s personal reaction to the disease and 
associated discomfort. Patients present their pain complaints 
related to their illness concerns, interpretations of symptoms 
and personal beliefs. As physicians focus more on disease 
and patients on illness, a discrepancy of the interpretation of a 
health care problem, for example pain, arises. The use of a 
standard one dimensional pain assessment scale forces the 
physician and the patient to use the same language and can 
overcome the differences in interpretation of the problem. 
These scales are validated to measure cancer pain intensity14 
and their use leads to a timely adaptation of pain treatment.16   
The patient could be better prepared to present their problems 
during the physicians’ visit by using the short version of “the 
Problems and Needs in Palliative Care questionnaire”, 
developed by Osse.48 This instrument helps to identify the 
problems affecting the patients’ quality of life and needs for 
care.  
The announcement and introduction of the guideline on cancer 
pain treatment was insufficient to improve the way pain is 
assessed as can be read in chapter 3. Other means must be 
found to convince medical specialists to follow the given 
recommendations, or otherwise to force them to do so in the 
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interest of the patients, who are trusted to them.49 According to 
the design of another still continuing study in the 
aforementioned hospitals a number of medical oncologists 
were especially trained by the author of this thesis in the 
assessment and treatment of pain in patients with cancer. This 
was a time-consuming activity and cannot be done with all 
medical oncologists. An e-learning module on the assessment 
and treatment of cancer pain was developed for physicians; 
this module can, with some adaptations, be used to train 
medical oncologists. The next step can be the introduction of 
quality indicators, which were developed for the evaluation of 
the guideline, but were not adopted by the health care 
authorities due to other priorities. The introduction of quality 
indicators on the assessment and treatment of postoperative 
pain in the USA showed an improvement from 45% to 72% in 
the presence of structural elements that are critical to 
improving pain management.50 Also in our Radboudumc, the 
obligation to measure postoperative pain, which is also 
facilitated by the electronic medical records system, 
tremendously increased adherence. 
The intensity of pain is not only a neurophysiologic entity, but 
depends on how a patient experiences his or her illness as 
was described by the model of Loeser with four concentric 
rings containing respectively nociception, pain sensation, pain 
experience and pain behavior .51 In this respect several factors 
can play a more or less important role as fear of death, 
disturbance of family life, fear of the unknown course of the 
disease and possible uncontrollability of the pain. These 
factors are not assessed by an one dimensional pain scale, 
but must be evaluated by a multidimensional questionnaire.39    
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The role of patients 
The proceedings of the Congress on Cancer Pain in 1978 
show that at that time patients’ opinion did not play a role on 
this topic, although Bonica advised to intensify information and 
education on cancer pain in the general public, patients and 
their caregivers.40  It seems obvious, that the opinion of the 
main player in the field of pain due to cancer should be heard.  
Almost all recommendations on the assessment and treatment 
of pain in patients of cancer are made with merely input of 
health care providers. The rare literature on patient opinions 
shows that a caring approach and willingness to listen were 
leading to more patient satisfaction than pain relief in itself.52 
Also the reduction of the impact of pain on emotional wellbeing 
and daily life has shown to be more important than alleviating 
pain per se.53  
There are several patient-related barriers to adequate 
assessment and treatment of pain in cancer as for example 
the reluctance to report pain, lack of caregiver knowledge and 
widespread misconceptions about opioids.54, 55  
In the working party for the composition of the Dutch guideline 
45 patients’ representatives were fully integrated. They were 
involved in the literature search and the formulation of the 
recommendations. The extensive chapters on information and 
education, and arrangement of care, which lack in most other 
guidelines, were written very much according to the opinions 
of the patients. This positive experience of the cooperation 
with patient representatives should be a stimulus to other 
health care providers to involve patients in the development 
and taskforce of guidelines. 
Thus the implementation of guidelines on pain assessment 
and treatment of pain, should be done in close cooperation 
with the patient. The awareness of patients and their proxies of 
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the important role they play themselves in the recognition and 
treatment of pain, patient empowerment, will force the health 
care providers to give more attention to the problem of 
adequate assessment and treatment of these patients.56  
Education 
Bonica recommended the development of intensive 
educational programs for medical students and other health 
care professionals about the causes and mechanisms of pain 
and the efficacy, indications, limitations and complications of 
the methods of pain relief.40  
Medical students 
 A Cancer Pain Structural Instruction Module (SCIM) 
developed by Sloan showed, that students who followed this 
program, developed better skills in pain treatment than a 
control group. This effect could be further optimized if the 
SCIM was combined with the possibility for the students to 
make a visit to and examine patients in a hospice. 57 Stevens 
showed that the implementation of a pain assessment and 
management curriculum for second year medical students 
resulted in long term increase in the students’ ability to use 
these skills in the treatment of acute and terminal pain.58 
Despite these important findings education in the assessment 
and treatment of cancer pain is not regularly offered in the 
basic medical curriculum. 59 The revision of the Dutch 
guideline on the diagnosis and treatment of pain in patients 
with cancer is under way. The publication of the revision could 
offer an excellent opportunity to integrate the education on 
cancer pain for medical students in the basic curriculum of the 
medical study in the Dutch Universities.  
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A prerequisite for this change in the medical curriculum is that 
the composers of these curricula must be convinced of the 
importance of this topic. This will not be easily performed and 
there is a lack of knowledge on the importance of the 
assessment and treatment of cancer pain among medical 
specialists, who determine the outline of the medical study.46  
Medical specialists 
The education of medical specialists in the various aspects of 
cancer pain is much more difficult to establish than for medical 
students. An important barrier is the discrepancy between 
perception and reality of knowledge of the treatment of cancer 
pain in these group of health care professionals.35, 60 After 
demolishing this barrier the education can be focused on the 
conquering of other barriers in adequate pain treatment as for 
example poor pain assessment and the reluctance to 
administer opioids. 61 
The introduction of a quality indicator to improve patient care 
in hospitals in the Netherlands 62 could be a motivation for 
medical specialists to fill their lack of knowledge in this field of 
medicine. However for this reason the quality indicators, which 
were developed for measuring the effectiveness of the 
treatment of pain in patients with cancer, must be broadly 
implemented in medical practices but not be overruled by 
others. Besides, using quality indicators is meant to assess 
current practice. Quality improvement activities are necessary 
to improve those aspects that are weak or absent.49  
Education on the treatment of pain in cancer can be organized 
in several ways. Started in 2008, in Japan an intensive 
educational program with workshops on improving care for 
patients with cancer proved to be successful. In three years 
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29,736 physicians followed the offered opportunity to improve 
their knowledge in palliative care and pain medicine. 63 
The workload of the required teachers can be diminished by 
the development of an e-learning program.  The in our 
department established e-learning program on the assessment 
and treatment of pain in patient with cancer for family 
physicians can be adopted for the education of medical 
specialists too.  
Patients 
The recommendations of intensive educational campaigns on 
the treatment of cancer pain by Bonica were also meant for 
patients and their families. In a systematic review on patient-
based educational interventions in 2009 Bennett et al 64 found 
a significant benefit from these interventions on the 
management of cancer pain. In the Dutch guideline it is stated 
that patients and their family caregivers must receive 
education and instruction on the background and the treatment 
of pain due to cancer, taking the intellectual capacity of the 
patient and family into account. Apart from the items that 
should be discussed in any case, specific recommendations 
for the development of educational programs were not given in 
the guideline. 
Patient training in cancer pain management with integrated 
print and video materials showed significant reduction in pain 
and barriers to pain relief in a randomized controlled trial 
(RCT) in Seattle.65 Educational interventions with a video or a 
booklet gave significant pain reduction in an RCT in 
Australia.66 In the revision of the guideline more emphasis 
should be given to the development of standard educational 
materials for patients. Apart from this positive effect on their 
pain level, patients who are aware of the different aspects of 
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cancer pain will give more feedback to health care 
professionals about their pain and force them to pay attention 
to this often neglected item.  This active involvement of the 
patient and the interaction with the health care professional will 
empower the patients to control their cancer pain.67 
Coming to the end of my discussion, I explained that Prof. dr. J 
Bonica formulated in 1978 the following recommendations on 
the improvement of pain management:  
1. Increase your efforts which should include:  
a) perform comprehensive epidemiological studies 
on the incidence and magnitude of cancer pain 
with each type of tumor;  
b) study of the neurophysiologic and biochemical 
and physiopathologic  mechanisms of cancer 
pain;  
c) evaluate the efficacy of the methods currently 
used to relieve cancer pain;  
d) develop new therapeutic modalities. 
2. Start intensive educational programs for medical 
students and other health care professionals, as well 
as practicing physicians including: 
a) knowledge about the causes and mechanisms 
of pain; 
b) the efficacy, indications, limitations, and 
complications of current methods of pain relief; 
and  
c) specific guidelines about proper management of 
these patients. 
3. Start intensive educational campaigns for the public, 
patients and families, as well as federal agencies. 
4. Provide better sources of information through the 
oncologic literature, books and special articles, and 
brochures on cancer pain. 
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These recommendations can be used unchanged in our days. 
But from my clinical experience and my in this PhD presented 
research, I can supplement the following 
recommendations to improve the diagnosis and treatment 
of pain in patients with cancer: 
1. Increase your efforts to introduce the recommendations 
in daily clinical practice compared to what was done 
after the publication of the first edition of the Dutch 
clinical practice guideline on the diagnosis and 
treatment of pain in patients with cancer.   
2. Implement the ready for use quality indicators on the 
assessment of pain in patients with cancer in daily 
clinical practice to improve pain registration in patients 
with cancer.   
3. Perform more studies on the efficacy and the broader 
introduction of telemedicine in the assessment and 
treatment of cancer pain. 
4. Start further studies on opioid action and rotation, 
pharmacologically and clinically. 
5. Facilitate training in interventional techniques on the 
treatment of cancer pain for anesthesiologists/pain 
specialists. 
6. Introduce a course in cancer pain treatment in the basic 
medical curriculum of all Dutch Universities. 
7. Introduce  post-graduate national courses on cancer 
pain treatment for medical specialists organized in 
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agreement with and supported by the different 
specialists societies. 
8. Develop and introduce systematic education devices 
specially focused on the patients and their caregivers .  
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Looking back at 36 years of treating pain in patients with 
cancer I made substantial improvements. 
In the first years of my training my knowledge increased 
by the inspiring congresses of the International 
Association for the Study of Pain (IASP) and the books 
published by this organization. 
In 1990 the  “Nederlandse Vereniging ter Bestudering 
van Pijn “ (NVBP), nowadays the Dutch Pain Society 
(DPS) published the so called “het Groene boekje” (“the 
Green booklet”) 12  as the first multidisciplinary guideline 
for the diagnosis and treatment of pain in patients with 
cancer in the Netherlands. This represented a 
tremendous support for the health care professionals, 
who became acquainted with the recommendations from 
this  “Green Booklet”.  
The care of patients with cancer improved substantially 
thanks to the acquired knowledge, the establishment of a 
close relationship between myself and the medical 
oncologists, with mutual understanding of our 
professional possibilities and restrictions. These two 
factors, knowledge and mutual understanding, were and 
are the basis of my daily practice in the hospitals in 
which I work. In my opinion, missing these two factors 
contributes to less adequate patient care.  In this thesis I 
quoted several times the proceedings of the International 
Symposium on Pain in Advanced Cancer, during which 
prof. John J. Bonica strongly advised the development of 
multidisciplinary teams, in which each member knows 
“all of the plays” and not just his own field. It should be 
the goal of the medical specialist societies to stimulate 
this multidisciplinary approach of patients with pain and 
cancer. 
According to Bonicas’ recommendations to publish 
books, there were several activities in the Netherlands. 
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In 2008 the first evidence based guideline on the 
diagnosis and treatment of patients with pain and cancer 
was published. 7  This was one of the reasons for the 
studies in this thesis. 
A special section on the treatment of pain was 
established in the Dutch National Society for 
Anesthesiology (Nederlandse Vereniging voor 
Anesthesiologie).  The efforts from members of this 
section produced the book on guidelines for pain 
treatment by anesthesiologists, which became the 
golden standard for the way anesthesiologists should 
practice.13 The English translation and revision of this 
book became the standard for the courses of the World 
Institute of Pain (WIP) and for the examination to 
become Fellow in Interventional Pain Practice (FIPP).14 
In the twenty first century there is extensive knowledge 
on the assessment and treatment of pain in patients with 
cancer. Several factors, ethical, political and economical, 
force us to improve the quality of patient care. The mere 
statement “we do our best” is not credible any more. The 
quality of patient care by health professionals must and 
will be measured. It is important that these health 
professionals take up their role in the establishment of 
the required quality indicators. Otherwise there is the risk 
that the quality indicators are more money than science 
centered. Once the quality indicators are established, it 
is the responsibility of the politicians and insurance 
companies to facilitate their implementation. 
Our patients with cancer deserve the most serious and 
up-to-date efforts of all participants in their care to relieve 
their suffering. 
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Summary 
 
Cancer has recently become the most frequent cause of death in the 
Netherlands, making it more important than cardio-vascular diseases. 
The number of new patients with cancer increases every year with 
3%, in parallel with the prolonged life expectancy. Pain is a frequently 
occurring symptom in patients with cancer that even nowadays is still 
under treated.  In 2008 a multidisciplinary guideline “Diagnostiek en 
behandeling van pijn bij patiënten met kanker” was published in the 
objective to improve the management of pain in patients with cancer.  
This thesis describes the development of this guideline. Possibilities 
to improve pain measurement and treatment, discussed in the 
guideline are further elaborated. The research on the effect of the 
publication of this guideline on the way different medical specialists 
register pain in patients with cancer is described.  
Chapter 2 discusses the development of the guideline with regard to 
the selection of the literature, the assessment of the quality of the 
published research and the levels of recommendations derived 
thereof. Special attention is paid to the pharmacological management 
of pain in patients with cancer. In the Netherlands, this guideline is 
the first that was developed by a group that was not solely composed 
of health care professionals, but representatives of the patient 
associations were also included. This resulted in a better assessment 
and consideration of the problem areas with regard to diagnosis and 
treatment of pain experienced by the patient. This is also the first 
multidisciplinary guideline to be approved by all the scientific 
professionals. In this way the guideline can be applied throughout the 
country in all the settings where patients with pain and cancer may be 
present.  
The pharmacological treatment of pain in patients with cancer is 
based on the World Health Organization (WHO) “pain ladder”, 
recommending the use of analgesics of increasing strength guided by 
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the pain intensity. Based on the studied literature the workgroup 
advises to skip step 2 of this pain ladder, and to start sooner with 
strong opioids. In this way adequate pain control is achieved faster 
and is more efficient. The management of opioid induced side effects 
and the use of drugs for the treatment of pain due to nerve damage 
(neuropathic pain) are described. 
Chapter 3 deals with the research regarding the effect of the 
publication of the guideline on the documentation of pain in the 
medical record filled-out by medical oncologists in different hospitals, 
academic and peripheral. Nowhere a structured pain measurement 
using a pain measuring instrument, as recommended in the guideline 
was performed. In the academic hospital the occurrence of pain was 
mentioned in half of the medical records, this was considerably more 
seldom in the other hospitals, suggesting that the implementation of 
the guideline with regard to correct pain registration has failed. 
Further research on a more structured implementation of the 
guideline should be performed.  As described in the literature the 
consideration of the opinion and advices of patients to increase the 
attention for pain registration and management by medical specialists 
may, in parallel with regard to the development of the guideline, have 
a positive influence.  
In chapter 4 the use of Short Message Service (SMS) and Interactive 
Voice Response (IVR) to improve the registration of the pain intensity 
and the speed to adapt the treatment of pain in patients with cancer 
is described. Using an ICT-steered way to communicate with patients 
and care givers regarding pain proved in this pilot study in patients 
with an advanced stage of cancer proved to be possible. This system 
allows a faster adaptation of the analgesics dose in case of increased 
pain intensity than with the conventional method, where the patient 
has to follow a longer way before having contact with the care giver. 
A potential burden for the patient to ask help in case of inadequate 
pain management is automatically overcome by the alarm when the 
pain score is too high. The patients were satisfied with this modern 
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way to register pain. This pilot study justifies more research to 
analyze whether this operation mode can be used in a larger number 
of patients and whether this approach improved the management of 
pain in patients with cancer.  
Chapter 5 describes the minimal invasive treatment of pain in 
patients with cancer, according to the multidisciplinary guideline. 
During the last decennia the possibilities of pharmacologic treatment 
of pain have seriously improved, resulting in the fact that the minimal 
invasive techniques for the treatment of severe pain due to cancer 
have lost popularity. In certain cases, however, for example for the 
treatment of pain secondary to pancreatic cancer and extensive vulva 
cancer, invasive treatment such as celiac plexus block or spinal 
administration of medication may offer pain reduction often with less 
side effects than when these conditions would be treated with high 
doses of opioids. Earlier consideration of invasive pain treatment than 
is currently done should be advised. In this chapter the indications, 
the techniques and the potential side effects are described.  
In chapter 6 the available evidence on opioid rotation for the 
treatment of severe pain in patients with cancer, according to the 
guideline is described. Opioids form the basic pharmacologic 
treatment for severe pain in patients with cancer. In certain situations 
satisfactory pain relief and/or acceptable side effects cannot be 
achieved. In these cases a switch for another opioid or another 
administration route may be considered; this technique is called 
opioid rotation. There are large inter-individual variabilities in opioid 
receptor effects, pharmacokinetics and pharmacodynamics of the 
different opioids in patients with cancer. A change of opioid or 
administration route may result in a better pain treatment and less 
side effects. There is no indication of which opioid or administration 
route will be the best choice in which patient. This can be defined by 
selective prescription and progressive dose titration. The conversion 
tables used for opioid rotation are not evidence-based and only give 
a broad indication of the dose that can be used. Therefore it must be 
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possible to monitor the effects and adapt the dose on a regular base. 
Further research is necessary to establish conversion tables that are 
based on comparative research of the opioids used when rotating.  
Chapter 7 relates the research on the application by the Dutch 
anesthesiologists/pain specialists of the recommendations formulated 
in the guideline “Diagnosis and management of pain in patients with 
cancer” by means of a vignette study. A vignette is a case description 
of a fictive patient, where the different aspects of the diagnosis and 
the treatment are discussed. The vignette used for this study 
describes a female patient with pancreatic cancer. The knowledge 
and the application of the recommendations from the guideline are 
assessed by means of a series of questions. This research shows 
that the Dutch Anesthesiologists/ pain specialists broadly apply the 
recommendations of the guideline for the pharmacologic and invasive 
treatment. There is however lack of structured measurements of pain. 
Therefore certain aspects of cancer-induced pain in the individual 
patient are not sufficiently elaborated and the treatment may be sub 
optimal. In case of a future revision of the guideline, more attention 
should be paid to the implementation of an adequate, structured pain 
measurement. This also becomes evident from the study described in 
chapter 2.  
Chapter 8 provides a general discussion of the different aspects, 
discussed in this thesis. A relation is made between the 
recommendations to improve the treatment of pain in patients with 
cancer formulated in the first congress on cancer pain in 1978 in 
Venice and the current situation concerning this topic. It is of utmost 
importance trying to introduce a mentality change with the medical 
specialists concerning the identification and the treatment of pain in 
patients with cancer. During the development of a revision of this 
guideline more attention should be paid to the implementation. 
Ideally, early in the medical curriculum attention should be paid to the 
multidisciplinary and multidimensional aspects of pain in patients with 
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cancer, as well as the correct approach of this problem, to make 
students used to the pain measurement.  
The patient should be involved as a full partner of the health care 
providers in the establishment of the proportion of the diagnosis and 
the potential treatment options of pain due to cancer.  
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Samenvatting 
 
Kanker is sinds enkele jaren de meest voorkomende doodsoorzaak 
in Nederland, meer dan hart- en vaatziekten. Door de toegenomen 
levensverwachting stijgt het aantal nieuwe patiënten met kanker 
jaarlijks met 3%. Het optreden van pijn is bij patiënten met kanker 
een vaak voorkomend symptoom, dat ook in de huidige tijd frequent 
onderbehandeld is. Ter verbetering van de behandeling van pijn werd 
in 2008 de multidisciplinaire richtlijn “Diagnostiek en behandeling van 
pijn bij patiënten met kanker” gepubliceerd. 
In dit proefschrift wordt de ontwikkeling van deze richtlijn beschreven, 
waarbij een aantal mogelijkheden ter verbetering van pijnmeting en 
pijnbehandeling uit de richtlijn verder uitgewerkt zijn.  Onderzoek 
naar het effect van de publicatie van de richtlijn wordt beschreven, 
met name de wijze waarop verschillende medisch 
specialistengroepen pijn bij kanker meten, registreren en 
behandelen. 
Hoofdstuk 2 behandelt de samenstelling van de werkgroep die de 
richtlijn ontwikkelde alsmede de adviezen voor farmacologische 
behandeling van pijn bij patiënten met kanker. Deze richtlijn is in 
Nederland de eerste, waarbij de werkgroep niet alleen bestond uit 
professionals vanuit de relevante vakgebieden maar ook uit 
vertegenwoordigers van de patiëntenvereniging.  De inventarisatie 
van door de patiënten ervaren knelpunten bij de diagnostiek en 
behandeling van pijn is daardoor beter tot zijn recht gekomen. 
Daarnaast hebben ook de behandeladviezen mede op basis van 
patiëntenervaringen vorm gekregen.  
De farmacologische behandeling van pijn bij patiënten met kanker 
berust op de “pijnladder” van de Wereld Gezondheid Organisatie 
(WHO), waarbij pijnstillers met toenemende sterkte worden 
voorgeschreven bij toenemende intensiteit van de pijn. Op basis van 
de bestudeerde literatuur adviseert de werkgroep stap 2 van deze 
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pijnladder, het voorschrijven van zwak werkende opioïden, weg te 
laten ten gunste van een eerdere start met sterkwerkende opioiden. 
Dit versnelt en verbetert een adequate pijnbehandeling. De 
behandeling van bijwerkingen van opioïden, alsmede het gebruik van 
medicatie ter behandeling van pijn ten gevolge van een beschadiging 
van het zenuwstelsel (neuropathische pijn) worden uitgebreid 
beschreven. 
In hoofdstuk 3 wordt een onderzoek beschreven naar het effect van 
de publicatie van de richtlijn op het vastleggen van het symptoom pijn 
in de status van medisch oncologen in verschillende ziekenhuizen, 
zowel academisch als perifeer. Structurele pijnmeting met behulp van 
een meetinstrument, zoals aanbevolen in de richtlijn, vond nergens 
plaats. Het op een andere wijze benoemen van het vóórkomen van 
pijn werd in de helft van de statussen in het bestudeerde academisch 
ziekenhuis gevonden, maar in veel geringere mate in de andere 
ziekenhuizen. Blijkbaar is de implementatie van de richtlijn op het 
gebied van het adequaat uitvoeren van pijnregistratie tekort 
geschoten. Verder onderzoek naar een meer structurele 
implementatie van de richtlijn dient daarom plaats te vinden. Het 
betrekken van de mening en adviezen van patiënten ter verbetering 
van de aandacht voor pijnregistratie van en behandeling door 
medisch specialisten kan, evenals bij de samenstelling van de 
richtlijn, een positieve rol spelen, zoals ook uit de literatuur blijkt. 
 
In hoofdstuk 4 wordt het gebruik van Short Message Service (SMS) 
en Interactive Voice Response (IVR) beschreven ter verbetering van 
de registratie van de ernst van pijn en de snelheid van aanpassen 
van de behandeling bij patiënten met kanker.  Het gebruik van deze 
ICT-gestuurde wijze van communiceren over pijn tussen patiënten en 
hulpverleners bleek in een pilotstudie bij patiënten in een verder 
voortgeschreden stadium van kanker goed mogelijk. De aanpassing 
van de medicatiedosis bij pijntoename kan op deze wijze veel sneller 
plaatsvinden dan bij een conventionele behandeling, waarbij een 
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patiënt een veel langere weg moet afleggen tot er contact met een 
hulpverlener is gelegd. Een eventueel bestaande drempel bij een 
patiënt om hulp te vragen bij inadequate pijnbehandeling wordt door 
de automatische alarmering bij een te hoge pijnscore vermeden. De 
patiënten bleken zeer tevreden over deze moderne wijze van 
pijnregistratie. Uitgaande van deze pilotstudie zal nader onderzoek 
plaats moeten vinden of de beschreven werkwijze ook bij grotere 
aantallen patiënten mogelijk is.     
Hoofdstuk 5 beschrijft de behandeling van pijn bij patiënten met 
kanker door middel van invasieve technieken. In de afgelopen 
decennia zijn de mogelijkheden van farmacologische pijnbehandeling 
sterk verbeterd. Het overwegen van een mogelijke invasieve 
behandeling bij ernstige pijn ten gevolge van kanker is daardoor wat 
op de achtergrond geraakt.  Bij een aantal oorzaken van pijn door 
kanker, bijvoorbeeld een pancreascarcinoom of een uitgebreid 
vulvacarcinoom, biedt een invasieve pijnbehandeling zoals 
respectievelijk een plexus coeliacus blokkade of spinale 
medicatietoediening een zeer goede mogelijkheid tot pijnreductie met 
vaak minder neveneffecten dan veroorzaakt door in deze situaties 
soms noodzakelijke zeer hoge doses opioïden. Het verdient daarom 
aanbeveling toepassing van invasieve pijnbehandeling eerder te 
overwegen in de gehanteerde behandelalgoritmen bij pijn door 
kanker dan op dit moment het geval is. De indicatie, uitvoering  en 
eventuele neveneffecten van de diverse toe te passen technieken 
worden in dit hoofdstuk uitgebreid beschreven.   
In hoofdstuk 6 wordt uitleg gegeven over de plaats van opioïdrotatie 
bij de behandeling van ernstige pijn. Bij de behandeling van ernstige 
pijn bij kanker vormen opioïden de basis van de farmacologische 
pijnbehandeling. In sommige situaties lukt het niet met een gegeven 
opioïd voldoende pijnvermindering te bereiken, dan wel zijn de 
bijwerkingen voor de patiënt onacceptabel. Het is dan te overwegen 
over te gaan naar een ander opioïd of andere toedieningsweg, 
hetgeen wij opioïdrotatie noemen. Er bestaat een sterke inter-
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individuele variabiliteit in opioïd receptoreffecten, farmacokinetiek en   
dynamiek van diverse opioïden bij patiënten. Verandering van opioïd 
of toedieningsweg kan daarom leiden tot een betere behandeling van 
pijn gepaard en  minder bijwerkingen. Het is niet op voorhand 
duidelijk welk opioïd bij welke patiënt, onder welke omstandigheden 
en in welke dosis de optimale keuze is. Dit dient door middel van 
titratie vastgesteld te worden. De bij opioïdrotatie gebruikte 
conversietabellen geven slechts een grove indicatie welke dosering 
bij rotatie kan worden gebruikt. De mogelijkheid tot regelmatige 
dosisaanpassingen in de eerste dagen na rotatie dient gewaarborgd 
te zijn. Verder onderzoek is noodzakelijk om nauwkeuriger 
conversietabellen bij het doen van opioïdrotatie vast te stellen. 
Hoofdstuk 7 bestaat uit het onderzoek naar het toepassen van de 
aanbevelingen uit de richtlijn “diagnostiek en behandeling  van pijn bij 
patiënten met kanker” door de Nederlandse 
anesthesiologen/pijnspecialisten met behulp van een vignettestudie. 
Een vignette is een casusbeschrijving van een fictieve patiënt, waarin 
diverse aspecten van diagnostiek en behandeling aan de orde 
komen. In de door ons gebruikte vignette wordt een patiënte met een 
pancreascarcinoom beschreven. De kennis en toepassing van de 
aanbevelingen uit de richtlijn worden  door middel van een aantal 
vragen getoetst. Uit dit onderzoek blijkt, dat de Nederlandse 
anesthesiologen/pijnspecialisten de aanbevelingen uit de richtlijn 
voor wat betreft farmacologische en invasieve pijnbehandeling 
grotendeels volgen. Er vindt echter onvoldoende structurele 
pijnmeting plaats, waardoor een aantal aspecten van pijn bij kanker 
bij een individuele patiënt niet voldoende aan de orde komen en de 
behandeling daardoor wellicht minder optimaal is. Bij de 
implementatie van een toekomstige revisie van de richtlijn dient meer 
aandacht aan het implementeren van een adequate, structurele  
pijnmeting gegeven te worden, hetgeen ook uit het in hoofdstuk 2 
beschreven onderzoek naar voren komt. 
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Hoofdstuk 8 beslaat de overkoepelende discussie van de diverse 
aspecten die in dit proefschrift besproken worden. Er wordt een 
relatie gelegd tussen aanbevelingen voor verbetering van de 
behandeling van pijn bij patiënten met kanker uit het eerste congres 
over kankerpijn in 1978 in Venetië en de huidige stand van zaken in 
deze problematiek. Het is  van eminent belang  te blijven proberen bij 
de medisch specialisten een mentaliteitsverandering te bewerken ten 
opzichte van het vaststellen van pijnproblematiek en de behandeling 
daarvan bij patiënten met kanker. Bij het opstellen van een revisie 
van de richtlijn zal daarom meer aandacht aan de implementatie 
gegeven moeten worden. Het is wenselijk al vroeg in het medisch 
curriculum aandacht te geven aan de multidisciplinaire en 
multidimensionele aspecten van pijn bij patiënten met kanker, zodat 
studenten vertrouwd raken met pijnmeting en een juiste benadering 
van deze problematiek. 
De patiënt dient als volwaardige partner van de hulpverleners  
betrokken te worden  bij het afstemmen van de proportionaliteit van 
de diagnostiek en de mogelijke behandelingen bij pijn ten gevolge 
van kanker 
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Tamis Cornelis (Kees) Besse was born on 12 April 1950 in Haarlem, 
the city where he grew up. He received his basic education at the 
Dreefschool in Haarlem and his High school education at the 1ste 
Christelijk Lyceum, where he graduated gymnasium B in 1969. 
He studied medicine at the Medical Faculty of the Free University in 
Amsterdam with graduation on 18-06-1976. During his medical study 
he taught pathophysiology at the nursing school of the St. Elisabeth’s 
Gasthuis in Haarlem. 
After graduation in Medicine Kees Besse started as a trainee in 
internal medicine in 1976 at the Juliana Hospital in Apeldoorn (chief 
educator dr. A. van Gelder). This traineeship was followed by his 
training in anesthesiology at the Institute of Anesthesiology ( head: 
prof.dr. B. Smalhout) in the Academic Hospital Utrecht, which was 
finished on 01-01-1981. During this training he was educated in pain 
medicine by prof. M. Mauve, who founded the department of pain 
medicine in Utrecht. He stayed as a staff anesthesiologist in the 
Academic Hospital Utrecht from 1981-1991. In 1982 he became head 
of the pain department after retirement of prof. M. Mauve. In 1982 he 
started as consultant in cancer pain at the Integraal Kankercentrum 
Midden Nederland (IKMN, Integrated Cancer Centre in the Centre of 
the Netherlands).  
During and after his training in anesthesiology he taught 
anesthesiology and pain medicine at the nursing school of the 
Academic Hospital. Furthermore he taught pain medicine at the 
Medical Faculty of the University of Utrecht. 
From 1985-1991 he was member of the commissie beroepsbelangen 
(committee on professional interests) of the Nederlandse Vereniging 
voor Anesthesiologie (NVA, Dutch Society of Anesthesiologists). 
From 1987-2006 he was treasurer of the Nederlandse Vereniging ter 
Bestudering van Pijn (NVBP, nowadays Dutch Pain Society) and until 
now treasurer of the Nederlands Tijdschrift voor Pijn (Dutch Pain 
Journal) . 
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In 1991 he changed his position from the Academic Hospital to the 
Overvecht Hospital  (later Mesos Medisch Centrum) in Utrecht as 
staff member of the department of anesthesiology. Together with 
Maarten Oefner and later Ina Groustra a large department of 
anesthesiology, intensive care and pain medicine was developed in 
this peripheral hospital. In this period an intense cooperation with the 
regional general practitioners in the field of palliative care was 
founded. Kees Besse became teacher in cancer pain medicine at the 
D-course of the central education of anesthesiologists. 
After following the “Beekbergen” course in palliative care he became 
consultant of the palliative care team of the IKMN in 1996. In 2004 he 
became member of the committee on palliative sedation of the 
Koninklijke Nederlandse Maatschappij voor Geneeskunde (KNMG, 
Royal Dutch Medical Society).   In 2005 he became SCEN-arts 
(consultant in questions of euthanasia). 
In 2008 Kees Besse switched from Mesos Medisch Centrum to 
department of Anesthesiology (head: prof.dr. G.J. Scheffer) of the 
Radboud University Medical Centre in Nijmegen as staff 
anesthesiologist. He is working in the sub department of pain 
medicine and palliative care (head: prof. dr. K.C.P. Vissers). In 
Nijmegen he is also consultant in palliative care of the Integraal 
Kankercentrum Nederland (IKNL, comprehensive Dutch Cancer 
Institute ) and SCEN arts. 
In 2008 he became member of the board committee of pain medicine 
of the Nederlandse Vereniging voor Anesthesiologie (NVA). 
He passed the exam of the World Institute of Pain and became 
Fellow in the Interventional Pain Practice (FIPP) in 2010 in 
Cleveland.   
Since 22 September 1978 Kees Besse is happily married with 
Pauline Steijn. They have two children, Maarten and Lotte, and two 
grandchildren Luna and Indy. 
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Een proefschrift komt niet tot stand als gevolg van een solitaire actie, 
maar is het resultaat van samenwerking met en steun van velen. Een 
woord van dank aan hen is dan ook zeker op zijn plaats bij de 
afsluiting van het wordingsproces. 
Prof.dr. K.C.P.Vissers, beste Kris. Toen je mij vroeg vicevoorzitter te 
worden van de werkgroep die de richtlijn pijn bij patiënten met kanker 
ging ontwikkelen, kon ik niet vermoeden, dat mijn loopbaan in de 
pijnbehandeling daardoor een heel andere wending zou krijgen. Mijn 
wens om meer betrokken te zijn bij onderwijs en opleiding is in 
Nijmegen in vervulling gegaan. Daarnaast is door jouw enthousiasme 
en ondersteuning dit proefschrift tot stand gekomen, een lang 
gekoesterde, stille wens, waarvan ik niet verwachtte dat die uit zou 
kunnen komen. Ik kijk met veel genoegen en genegenheid terug op 
onze samenwerking en hoop die nog geruime tijd voort te zetten. Ik 
dank je zeer en hoop voor onze afdeling, dat je nog lang ons 
boegbeeld zult zijn. 
Prof.dr. M.J.F.J.Vernooij-Dassen, beste Myrra. Je hebt mede aan de 
wieg van dit proefschrift gestaan en de weg gewezen in diverse 
onderzoeksprojecten. Het kind heeft wat groeistuipen gekend, maar 
is nu, zeker ook door jouw toedoen, toch volwassen geworden. Ik 
dank je zeer voor je steun bij het uitwerken van de 
onderzoeksgegevens en de  bewerking van de tijdschrift artikelen. Ik 
wens je nog vele gezonde jaren bij je emeritaat.  
Dr. Y.M.P.Engels, beste Yvonne. Gedurende de jaren waarin dit 
proefschrift tot stand gekomen is, heb je mij aan de hand door 
wetenschapsland geleid. Dank zij jouw kritische, maar hulpvaardige 
ondersteuning zijn de onderzoeksprojecten tot een goed einde 
gekomen. Ik kijk met veel genoegen terug op onze “promotie 
overleggen”, waarin we ook over fietsen, ons beider hobby, 
diepgaand gesproken hebben. Ik dank je zeer en hoop je nog vaak te 
ontmoeten op onze afdeling. 
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Dr. M.A.H.Steegers, beste Monique. Wij werken al vele jaren samen 
op de afdeling pijngeneeskunde en zijn samen Fellow of the 
Interventional Pain Practice geworden in Cleveland.  De laatste jaren 
heb je mij zeer geholpen en gesteund bij het tot stand komen van dit 
proefschrift. Ik heb veel bewondering voor de wijze waarop je een 
druk gezin en een drukke pijnafdeling in goede banen leidt. Ik dank je 
zeer en hoop nog geruime tijd en met plezier met je samen te 
werken. 
Leden van de manuscriptcommissie, prof.dr.W.T.A. van de Graaf, 
prof.dr. G.J.Scheffer, prof.dr.M. van Kleef. Beste Winette, Gert Jan 
en Maarten. Het afwachten van een oordeel over het manuscript is 
een spannende periode voor een promovendus. Ik dank jullie voor de 
tijd die, ondanks drukke werkzaamheden, genomen is voor de 
beoordeling van mijn proefschrift en de positieve uitkomst daarvan . 
Ik wens jullie veel sterkte bij het uitvoeren van belangrijke taken en 
hoop jullie nog vaak te ontmoeten.  
N.D.Faber- te Boveldt, MSc, beste Nienke. We zijn samen begonnen 
aan het onderzoeksproject “Pijnsein” en ronden ons promotietraject 
dit jaar af. Ik kijk met genoegen terug op onze samenwerking, waarin 
we vele uren op pad zijn geweest  om kennis te verspreiden en de 
trein van het onderzoek rijdende te houden met groene seinen. 
Hoewel de rails wel eens glad waren op de onderzoekslocaties zijn 
we toch op tijd aangekomen. Ik dank je zeer voor onze 
samenwerking en wens je nog een lang en gelukkig leven.  
Dank ben ik verschuldigd aan de medisch oncologen en longartsen in 
het Radboudumc en de medisch oncologen in de aan “Pijnsein” 
deelnemende ziekenhuizen voor hun medewerking bij het 
uitgevoerde onderzoek. Wij mochten zonder restrictie hun gegevens 
inzien en verzamelen voor inventarisatie van pijnregistratie. Zij 
verdienen daarvoor groot respect. 
G. Janssen, verpleegkundig specialist, beste Ge. Jouw idee over het 
gebruik van moderne communicatie middelen heeft geleid tot een 
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belangrijk onderzoeksthema. Bij de pilot heb je een enorme inzet 
getoond, waardoor dit project zeer geslaagd is. Deze inzet spreid je 
ook ten toon bij de patiëntenzorg, waardoor de patiënten je op 
handen dragen. Ik dank je zeer voor onze samenwerking en wens je 
alle goeds voor de toekomst. 
De sponsoren van het Pijnsein onderzoek. De stichting “Bergh in het 
zadel” heeft zich enorm ingespannen om fondsen te werven voor het 
onderzoek ‘Pijnsein”. Wij zijn daarvoor veel dank verschuldigd. Als 
vertegenwoordigers van Bergh in het zadel dank ik met name Ankie 
Kramer en Wim Hendriksen, met wie ik het meeste contact heb 
gehad.  
N. Van den Hecke, beste Nicole. Je hulp bij het tot stand komen van 
het manuscript van mijn proefschrift is onverbeterlijk. Je bent een 
enorme steun op het gebied van “drukklaar” maken en vormgeving 
van wetenschappelijke artikelen en van dit “boekje”. Ik ben je 
daarvoor zeer erkentelijk. 
Mijn paranimfen, Han Langemeijer en Maarten Oefner. Beste Han, 
wij kennen elkaar al sinds onze opleiding in het Academisch 
Ziekenhuis Utrecht. Wij hebben in ons vak en privé veel dingen 
samen ondernomen, waardoor er een hechte vriendschap is ontstaan 
die ik koester. Beste Maarten, ook wij kennen elkaar uit het AZU. 
Daarna hebben wij als maten een geweldige tijd gehad in ziekenhuis 
Overvecht in Utrecht en zijn we zeer bevriend gebleven in soms 
woelige tijden. Ik prijs me gelukkig, dat jullie je willen kwijten van je 
taak als mijn paranimfen. 
Stafleden en fellows van de afdeling Palliatieve zorg en 
pijngeneeskunde van het Radboudumc, beste Anouk, Carel,Christel, 
David, Ellen, Frank, Heinrich, Kris, Lieven, Marieke, Marjan, 
Monique, Oliver, Robert, Sandra, Selina en Steven. Onze plezierige 
en collegiale samenwerking is de basis voor een goed 
functionerende afdeling, waarin ook plaats is voor wetenschappelijk 
onderzoek passend bij een Academisch ziekenhuis. De uitstekende 
Chapter 12 
 265 
onderlinge verhoudingen maken elke werkdag tot een mooie 
ervaring, die veel energie geeft en waarvoor ik jullie hartelijk dank. Ik 
hoop nog enige tijd deel te mogen uitmaken van dit illustere 
gezelschap. 
Arts assistenten anesthesiologie, amici. Jonge, kritische dokters 
houden de oude dokter(s) bij de les. Ik geniet dagelijks van onze 
samenwerking, waarvoor ik jullie hartelijk dank. Ik hoop in de 
komende tijd een bijdrage te blijven leveren aan jullie opleiding. 
Verpleegkundigen van de afdeling pijngeneeskunde en Palliatieve 
zorg, beste Birgit, Floor, Henny, Inge, Jolande, Jose, Jutta, Marijke, 
Petra , Rianne en Suzanne. Onze samenwerking verschaft mij 
dagelijks veel genoegen. Jullie hebben een belangrijke inbreng bij de 
patiëntenzorg. Jullie kennis en kunde zijn een goed voorbeeld voor 
multidisciplinaire zorg voor patiënten met pijn. Ik dank jullie voor deze 
bijzondere samenwerking  en hoop nog geruime tijd deel uit te maken 
van dit team. 
Medewerkers van de operatiekamer in Dekkerswald, beste Beppie, 
Esther, Ineke, Kees, Lisette, Thea en Wietske. Elke prikdag is voor 
mij een feest, dat jullie verzorgen. Jullie inzet leidt tot zeer grote 
waardering bij de patiënten en behandelaars. Daarnaast is de sfeer 
altijd goed, ondanks de vaak drukke werkzaamheden. Ik dank jullie 
voor onze fijne samenwerking, die wat mij betreft nog lang mag 
worden voortgezet. 
Röntgenlaboranten in Dekkerswald, beste Jiska, Marjan en Rob. 
Anesthesiologische pijnbehandeling staat of valt met goede 
röntgendoorlichting. Jullie kwaliteit is boven elke twijfel verheven, 
bovendien zijn jullie zeer aangenaam in de omgang, waarvoor mijn 
dank. Ik hoop nog lang met jullie samen te werken. 
De collegae van de multidisciplinaire polikliniek pijngeneeskunde in 
Dekkerswald, beste Erkan, Han, Jan, Maarten en Manon. Het 
uitpluizen van ingewikkelde pijnproblemen is jullie dagtaak, welke 
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onnavolgbaar uitgevoerd wordt. Het op onze afdeling vormgegeven 
multidisciplinaire overleg is een belangrijke aanwinst voor de zorg 
van patiënten met chronische pijn; dat het daarnaast altijd met 
wederzijds respect en in goede harmonie verloopt is een extra 
pluspunt. Ik dank jullie hartelijk voor onze samenwerking, die zich de 
komende tijd zal voortzetten. 
Het secretariaat de afdeling Anesthesiologie, Pijngeneeskunde en 
Palliatieve zorg, beste Ando, Anneke, Bert, Bianca, Diana, Léon, 
Lydia, Monique, Monique, Nicole, Rina en Xandra. Het secretariaat is 
een belangrijke pijler onder onze afdeling en ons visitekaartje voor de 
buitenwereld. Jullie maken er een heel mooi kaartje van. Naast de 
professionele invulling van jullie taken is het ook altijd gezellig als je 
even binnenvalt. Ook jullie dank ik daarvoor en ik hoop nog vaak 
langs te kunnen komen. 
Het secretariaat in Dekkerswald, beste Anita, Constance, Francis, 
Gert-Jan, Inge, Jolanda, Lieke,  Lies, Lisanne, Lucie,  Marion, 
Marleen, Monique, Nancy, Rosita, Sandy en Trudy .  Jullie vormen de 
spil waar de polikliniek pijngeneeskunde om draait. Dit is niet altijd 
een gemakkelijke taak, die jullie echter toch met veel inzet uit 
proberen te voeren. Ook bij jullie is het aangenaam binnen vallen. Ik 
dank jullie daarvoor zeer en hoop op een nog lange samenwerking. 
Bij mijn inmiddels lange loopbaan in de geneeskunde hebben velen 
een rol gespeeld bij de vorming tot mijn huidige arts zijn. 
Prof.dr.B.Smalhout, Hooggeleerde heer, bij u heb ik mijn opleiding 
genoten tot anesthesioloog. Ik kijk daarop met warme gevoelens 
terug. Naast mijn opleiding tot anesthesioloog in engere zin kreeg ik 
de gelegenheid mij te bekwamen in de pijngeneeskunde. Ik ben u 
daarvoor veel dank verschuldigd. Ik wens u in uw huidige, moeilijke 
omstandigheden veel sterkte. 
De collegae van de vroegere  maatschap anesthesiologie van het 
Mesos Medisch Centrum te Utrecht. Beste Godfried, Ina, Jaap, 
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Maarten en Odette. Wij hebben een mooie tijd gehad in Utrecht. 
Hoewel onze maatschap op het laatst in zwaar weer kwam, 
overheerst bij mij een gevoel van tevredenheid over wat wij tot stand 
gebracht hebben. Ik ben jullie daarvoor veel dank verschuldigd. 
Voor mij bestaat het geneeskundig vak niet alleen uit anesthesiologie 
en pijngeneeskunde, maar ook uit Palliatieve zorg en het behandelen 
van problematiek rond het levenseinde. In het Palliatieteam Midden 
Nederland vond ik een inspirerend samenwerkingsverband om tot 
verdieping van kennis op dit gebied te komen. Ik kijk met grote 
genegenheid terug op de periode in mijn leven, waarin ik van dit team 
deel uitmaakte. Ik dank de collegae consulenten en de secretaresse 
voor de geweldige teamgeest. Het stemt mij droef, dat Sicco niet 
meer bij ons is.  
De samenwerking binnen de SCEN-artsen groep Utrecht, de peer-
groep Palliatieve zorg Ede/Wageningen/Amersfoort, het 
Ondersteuningspunt Palliatieve Zorg te Nijmegen en de SCEN-artsen 
groep Nijmegen gaven en geven een belangrijke verdieping aan mijn 
kennis en vaardigheden. Ik dank de collegae daarvoor hartelijk. 
Het bestuur van de sectie pijn van de Nederlands Vereniging voor 
Anesthesiologie dank ik voor de aangename samenwerking 
gedurende da laatste zes jaren. We zijn in een moeilijke periode 
beland door de opstelling van de zorgverzekeraars en de overheid. Ik 
heb er alle vertrouwen in, dat het toekomstig bestuur weer een 
opgaande lijn voor de pijnbehandeling in Nederland zal weten te 
vinden. 
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Last but not least kom ik tot een dankwoord aan mijn familie.   
Mijn moeder. Lieve mam, je hebt je altijd enorm ingezet om mij de 
opleiding te laten volgen die ik graag wilde. Dit heeft bovenmenselijke 
inspanningen van je gevergd, wat je nooit zo hebt gevoeld of hebt 
laten merken. Ik ben je daar eeuwig dankbaar voor en vind het fijn, 
dat je op zeer hoge leeftijd de voltooiing van dit proefschrift mee mag 
maken. 
Mijn kinderen, lieve Maarten en Lotte. Wat is het geweldig om jullie 
als kinderen te hebben. We voelen een diepe genegenheid voor 
elkaar. Ik zie met veel genoegen hoe jullie je een plaats op deze 
wereld veroveren. Onze liefde zal eeuwig blijven bestaan. 
Mijn kleinkinderen, lieve Luna en Indy. Opa is altijd druk met het werk 
en zijn “ boekje”. Nu dit af is komt er meer tijd voor bezoek en spel; 
daar mogen jullie op rekenen. 
Mijn echtgenote, lieve Pauline. Wij zijn al vele, gelukkige jaren 
samen. Je hebt mij altijd gesteund, terwijl mijn aandacht regelmatig 
oneerlijk verdeeld werd tussen jou en het werk. Nu het  “boekje” klaar 
is en het werk in intensiteit gaat afnemen, komt de verdiende 
aandacht meer bij jou te liggen en gaan we, hoop ik, nog vele 
gezonde jaren samen tegemoet. Ik dank je voor je onvoorwaardelijke 
liefde. 
 
